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Abstract 
In the U.S., there are 400,000 respiratory failure deaths. Conventional treatment for acute 
respiratory failure employs lung damaging mechanical ventilation. The only long term treatment 
for chronic respiratory failure is lung transplantation. However, only 1800 transplants are 
performed each year due to donor shortages, resulting in the need for a destination therapy. 
Extracorporeal gas exchangers have been used as an alternative to mechanical ventilation in acute 
respiratory failure and as a bridge to transplantation in chronic respiratory failure. Blood is diverted 
to an extracorporeal gas exchanger, where oxygen is added and carbon dioxide is removed before 
returning the blood to the patient. Current gas exchangers are limited by their high resistance and 
low biocompatibility that lead to patient complications and device clot formation. This dissertation 
discusses three gas exchangers; the compliant thoracic artificial lung (cTAL), the compact 
cardiopulmonary support device (CCSD), and the pulmonary assist device (PAD).  
Fourteen day in vivo studies evaluated the cTAL’s long term performance and 
biocompatibility. The uncoated cTAL was capable of 14 days of support without a resistance 
increase or clot formation. In the future, the cTAL will be coated with anti-coagulant coatings and 
tested in vivo for 2 months. Individual components of the CCSD were designed and when tested, 
met design goals. However, enclosure pressures of negative 197 mmHg at flowrates of 4 L/min 
were encountered in CCSD system testing, causing gas embolus formation. The risk of gas 
embolus resulted in the discontinuation of CCSD development. The PAD was designed for long 
term use as a bridge to transplantation and destination therapy. Computational simulations were 
used to design the PAD with a theoretical resistance of 1.50 mmHg/(L/min) and a 98.3 percent  
xv 
 
blood outlet oxyhemoglobin saturation at blood flowrates of 1.25 L/min. In vitro testing of the 
PAD yielded lower gas exchange performance (88.4 percent saturation) and higher resistance (3.47 
mmHg/(L/min)). However, the gas exchange performance was skewed negatively by two devices 
with fabrication defects. PADs without defects were closer to the gas exchange goal. Future 
computational models will be improved, and the PAD will be redesigned for lower resistance and 
higher gas exchange.  
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Chapter 1: Background 
 In the United States, there are approximately 400,000 deaths from lung disease of various 
forms.(1) Respiratory diseases can be largely divided into acute respiratory failure (ARF) and 
chronic respiratory failure (CRF). A particulary severe form of ARF, acute respiratory distress 
syndrome (ARDS), affects approximately 190,000 people a year in the U.S. with a 27-40% 
mortality rate.(1, 2) Chronic respiratory failure, including chronic obstructive pulmonary 
disease(COPD), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis (CF), affects over 12.1 
million Americans with over 127,000 dying per year (largely from COPD).(1) Although there has 
been a great deal of research focusing on developing new treatment techniques, respiratory disease 
still is an unresolved problem that necessitates work in new treatments including improved gas 
exchange devices. 
1.1. Respiratory Failure and Conventional Treatment 
1.1.1 Respiratory Failure 
 Due to a variety of causes, the respiratory system can fail to adequately oxygenate and/or 
remove carbon dioxide from the blood. There are two methods for specifying the type of 
respiratory failure; based on the gas exchange inadequacies and based on the time progression of 
the disease. Type 1 Hypoxemic respiratory failure, is classified by an arterial partial pressure of 
oxygen, PaO2, less than 60 mmHg.(3, 4) Type 2 Hypercapnic respiratory failure is classified by an 
arterial partial pressure of carbon dioxide, PaCO2, greater than 50 mmHg.(3, 4) Respiratory failure 
can be Type 1, Type 2, or often a combination of the two.(3, 4) In terms of time frame, respiratory 
failure can be either further classified as acute respiratory failure (ARF) or chronic respiratory  
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failure (CRF).(3) Additionally, CRF patients can experience a sudden worsening of their disease, 
known as an acute exacerbation or acute on chronic respiratory failure.(3, 5) The stimulus of acute 
exacerbations varies, but they are often caused by a bacterial infection.(5) 
1.1.2 Acute Respiratory Failure 
Diseases and Conventional Therapy:  
 Acute respiratory failure (ARF) is a complex disease state encompassing many underlying 
conditions that cause a degradation in gas exchange. One particularly severe form of ARF is acute 
respiratory distress syndrome or ARDS. Patients with ARDS typically are in a state of extreme 
inflammation and pulmonary edema that can cause large decreases in lung compliance and gas 
exchange efficiency.(3) Like ARF in general, ARDS is usually a result of an underlying condition 
such as sepsis, aspiration, trauma, pneumonia, etc.(3, 6, 7) ARDS with sepsis as the underlying 
cause is associated with the highest incidence of mortality. (8) 
 The most recent consensus definition of ARDS, the Berlin Definition, breaks down ARDS 
into three designations according to severity of oxygen deficiency.(2) In general, according to this 
definition ARDS must develop within one week of a known clinical insult or new or worsening 
symptoms.(2) Additionally, the patient must have bilateral opacities in chest imaging that is not 
fully explained by effusions, lobar/lung collapse, or nodules.(2) Lastly the edema experienced by 
a patient must not be fully explained by cardiac failure or fluid overload.(2) The first designation 
of ARDS is “Mild” ARDS where the ratio of PaO2 and fraction of inspired air composed of oxygen 
(FiO2), PaO2/FiO2, is between 200 mmHg and 300 mmHg with a positive end-expiratory pressure 
(PEEP) or continuous positive airway pressure (CPAP) greater than or equal to 5 cmH2O.(2) 
“Moderate” ARDS is defined when a patient has a PaO2/FiO2 ratio between 100 mmHg and 200 
mmHg with a PEEP greater than or equal to 5 cmH2O.(2) Lastly, “Severe” ARDS is defined when 
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the PaO2/FiO2 ratio is less than or equal to 100 mmHg with a PEEP greater than or equal to 5 
cmH2O.(2, 6) Mortality rates for mild, moderate, and severe ARDS are 27%, 32%, and 45%, 
respectively.(2) 
 Since ARDS is usually coupled with an underlying condition, treatment of the two disease 
states must be done in tandem. Treatment of the ARDS symptoms is performed as a temporary 
support for the respiratory needs of the patient while the underlying condition is treated.(6) It is 
not until the underlying condition is cured that the ARDS can resolve.(6) The first and least 
injurious treatment of ARDS is administration of supplemental oxygen without intubation using 
either an oxygen mask or nasal cannulas.(4) Although lung injury can ensue from oxygen toxicity 
at levels greater than 50%, supplemental oxygen can in some cases be sufficient to resolve the 
hypoxemia induced by ARDS.(6) 
 If administration of noninvasive ventilation is not sufficient, the patient can be intubated 
and treated with mechanical ventilation.(6) Mechanical ventilation is a technique where a patient 
is intubated endotracheally and gas is forced into and out of the lungs of a patient using a 
mechanical ventilator. The ventilator takes over the work of breathing from the body and allows 
for very controlled ventilation with adjustment of respiratory rate, tidal volume, peak inspiratory 
pressure (PIP), inspiratory to expiratory ratio, PEEP to prevent alveolar collapse, and fraction of 
inspired oxygen (FiO2) to name a few.  
Ventilator Induced Lung Injury 
 Invasive mechanical ventilation is able to provide adequate oxygenation and CO2 removal 
for many patients, but this comes at a cost. Injury can result from mechanical ventilation and is 
commonly known as ventilator induced lung injury or VILI. In addition to oxygen toxicity, the 
ventilator has the potential to induce barotrauma, an injury to the native lungs induced by over-
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pressurization.(9, 10) ARDS patients are inundated with large amounts of pulmonary edema 
dispersed throughout the lung, decreasing the lung volume and changing the distribution of 
compliance within the lung. As the ventilator forces large tidal volumes of gas through the 
decreased volume, decreased compliance lung, high pressures are built up and the alveoli of the 
lung are damaged.(9)  
 Another suspected form of injury induced by mechanical ventilation is related to 
inflammation in the lungs and is known as biotrauma. There have been studies that show that even 
at low tidal volumes and pressures, mechanical ventilation induces release of inflammatory 
mediators in the lung.(9) Barotrauma of the lungs as well as cellular damage from repeated opening 
and collapsing of alveoli can induce the release of inflammatory mediators.(11) It has been 
theorized that the local inflammatory mediators in the lung arising from mechanical ventilation 
can spill over into the systemic circulation and contribute and may contribute to the development 
of multiple system organ failure in ARDS patients.(11-13) In addition to these forms of VILI, 
mechanical ventilation is plagued by ventilator associated infections, and patent sedation during 
many ventilation modes can result in patient weakening or deconditioning.(6, 14, 15) 
 Better understanding of these problems have led to changes in the way ARDS patients are 
treated. One of the most impactful is the utilization of lung protective ventilation strategies that 
focus less on maintaining normal blood gases and more on protecting the lung from barotrauma.(9) 
In these strategies, the tidal volume is limited to a maximum of 6 mL/kg body weight and ventilator 
plateau pressures are limited to less than 28-30 cmH2O with the application of PEEP. These low 
tidal volume ventilator strategies have lowered the ARDS mortality rate(9). When safe ventilator 
settings have reached their limit, the physician can resort to a technique of permissive 
hypercapnia.(6) During permissive hypercapnia the patient is allowed to remain hypercapnic while 
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the pH imbalance is corrected using sodium bicarbonate.(6) Additionally, a conservative fluid 
management technique for reducing the level of pulmonary edema has increased lung function and 
reduced the number of days patients remain on a ventilator during ARDS.(16) Lastly, there have 
been studies coupling mechanical ventilation with other extracorporeal respiratory support 
techniques that have found that lowering tidal volumes below 6 mL/kg body further improves 
patient outcomes.(17-19) This suggests that VILI is still present when protective ventilation 
measures are employed. (17) 
1.1.3 Chronic Respiratory Failure: 
Diseases and Conventional Therapy:  
 Chronic respiratory failure (CRF) is characterized by a gradual decline in respiratory 
function marked by more rapid, transient acute exacerbations. A majority of CRF is caused by 
three diseases; chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and idiopathic 
pulmonary fibrosis (IPF). Although there are some medical treatments that can temporarily 
alleviate symptoms, the is only cure for CRF diseases lung transplantation.(1, 20) 
 COPD includes two disease states, chronic bronchitis and emphysema, that sometimes 
overlap.(5) The American Lung Association defines chronic obstructive pulmonary disease as “the 
presence of a mucus-producing cough most days of the month, three months of a year for two 
years in a row without other underlying disease to explain the cough.”(1) Due to blockage of 
airways with mucous, a patient with chronic bronchitis has decreased ventilation and typically 
cannot support their oxygen requirements, resulting in hypoxemia.(5) On the other hand, 
emphysema is a destruction of the alveoli, which leads to a decrease in lung elasticity.(5) 
Emphysema patients are typically able to maintain normal oxygen saturations for a period of time 
since ventilation and perfusion are decreased simultaneously.(5)However, over time they become 
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hypercapnic.(5) The chronic disease is slow to progress, but acute exacerbations lead to periods in 
a severe disease state that can lead to patient mortality. The first onset of a disease exacerbation 
that leads to ARF is an indicator for poor patient lifespan with a mortality rate of two thirds after 
two years.(5) During these exacerbations, the symptoms of the chronic disease are increased often 
to a point that requires hospitalization of the patient due to hypercapnia and hypoxemia. The 
stimuli for exacerbations can vary, but often they result from a bacterial infection of the lungs.(5) 
 Treatment of an acute exacerbation begins with relatively simple medical interventions 
such as inhaled β-agonist drugs to decrease obstruction and broad spectrum antibiotics for any 
underlying bacterial infection.(5) The progression of treatments of acute exacerbations of COPD 
is very similar to that for ARDS, with initial administration of supplemental oxygen, then CPAP, 
and, if the patient degrades even further, eventual intubation and mechanical ventilation.(6) 
 Treatment of the chronic state of COPD is accomplished largely with pharmacologic agents 
to reduce the symptoms, but eventually the disease will progress and create the need for lung 
transplantation. The most common treatment for the chronic disease state of COPD is using an 
inhaled anticholineric, such as ipratropium bromide, as a bronchodilator.(5) Chronic hypoxemia 
related to COPD can also be treated using naturally breathed supplemental oxygenation.(5) The 
quality of life of the patient can also be improved with respiratory rehabilitation sessions,(1) but 
over time the patients become tethered to supplemental oxygen until they expire. 
 Cystic fibrosis is an inherited disease that leads to an excess of thick mucus in the lungs, 
resulting in obstructed airways and airway inflammation.(1) This disease affects many organs 
including the lungs of a patient from a fairly young age(1), with patient mortality typically 
occurring by a median age of 37(21). Medical treatment of CF depends on a combination of 
therapies. Since respiratory infections are fairly common in CF patients (1), patients are often 
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treated with chronic antibiotics.(22) Ibuprofen treatment is also used in young patients to decrease 
lung inflammation and damage.(22) Dornase alpha is often administered to patients to degrade the 
DNA material in the mucous excretions, resulting in an improvement in lung function.(22, 23) In 
addition to drug administration, physical methodologies for loosening and clearing mucous from 
the lung have been developed, including handheld and vest worn vibration devices.(24) 
 According to the American Thoracic Society idiopathic pulmonary fibrosis (IPF) is “a 
specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring 
primarily in older adults, limited to the lungs, and associated with the histopathologic and/or 
radiologic pattern of usual interstitial pneumonia.”(20) This fatal disease progresses slowly in most 
patients, but there is a fairly wide range of deterioration rates in the patient populations with a very 
small 5-10% of patients who have an acute exacerbation each year.(20, 25-29) Although 
corticosteroids can prove useful in acute exacerbations of the disease, there are no effective 
pharmacologic treatments for the chronic disease state.(20) The quality of life of patients can be 
improved with pulmonary rehabilitation and administration of naturally inhaled oxygen can treat 
hypoxemia in IPF patients, but the only final long term treatment for IPF is lung 
transplantation.(20, 30) Lung transplantation in these patients is hindered by the extremely varied 
nature of IPF disease progression which makes it very difficult to predict when a patient will need 
a lung transplant.(30) As a result transplantation, some clinicians recommend transplantation of a 
patient in the mild to moderate stages of the disease before the disease progresses to an 
untransplantable state.(30) 
 When chronic lung disease advances to its latest stages the patient will need a lung 
transplant to recover from the disease. Prior to 2005, patients were selected for a lung transplant 
largely based on how long they were waiting on the lung transplant list. This system favored 
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patients who were entered into the 
system in early disease states rather than 
patients who needed the transplant most 
urgently, leading to a high waitlist 
mortality.(31) In 2005 the lung 
allocation score (LAS) system for 
distributing donor lungs was 
implemented.(31) The LAS system is 
based on a weighting of urgency and 
chance of survival rather than time on 
the waitlist.(31, 32) As can be seen in Figure 1.1 for patients with COPD, CF, IPH, and idiopathic 
pulmonary hypertension, the waitlist mortality has decreased since the implementation of the 
LAS.(31) However, the severity and unpredictability of IPF leads to a higher post-transplant 
mortality of these patients.  
1.1.4 Pulmonary Hypertension 
 Pulmonary hypertension (PH) is a disease state that can be caused by respiratory diseases 
or exist as a primary vascular disease.(33) A normal mean pulmonary artery pressure (mPAP) in 
a healthy patient is 14 mmHg, however when a patient develops pulmonary hypertension their 
mPAP is equal or greater than 25 mmHg.(33) The increased pulmonary artery pressure will 
overload the right heart, eventually leading to heart failure. Edema occurs as a result of increased 
pulmonary pressures, and can exacerbate other conditions.(33) Pulmonary hypertension results 
from a single or multiple known or unknown disorders, with unknown causes being described as 
idiopathic pulmonary hypertension (IPH).(33) The underlying causes of PH are used to designate 
Figure 1.1: Cumulative instance curves of patients 
transplanted or died on waiting list; pre-LAS 
(dashed) and post-LAS (solid)). (31) 
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the type of pulmonary hypertension on two levels. In the first level, pulmonary hypertension is 
described according to the location of the underlying condition as being either pre-capillary or 
post-capillary hypertension. Precapillary and post capillary hypertension are judged based on the 
pulmonary artery wedge pressure (PAWP) as an estimate of left atrial pressure. Pre-capillary PH 
occurs when the PAWP is less than or equal to 15 mmHg, and post-capillary PH occurs when the 
PAWP is greater than 15 mmHg.(33)  
 Pulmonary hypertension is further classified into 5 groups, Group 1-5. (Table 1.1) (33) 
Group 1 PH is a pre-capillary hypertension known as pulmonary arterial hypertension (PAH) 
where hypertension can result from a multitude of underlying conditions that increase the pressure 
in the arterial side of the pulmonary system including pulmonary venous occlusive disease.(33) 
Group 2 PH is a post-capillary pulmonary hypertension due to an underlying left heart condition 
such as a valvular disease.(33) A valvular disorder of the left heart or left ventricle causes an 
elevated left atrial pressure.(34) As a result, the upstream pulmonary venous pressure becomes 
increased.(34) Further upstream the pulmonary artery pressure becomes elevated from the back 
pressure of the pulmonary veins, leading to pulmonary hypertension.(34)  Group 3 PH is a pre-
capillary pulmonary hypertension due to underlying respiratory diseases such as COPD.(33) 
Group 4 PH is a pre-capillary PH due to pulmonary artery remodeling as a result of major vessel 
Table 1.1: Definitions of pulmonary hypertension in to pre and post capillary, and into groups 1-5.  
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thromboembolism.(33) Group 5 PH can be a pre-capillary and/or post capillary PH from either 
unknown causes or a combination of causes from other groups.(33) Treatment for pulmonary 
hypertension varies according to the group and disease severity with treatments ranging from lung 
transplantation to drug therapy to left heart repair.(33) 
1.2 Extracorporeal Gas Exchange 
 In acute and chronic respiratory failure, there are extracorporeal gas exchange devices that 
have been developed to address shortcomings in traditional treatment methods. These 
extracorporeal gas exchange devices function by diverting blood to a gas exchanger where carbon 
dioxide is removed from the blood and oxygen is added. In ARF, there is a point where mechanical 
ventilation is either not satisfactory in supporting the patient’s respiratory needs, or the ventilator 
must be used with injurious settings to accomplish support. In these situations, extracorporeal gas 
exchangers have the potential to be used either in conjunction with mechanical ventilation or in a 
standalone mode.(10) In chronic respiratory insufficiency, artificial lungs are sometimes used as a 
bridge to lung transplantation.(35-38)   
 In the United States there are currently approximately 1800 patients a year who receive 
lung transplants for chronic respiratory failure, however 350 patients die on the waiting list each 
year while searching for a suitable donor.(39) Patients on the lung transplant list are typically in 
very advanced disease states and often require mechanical ventilation. However, mechanical 
ventilation is a contraindication to lung transplant due to lower long term survival rates post-
transplant (61% vs. 71% 2 year survival with without mechanical ventilation) resulting from a 
possible combination of ventilator induced lung injury, ventilator associated infection, and 
muscular weakening of the patient.(14, 15, 40-42) In order to extend the amount of time a patient 
can stay on a waitlist and improve the patient’s health and chances of surviving pre and post 
11 
 
transplant, extracorporeal gas exchange devices are being developed as a bridge to lung 
transplantation.(35-38) In addition to patients who will be bridged to lung transplantation, there 
are millions of patients with chronic respiratory failure who will never receive a lung transplant 
due to the mismatch between donor lung numbers and patients in need of a lung transplant. These 
patients have no alternatives and extracorporeal gas exchangers may be a suitable alternative in 
the coming years.(43) 
1.2.1 Extracorporeal Gas Exchanger Function 
 Modern extracorporeal gas exchangers all function with the same premise of pulling blood 
high in carbon dioxide and low in oxygen from the body, using concentration gradients with a 
sweep gas supply to exchange gas with the blood, and finally returning it to the patient’s body.(44) 
Once inside a gas exchanger, the patient’s blood flows through a bank of hollow fibers with blood 
flowing on the outside of each fiber. (Figure 1.2) Concurrently a sweep gas typically composed 
of pure oxygen is pumped through the inside of each fiber.(44) A concentration gradient exists 
between the carbon dioxide and oxygen in the blood on the outside of a fiber and the pure oxygen 
flowing through the inside of a fiber. The wall of this fiber is permeable to both oxygen and carbon 
dioxide diffusion, but not blood. As a result the blood 
and the gas are largely separated by a physical barrier 
with only diffusion of oxygen into the blood and 
carbon dioxide out of the blood through the fiber wall. 
(Figure 1.2) The blood exiting the fiber bank is 
increased in its oxygen content and reduced in its 
carbon dioxide content as a result of the gas exchange. 
The sweep gas exiting the fiber follows the opposite 
Figure 1.2:  A schematic section of a gas 
exchanger hollow fiber bank with blood 
in red and sweep gas in blue. 
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pattern.  
 Extracorporeal gas exchangers functioning in this manner can be effective at providing gas 
exchange support for a patient with respiratory failure. However, the functioning of a gas 
exchanger can be severly impaired by clot formation and plasma leakage.(44-46) The foreign 
surface of the device activates platelets and when procoagulant molecules build up in regions of 
stasis and recirculation clot forms.(46) This clot formation shed from the device to create an 
embolus and/or stay within the gas exchanger and cover the fiber. When significant portions of 
fiber are covered with thrombus formations, the gas exchange suffers and the resistance increases. 
The gas exchange capabilities can also be impaired by plasma leakage through certain fiber 
materials, such as microporous polypropylene.(45) Plasma from the blood crosses the wall of the 
fiber into lumen where gas flows. This clogs up the inside of the fibers and leads to a reduction in 
gas exchange performance.(45)  
1.2.2 Extracorporeal Attachment Modes 
Attachment Mode 
 Extracorporeal gas exchangers can be attached to the vasculature at any combination of 
locations where enough blood flow can attained for adequate gas exchange. The most common 
attachment modes include veno-arterial access (VA), veno-venous access (VV), hybrid veno-
arterio-venous access (VAV), hybrid veno-veno-arterial access (VVA), and arterio-venous access 
(AV). Each attachment mode has different capabilities in terms of gas exchange, blood flowrates, 
etc. 
 Veno-arterial access involves the pumping of systemic venous blood into the gas exchanger 
circuit and then back into the systemic arterial system (Figure 1.3).(47, 48) As the blood moves 
from the low pressure venous system to the high pressure arterial system, a blood pump is needed. 
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The pumping of blood 
from the venous to the 
arterial system in this 
attachment mode has the 
advantage of providing 
both cardiac and 
respiratory support for a patient.(47) However, the pump can cause a large amount of platelet 
activation and blood damage as it must pump at relatively high RPMs to generate the pressure 
head necessary to pump into the high pressure arteries.(47) As the drainage blood is systemic 
venous blood, it is high in carbon dioxide and low in oxygen, so respiratory support can be attained 
for both oxygen and carbon dioxide.   
 Veno-venous access involves the pumping of systemic venous blood through the gas 
exchanger circuit and back to the systemic venous system.(47) (Figure 1.4) (49) Since the blood 
is being withdrawn and returned to the same low pressure system, this attachment mode also 
requires a pump. Although the pump can cause blood damage and platelet activation, it is typically 
lower than during VA support as the pump can operate at lower RPMs. . The lower pressures in a 
VV system also typically result in fewer complications in comparison to VA systems.(47) As with 
VA attachment, VV attachment modes can provide both carbon dioxide and oxygen gas exchange 
support. However, since 
VV access pumps to and 
from the venous system 
no cardiac support is 
attained, somewhat 
Figure 1.3:  Two site VA attachment. Adapted from (48) 
Figure 1.4:  Two site VV attachment. Adapted from (48) 
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limiting the patient 
population.(47, 50) VV 
access also has the 
disadvantage of decreased 
gas exchange efficiency 
arising from some portion 
of the oxygenated blood from the reinfusion location being pulled back into the drainage location 
before it can enter into the systemic arterial system.(51, 52) As will be discussed in subsequent 
sections there have been efforts to reduce recirculation of oxygenated blood, but it still remains a 
concern in VV attachment modes.(51, 52)  
 Hybrid VVA and VAV attachment modes are essentially the same circuits with systemic 
venous blood drained from the body and reinfused back into the systemic arterial and systemic 
venous systems.(Figure 1.5) (50) However, the order in which the vasculature was attached to the 
circuit varies between VVA and VAV attachment modes. In a VAV mode, the patient is originally 
supported in a VA attachment mode, but is switched to a VAV mode when a venous reinfusion 
access point is added to provide increased oxygenation to the upper body.(50) In a VVA mode, 
the patient is typically originally supported in a VV mode, but subsequently requires some cardiac 
support, so an arterial reinfusion point is added.(50) As these hybrid systems drain from the low 
pressure systemic venous system, they require a pump and are able to provide both carbon dioxide 
removal and oxygenation. These attachment modes are more complex, but in some patients VVA 
and VAV modes are needed to adjust for changing physiology where a patient needs increased 
cardiac or respiratory support.(50)  
 Arterio-venous attachment modes passively drains blood from the arterial system and 
Figure 1.5:  Hybrid VVA or VAV attachment. Adapted from (48) 
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returns it to the venous system. These AV systems can be 
attached as either purely pulmonary  (Figure 1.6) or more 
typically purely systemic circuits (Figure 1.7).(44, 53) As the 
blood travels from the high pressure arterial system to the low 
pressure venous system a blood pump is not required to 
maintain flow.(44, 53) This reduces the size and complexity of 
the system and eliminates the blood damage caused by the 
pump. However, the entire circuit must maintain a relatively 
low resistance and a patient must be able to maintain adequate 
blood pressures to maintain proper flowrates through the 
devices.  
 The systemic AV attachment mode has been used extensively for its simplicity, however it 
can only provide carbon dioxide removal and not significant oxygen transfer.(53-55) The 
attachment is predominantly limited because less than 20% of the cardiac output can be diverted 
through the device.(54-57) . Furthermore, the arterial drainage blood is already relatively high in 
oxygen content and thus a lesser amount can be transferred to it.(54, 56) The systemic AV shunt 
can also lead to hemodynamic instability.(58) The pulmonary AV attachment, typically pulmonary 
artery to left atrium, does have the ability to provide oxygen and carbon dioxide support since the 
pulmonary arterial blood is equivalent to systemic venous blood. Additionally, the pulmonary AV 
attachment mode has 
been used to provide a 
parallel, low resistance 
pathway around the 
Figure 1.6: Pulmonary AV 
Attachment. Adapted from 
(44) 
Figure 1.7:  Systemic AV attachment. Adapted from (48) 
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native lungs in patients with pre- capillary pulmonary hypertension.(55, 59-62) This low resistance 
parallel pathway lowers the total system resistance and unloads an overworked right heart. 
However, pulmonary AV attachment modes typically require a highly invasive thoracotomy to 
attach to the pulmonary vasculature.(62)  
 The attachment modes discussed have a range of capabilities, disadvantages, and 
advantages that dictate their use in different situations as seen in Table 1.2. Additionally, the 
attachment modes have an impact on the design and choice of other circuit components. In 
pumpless attachment modes, the gas exchanger circuit--including gas exchanger and attachment 
connections--must be of low resistance to maintain adequate blood flow. However, pumped 
attachment modes can also benefit from low resistance gas exchange circuits as the blood pumps 
can be used with settings less injurious to blood. Pumpless attachment modes can also be outfitted 
with pumps to increase and/or provide more controlled blood flow through the gas exchange 
circuit. Overall, each attachment mode can be used with a variety of circuit components depending 
on patient needs.  
Vascular Access Connections 
 There are three primary types of attachment apparati that can be used for connecting to a 
patients vasculature: the cannula, the graft, and the combination graft-cannula. All have their 
positive and negative traits. The cannula is essentially a tapered tube with various blood flow ports 
Table 1.2: Attributes and capabilities of extracorporeal attachment modes.  
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(Figure 1.8)  that is inserted into a cut in the 
vasculature and secured with simple suture 
techniques.(63) These cannulas can be inserted 
very quickly with minimal surgical trauma. Early 
cannula designs were primarily single lumen 
cannulas requiring at a minimum two cannulas, 
one for drainage of blood and one for reinfusion 
of blood.(51) Depending on location sites for 
these cannulas, they can suffer from recirculation where oxygenated blood from the reinfusion 
cannula is pulled back into the drainage cannula before entering the systemic circulation.(51) This 
results in inefficient gas exchange and perfusion of the body.(51) Today, a range of cannulas are 
available, including a dual lumen cannula that allows for the application of a single cannula for 
both drainage and reinfusion with a port configuration designed for minimal recirculation.(51) The 
two largest drawbacks to cannula usage is the high fluid resistance through each cannula, and the 
fact that the cannula takes up a majority of the flow cross-section of a vessel possibly resulting in 
impaired blood flow to or from the vessel upstream of the cannulation site.(63, 64) Impaired blood 
flow upstream of a cannula can lead to ischemia or increased pressures upstream in areas such as 
the brain.(64) 
 Synthetic grafts are typically polyester or PTFE fabric tubes that are used most commonly 
for vascular repair and replacement. However, they have been used in animal models of 
extracorporeal gas exchange by interfacing the graft with a piece of blood conduit tubing.(Figure 
1.9)(65-68) The vasculature can be cut on its side and the synthetic graft can be sutured to the 
vasculature with its bore over the opening to form an end-to-side anastomosis. The tubing section 
Figure 1.8: Two venous drainage cannulas. 
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of the graft 
assembly can 
then be attached 
to an 
extracorporeal 
circuit. The 
grafting method results in a much lower resistance attachment than a cannula and it does not 
obstruct the flow of the vasculature.(65-68) However, this process is more invasive than 
cannulation and the graft assemblies are not readily available on the commercial market.  
 A third combination method has been recently developed that combines a more 
commercially available cannula with a section of synthetic graft material.(64, 69) In this 
configuration the vessel is cut on its side and a section of synthetic graft material is sutured with 
its bore over the cut. A cannula is then fed into the graft until the tip is extended to the opening of 
the vasculature and the cannula is sutured to the graft.(64, 69) All of the components of this graft 
cannula assembly are commercially available and this configuration avoids blocking of the 
vasculature with the cannula.(64, 69) However, the surgical attachment and detachment of the 
assembly is more involved than cannula placement and it still utilizes a high resistance 
cannula.(64, 69) 
 The choice of attachment mode comes down to the balance of expected duration of 
treatment, surgical trauma, speed of deployment, resistance of the attachment, potential 
complications, and commercial availability. For instance, in a patient treated with ARDS the 
duration of treatment is relatively short, so the usage of a cannula that is simple to introduce and 
remove is a better option than a more invasive graft. Table 1.3 shows the tradeoff’s between each 
Figure 1.9: A 18mm synthetic graft assembly.  
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attachment mode. Today a vast majority of extracorporeal gas exchange circuits utilize cannulas 
for attachment, however in the future this may shift as new technologies emerge.  
1.2.3 Perfusion Modes 
 Blood flow exiting the heart into the arterial system is highly pulsatile. As the blood travels 
through the compliant arterial blood vessels, it is damped out and largely steady once it reaches 
the venous system. Since the advent of cardiopulmonary bypass, there has been debate over 
whether extracorporeal gas exchange circuits should mimic the pulsatility of the heart when blood 
is reinfused to the arterial system. In the 1950’s, in studies by Wesolowski, it was concluded that 
steady blood flow was sufficient to maintain adequate perfusion of the organs.(70, 71) This was 
welcomed by many, as reliable pulsatile flow blood pumps were not available at the time.(72) 
With the exception of pumpless systemic AV systems, commercial gas exchanger circuits in 
clinical use employ steady flow perfusion. However, over the years there have been studies in 
steady flow systems such as cardiopulmonary bypass that suggest poor perfusion of the renal 
system(73, 74), the myocardium(75), and the cerebral vasculature(76, 77). As a result there has 
been continued study of whether there is a benefit from maintaining pulsatile flow in VA 
attachment modes.(78-83) 
 Shepard, et al. mathematically described the increased perfusion capabilities of pulsatile 
perfusion in terms of energy equivalent pressure according to Equation 1.1.(84) 
Table 1.3: Tradeoffs between vascular access connections.  
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𝐸𝐸𝑃 =
∫𝑓(𝑡)∗𝑝(𝑡)𝑑𝑡
∫𝑓(𝑡)𝑑𝑡
           (1.1) 
Where EEP is the energy equivalent pressure, f(t) is the blood flowrate with time, p(t) is the blood 
pressure with time, and t is time.(84) In steady flow, f(t) and p(t) become constants and the energy 
equivalent pressure is equal to the mean arterial blood pressure. However, in physiologic pulsatile 
flow from the heart the integration yields an EEP approximately 10% greater than with steady 
flow.(85) The higher energy equivalent pressure delivered to the blood results in a stronger driving 
pressure that can in theory perfuse more distant capillary beds.(86) Recently, short 3 hour in vivo 
experiments involving a piglet model of extracorporeal membrane oxygenation (ECMO, described 
in Section 1.3.1) have provided further evidence that pulsatile flow results in increased 
perfusion.(78) In these experiments the test subjects were supported on steady and pulsatile flow, 
and near infrared spectroscopy was used to measure perfusion of the kidneys.(78) After an hour of 
ECMO the pulsatile group showed higher levels of local saturation in the frontal lobes of the 
kidneys than the steady flow group.(78)  
 These recent short term studies and past mathematical descriptions of pulsatile flow yield 
positive results in terms of perfusion. However, additional studies are needed to confirm its benefit, 
and long term tests are needed to study whether the higher shear stresses seen during systole in the 
gas exchanger, stasis in the gas exchanger during diastole, cannulas, and vasculature have 
deleterious effects. Pump technologies have improved and a new ECMO pump has been produced 
in Europe that is capable of reproducing physiologic pulsatile flows in a reliable manner.(79) 
1.2.4 Desired Attributes of Acute and Chronic Extracorporeal Gas Exchange Systems 
 The requirements of gas exchange systems vary depending on the timeframe that they will 
be used. In an acute setting, the gas exchanger only needs to last one to two weeks and the main 
focus is on providing enough gas exchange for a patient to be supported on minimal ventilator 
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settings or without a ventilator entirely.  
 In a patient being treated for chronic respiratory failure the requirements of the gas 
exchanger and system are much more stringent. When bridging a patient to lung transplantation, 
the gas exchanger would ideally be able to last for up to a month or two and limit blood damage 
and activation. When patients require multiple blood transfusions due to blood trauma, immune 
system reactions can result that endanger the patient.(44) Additionally, there have been recent 
studies showing that patients being bridged to lung transplantation benefit from being able to 
perform physical therapy and walking while being bridged.(36, 87-89) As a result, many patients 
may benefit by a gas exchanger and associated system that is compact enough for ambulation. 
 In patients with chronic respiratory disease who will not receive a donor organ, a 
destination therapy gas exchange system has the potential to extend and improve the lives of many 
patients in a manner similar to ventricular assist device use as a destination therapy for chronic 
cardiac failure patients.(51) A destination therapy system must be extremely compact so as to 
allow full ambulation of a patient outside of a hospital. Also the device longevity will need to be 
at least 2 to 3 months, with periodic replacement to allow for treatment over a period of years. It 
also must induce little biochemical response from the body and avoid damaging the blood of the 
patient as repeat transfusions will not be an option for a patient supported for an extended period 
of time outside of a hospital. A summary of the requirements for a gas exchanger for ARF patients, 
CRF bridge to lung transplant patients, and CRF destination therapy patients can be seen in Table 
Table 1.4: Desired attributes for a gas exchange system for ARF, CRF bridge to lung transplant, and 
CRF destination therapy patients.  
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1.4.  
1.3 Current Extracorporeal Gas Exchange Systems 
1.3.1 Extracorporeal Membrane Oxygenation 
 The first extracorporeal gas exchange system to be used for extended period of time outside 
of the operating room was extracorporeal membrane oxygenation (ECMO). ECMO is a complex 
system similar to cardiopulmonary bypass that pulls blood from the body, performs gas exchange 
on the blood, and returns it to the body at flowrates often greater than 4 L/min in adults.(47, 90) A 
basic ECMO circuit consists of a drainage cannula to pull blood from the body, tubing, a sealed 
reservoir, a blood pump, a gas exchanger, a heat exchanger to maintain body temperature at a 
predefined level, a reinfusion cannula to return blood to the body, monitoring equipment, and other 
possible small components, such as bubble traps.(47) Cannulas and/or combination graft cannulas 
are currently used today as vascular connections in ECMO circuits.  
 ECMO is very flexible in its configuration with VV, VA, VAV, and VVA attachment 
modes utilized with either single lumen or dual lumen cannulas. Early success of ECMO mostly 
occurred in in neonatal and pediatric patients, but recently has been successfully used in adult 
patients for both ARF and CRF. The use of ECMO over conventional mechanical ventilation has 
been a matter of argument for decades. However, several recent findings have led to expanded 
ECMO use. First, during the H1N1 flu pandemic, ECMO was successfully used to treat severely 
ill patients that were likely to die without ECMO support.(91)  Second, the CESAR trial compared 
use of ECMO and mechanical ventilation for ARDS patients, showing a benefit of ECMO 
treatment in patients.(92) This study was later criticized for having a control group where doctors 
were allowed to treat as they normally would and thus some did not follow ARDSnet 
recommendation for lung protective mechanical ventilation.(93)  
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 The used of ECMO as a bridge to lung transplantation has seen renewed practice since the 
LAS system for donor lungs shortened waitlist times in 2005. Despite ECMO patients often being 
in a more severe clinical state, several groups of researchers saw similar or better long term 
mortality rates for ECMO bridged patients as ventilator bridged or non-bridged patients.(38, 94-
97) Graft rejection is more prevalent in the ECMO patients than mechanical ventilator patients, 
since there are a large number of transfusions given to ECMO patients and ECMO induces a 
systemic immune response.(94) 
 Despite recent positive results, ECMO is not a perfect treatment option. The ECMO system 
is very complex and expensive, necessitating a very large team to monitor and adjust the 
system.(92) The large number of blood contacting components and the pump used to drive the 
blood cause blood damage, clotting, and systemic immune system activation that can lead to 
damage of organs.(47) Multiple red blood cell (RBC) and platelet transfusions are needed to keep 
up with blood damage and consumption by the system, which can lead to patient deterioration.(98-
100) Although there is large variation between ECMO centers and patients(99), the median daily 
RBC and platelet transfusion requirements 0.16-2 units and 0-3 units, respectively.(98) Larger 
physiologic complications include limb ischemia in VA ECMO (94) and intracranial 
hemorrhage(45, 52, 93). When used in ECMO, the oxygenators have a lifespan limited to 
approximately two to three weeks even with anti-thrombogenic coatings.(101-104) This limited 
device lifespan limits ECMO’s use to bridge to transplantation rather than destination therapy. As 
a bridge to transplantation, ECMO can benefit those patients eligible for lung transplantation. 
However, it does not expand the pool of patients treated since the limiting factor to the number of 
patients treated is the shortage of donor organs. 
Awake and Ambulatory ECMO 
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 New strategies for ECMO used in 
bridging patients to lung transplantation 
include awake and ambulatory ECMO. In 
traditional ECMO, the patient is typically 
sedated and laying down in bed, which 
leads to muscular deconditioning that can 
reduce the chances of survival pre and post 
transplant. In awake ECMO the patient is 
not sedated without ventilator support, 
allowing them to sit up in bed and perform tasks such as eating. When a single dual lumen cannula 
is utilized, the patients can ambulate and perform physical therapy in what is known as ambulatory 
ECMO.(88)  (Figure 1.10) Several studies comparing ambulatory ECMO bridged patients to non-
bridged patients showed equal or improved outcomes in the sicker ambulatory ECMO bridged 
patients.(38, 95, 97)  
1.3.2 Extracorporeal Carbon Dioxide Removal 
 Carbon dioxide removal systems are used to reduce ventilator settings or remove the need 
for a ventilator by providing full or partial carbon dioxide removal for patients with largely 
hypercapnic respiratory failure.(105) However, they typically provide low oxygen exchange due 
to low blood flowrates and/or drainage of systemic arterial blood.(105) These carbon dioxide 
removal systems include arterio-venous carbon dioxide removal (AVCO2R) systems and modified 
VV ECMO (VVCO2R) systems.(105) 
Aterio-Venous Carbon Dioxide Removal 
 One of the most commonly used carbon dioxide removal systems is AVCO2R.(106-110) 
Figure 1.10: A patient walking while being treated 
with ambulatory ECMO. (38) 
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AVCO2R systems consist of a systemic 
arterial drainage cannula, a low resistance 
gas exchanger, and a systemic venous 
reinfusion cannula.(106-110) The pressure 
gradient of the AV cannulation, typically 
from the femoral artery to femoral vein 
(Figure 1.11), induces blood flows of 1-
2.5 L/min through a low resistance gas 
exchanger.(106, 109) This system has 
been successfully utilized in clinical trials 
to reduce the ventilator settings in patients 
with ARDS.(106-110) In CRF patients 
there have been several successful studies using the Novalung iLA in an AVCO2R configuration 
to bridge a small number of patients to lung transplantation while either reducing ventilator settings 
(n=12, 83% survived to transplant, 80% post transplant 1 year survival) or removing the patient 
from the ventilator (n=2, 100% survival to transplant).(111, 112) However, AVCO2R is not 
without its complications. One of the major risks of AVCO2R is limb ischemia for the cannulated 
limbs, as the peripheral arterial supply is shunted towards the gas exchanger.(106, 108) This 
systemic AV shunt also only allows for very minimal oxygenation (112) and can lead to 
hemodynamic instability. (58) The pumpless circuit avoids some blood damage, but an arterial to 
venous pressure gradient of at least 60-80 mmHg is needed to maintain effective flow through the 
circuit, so patients with poor cardiac function cannot be treated effectively with AVCO2R.(106) 
The longevity of the Novalung ILA is also very short with the devices needing to be changed out 
Figure 1.11: A Novalung iLA gas exchanger used in 
a femoral artery to femoral vein AVCO2R 
configuration. (42) 
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an average of every 10 days due to clot formation despite antithrombogenic coatings.(112) Laslty, 
the femoral cannulation typically used prevents any ambulation of a patient. As a result of these 
issues, the patient population who could use AVCO2R is limited. 
Veno-Venous Carbon Dioxide Removal 
 VVCO2R is a method of CO2 removal that spun off from VV ECMO that removes carbon 
dioxide from the blood using lower blood flow rates than traditional ECMO.(105) VVCO2R 
cannulation sites are the same as VV ECMO, but the circuit can vary in its complexity.(105) One 
of the simplest systems the iLA Activve system, which uses a console that combines a Novalung 
iLA gas exchanger and a centrifugal blood pump into one unit.(105, 113, 114) This system is a 
simplified ECMO system that can be used with flowrates as low as 0.5 L/min for removing CO2 
and as high as 4.5 L/min for ECMO.(105, 113) In a larger study of an early VVCO2R system that 
utilized flow rates of 2 L/min, similar complications to traditional VV ECMO were found; 
bleeding, clotting, and blood product consumption.(115)  
 An ultralow flowrate version of VVCO2R is known as respiratory dialysis has been gaining 
some adoption.(105, 116-119) Respiratory dialysis utilizes a dual lumen cannula that drains from 
the superior vena cava and reinfuses blood 
into the right atrium accessed through 
either the femoral or jugular vein.(116-
119)  The Hemolung gas exchanger used 
in respiratory dialysis combines a 
centrifugal pump and gas exchanger into a 
single unit (Figure 1.12).(116-119) The 
mixing induced by the pumping portion of 
Figure 1.12: A cross-sectional view of the Hemolung 
gas exchanger-pump used in respiratory dialysis 
VVCO2R. (116) 
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the device enhances gas exchange, allowing for the lower flowrates on the order of 400-600 
mL/min.(116-119) A preliminary clinical trial in acute exacerbation of COPD showed promise 
with most patients either being removed from ventilation, avoiding ventilation, or having a 
reduction in ventilator settings.(118) However, the low blood flow rate results in very little 
oxygenation of the blood in comparison to other VVCO2R systems.  
1.3.3 Thoracic Artificial Lungs 
 A thoracic artificial lung (TAL) is a pumpless pulmonary gas exchange circuit consisting 
of a pulmonary arterial drainage (typically pulmonary artery), a gas exchanger, and a pulmonary 
venous (right atrium) or arterial (pulmonary artery) reinfusion. In a pulmonary artery to left atrium 
(PA-LA) configuration the gas exchanger is placed in parallel to the natural lungs in a pulmonary 
AV attachment, while the pulmonary artery to pulmonary artery (PA-PA) configuration places the 
gas exchanger in series.(Figure 1.13) Both configurations allow for oxygenation and carbon 
dioxide removal while the pumping through the gas exchanger is driven by the pumping of the 
right heart. An in series (PA-PA) connection has a high total resistance, but it has the benefit of 
retaining the lungs 
natural embolus 
filtration function and 
metabolic 
functions.(44, 120, 
121) In parallel 
configurations have 
very low resistance and 
can unload the right Figure 1.13: Left: A TAL in a PA-LA configuration. Right: A TAL in a 
PA-PA configuration. (44) 
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heart in cases of pulmonary hypertension, however there is some risk for embolus migration to the 
arterial side of circulation and a reduction in the metabolic functions of the native lungs.(44, 120, 
121) In either configuration, the gas exchanger circuit must have a low resistance often 
necessitating the use of a large bore synthetic graft assembly and an ultra-low resistance gas 
exchanger. (65, 66, 68, 122-126)  
  TALs have advantages and disadvantages in their use. The simple, compact pumpless 
circuit allows for a patient to ambulate during treatment and avoids a blood damaging pump. 
Moreover, the blood flowrate and therefore gas exchange is controlled by the patient’s own 
physiology. Additionally, the central grafting or cannulation attachment mode eliminates the risk 
of limb ischemia posed in peripheral cannulation. However, this central attachment requires a 
highly invasive thoracotomy for attachment and removal of the system, effectively eliminating its 
use as an ARF treatment. TALs are also in their infancy on comparison to other extracorporeal gas 
exchange systems.  
 Commercially available gas exchangers such as the Novalung have been used in a TAL 
configuration for a very limited number of cases. They were fairly successful in these small number 
of patients with 10 of the 11 patients surviving to transplantation.(59, 61, 62, 127) However they 
were hampered by a relatively high resistance, low gas exchange, and a device longevity that 
required replacement every two to three weeks despite anti-thrombogenic coatings.  
 There are some specifically designed thoracic artificial lungs (TAL) that are being tested 
in animals as a long term bridge to lung transplantation.(65, 66, 68, 122, 124-126) The MC3 
Biolung has shown promise in animal studies with a low resistance of 1.8 mmHg/(L/min) and a 
device longevity of approximately 9.5 days without anti-thrombogenic coatings. The cTAL 
discussed in later chapters is also being developed as long term TAL with an ultra-low benchtop 
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resistance of 0.5 mmHg/(L/min). However, none of these experimental devices are currently 
available on the commercial market. TALs may one day be successful bridge to lung transplant or 
destination therapy device due to their simple circuit, but commercially available gas exchangers 
with an extended longevity and low resistance will be needed first.  
1.4 Experimental Gas Exchangers 
 Three gas exchangers were studied for this work and will be discussed in the following 
chapters; the compact cardiopulmonary support device (CCSD), the compliant thoracic artificial 
lung (cTAL), and the pulmonary assist device (PAD). (Table 1.5) The compact pulmonary support 
device is a gas exchanger that is designed to provide cardiac and full respiratory support as a 
replacement for VA ECMO. The CCSD integrates a pulsatile blood pump, compliant housing gas 
exchanger, and heat exchanger into a single unit, allowing for patient ambulation and a reduction 
in blood contacting surface area. The compliant thoracic artificial lung is a TAL designed with a 
compliant housing that dampens out flow pulses from the right heart to reduce blood flow 
impedance and unload the right heart. The cTAL allows for a high level of patient mobility, and 
can provide full respiratory support for patient. The pulmonary assist device is a compact, modular 
gas exchanger system designed to provide partial respiratory support. Each PAD gas exchange 
module is composed of a solid housing, and is very compact to allow for a high level of patient 
Table 1.5: A summary of the attributes of the gas exchangers that were designed and tested as 
discussed in subsequent chapters.  
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ambulation. When paired with a ventricular assist device quality pump, one or two gas exchange 
modules can be attached in a variety of pumped configurations. Additionally, the low resistance 
of the PAD will allow it to function in a pumpless TAL PA-LA configurations. A summary of the 
basic attributes of all gas exchangers discussed in future chapters can be seen in Table 1.5.  
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Chapter 2:  Compact Cardiopulmonary Support Device 
2.1 Introduction 
 Extracorporeal membrane oxygenation (ECMO) is a treatment where blood is pumped 
from the large vessels of the body through a circuit that removes carbon dioxide from the blood, 
adds oxygen to the blood, and returns the blood to the large vessels of the body. A large ECMO 
circuit (Figure 2.1) (1) 
consists of a centrifugal or 
roller pump, heat 
exchanger, gas exchanger, 
cannulas for the vessels, a 
blood reservoir, tubing, and 
monitoring equipment. 
ECMO systems are large 
with multiple devices with 
large resistances. This leads 
to excessive heat loss, large amounts of blood damage, limited ambulation, and a high level of 
required monitoring. Moreover, current ECMO systems employ steady blood flow. As discussed 
in Chapter 1, this steady blood flow regime is a deviation from the physiologic pulsatile flow 
regime, and there have been studies that suggest that poor organ perfusion results.(2-7) 
 Thoracic artificial lungs (TAL) have been proposed as replacements for ECMO, but they 
typically require a highly invasive thoracotomy.(8-11) As a result of a large surgical trauma to the  
Figure 2.1: A large pediatric ECMO circuit. (1) 
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patient when a TAL is employed, it is not an option for patients who only require short term 
support. The compact cardiopulmonary assist device (CCSD) has been designed as a more 
compact replacement for ECMO that also produces a more physiologically similar pulsatile flow 
regime. The CCSD combines the heat exchanger, pump, and gas exchanger into one unit that is 
able to support a patient’s gas exchange needs while theoretically providing better end organ 
perfusion when used in a VA attachment mode.(12, 13) The combining of multiple components 
into a single component should reduce heat exchange requirements, enhance patient mobility, 
reduce shear induced blood trauma, and reduce the level of monitoring required. Early prototype 
CCSD systems failed to produce blood flowrates adequate for supporting a patient. This study 
focuses on designing an improved CCSD system capable of delivering flowrates of at least 4 L/min 
to a patient.  
2.2 Methods  
2.2.1 CCSD System Description 
 The CCSD system is composed of 6 components (Figure 2.2); the gas exchange unit, the 
gas exchange enclosure, a pulsatile blood pump (Harvard Apparatus, Holliston, MA), a fluid 
warmer, and tubing for blood and saline. The CCSD contains two fluid systems separated by the 
flexible wall of the gas exchanger; the saline system and the blood system. Blood flows from the 
patient’s large blood vessel(s) through a cannula, through a one way inlet valve in the gas 
exchanger, through the fiber bundle of gas exchanger where gas exchange occurs, through a one 
way outlet valve, back through a cannula, and into the patient’s large blood vessel(s). The CCSD 
system functions in a cycle very similar to the cardiac cycle as seen in Figure 2.3. Saline is pumped 
from a pulsatile pump through a fluid warmer and into the CCSD rigid outer enclosure. As saline 
is pumped into the rigid enclosure, the pressure builds up inside the enclosure, and in turn the 
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blood inside the gas exchanger is also 
pressurized through the flexible wall 
of the gas exchanger.  (Figure 2.3 B) 
Once the enclosure pressure exceeds 
the opening pressure of the gas 
exchanger’s blood outlet valve, the 
housing of the gas exchanger 
compresses towards the fiber bundle 
and blood is pumped to the patient’s 
venous or arterial 
vasculature.(Figure 2.3 C) At the 
end of systole the pressure gradient 
between the enclosure and the blood 
outside the outlet valve is equalized, 
and the blood outlet valve closes into 
its natural position.(Figure 2.3 D) As 
the pump cycles back, saline is 
pumped out of the rigid enclosure 
creating a negative pressure in the 
enclosure and on the blood inside the 
gas exchanger.(Figure 2.3 E) Once 
the enclosure pressure drops below 
the blood inlet valve opening pressure, the inlet valve opens.  The housing of the gas exchanger  
 
Figure 2.2: Top: The original prototype CCSD 
enclosure and gas exchanger assembly.  Middle: The 
original prototype CCSD external ball valves.  Bottom: 
The original prototype CCSD Harvard pulsatile pump. 
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Figure 2.3: Pumping cycle of the CCSD. 
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expands away from the fiber bundle and pulls venous blood from the patient. (Figure 2.3 F) At 
the end of diastole, the enclosure pressure is equalized and the blood inlet valve closes back to its 
natural position to start the cycle again.(Figure 2.3 A) Since the saline entering the outer enclosure 
is warmed, heat is also added to the blood through the wall of the gas exchanger housing. This 
process repeats and cyclically draws blood from the patient, exchanges gasses with the blood, heats 
the blood, and pumps the blood back to the patient.  
Early CCSD Prototype Shortcomings 
 Early prototype CCSD systems failed to produce adequate blood flowrates with cannula 
attachment due to excessive flexure of the CCSD enclosure and poor valve performance. The 
original prototype system shown in Figure 2.2 employed external ball valves designed for non-
medical applications (Figure 2.2 Middle) and a thin walled enclosure susceptible to stroke loss 
from flexure of the housing at high positive and negative pressures. Additionally, the blood conduit 
connectors attached to the enclosure had a tendency to leak during operation. An improved CCSD 
system was designed and tested to improve on these shortcomings as well as integrate more 
biocompatible valves into the gas exchange device itself. The development of the improved CCSD 
system is described in the following sections. The design and testing of the CCSD was broken 
down into three main sections; design of a more rigid housing with integrated blood conduit 
connections, design of integrated biocompatible valves, and testing of the overall CCSD system. 
2.2.2 CCSD Enclosure Design and FEA Modeling 
 Based upon estimates from testing of the first generation CCSD system, the outer rigid 
enclosure of the device may experience pressures as high as 300 mmHg and as low as -200 mmHg. 
Flexing of the housing during pumping of the pulsatile saline pump leads to a loss in stroke volume 
and reduces pumping efficiency of the system. An enclosure flexure stroke loss of 10 mL as the 
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pump cycled from -200 mmHg to 300 
mmHg was chosen as the maximum 
acceptable stroke loss when designing the 
enclosure. An initial enclosure design was 
drafted in Solidworks (Dassault Systems, 
Velizy-Villacoublay Cedexx, France) and 
was composed of two halves that bolt 
together encapsulate the gas exchanger. In 
order to accommodate the blood inlet and 
outlet ports, the two halves of the housing 
were unequal in thickness. The thicker half 
referred to as the “large half” included 
integrated blood inlet, blood outlet, gas 
inlet, and gas outlet ports.(Figure 2.4) The 
thinner half referred to as the “small half” 
included a saline port.(Figure 2.5) CAD 
models of this initial enclosure design were produced with wall thicknesses of 0.5, 0.75, 1, and 
1.25 inches.  
 Ansys Mechanical finite element solver and Ansys Results modules (ANSYS Inc., 
Canonsburg, PA) were used to estimate the stroke volume loss due to enclosure flexure for 
enclosure designs with different wall thicknesses. The large half and small half of each enclosure 
were modeled separately and the volume stroke loss for each half were summed to yield a total 
volume loss for the enclosure. In order to capture the volume loss over one pressure cycle, the 
Figure 2.4:  Large half of CCSD enclosure used 
in finite element modeling. 
Figure 2.5:  Small half of CCSD enclosure used 
in finite element modeling. 
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maximum positive and negative pressures 
of 300 mmHg and -200 mmHg were 
modeled for the entire enclosure and the 
results were summed to yield a total stroke 
volume loss.  
Geometry and Meshing 
 The Solidworks part file was 
converted to an .igs file and was imported 
into the Ansys Static Structural module. 
The Ansys Meshing program was used to 
create a free mesh that discretized the 
geometry finite element analysis. A global 
grid spacing was specified for the entire 
body, and a refined face grid spacing was 
imposed for all small and/or curved faces. A named selection of “inside faces” was created on all 
inside surfaces of the enclosure for later load creation.(Figures 2.6 & 2.7) In order to perform a 
grid independence study, a refined mesh was also created with spacings half the size of the original 
grid spacings. The original and refined grid spacings are listed in Table 2.1, and sample meshes 
can be seen in Figures 2.8 and 2.9. The total stroke volume loss was calculated for the two grid 
Figure 2.6:  Inside faces of the large half of 
CCSD Enclosure. 
Figure 2.7:  Inside faces of the small half of 
CCSD Enclosure. 
Table 2.1: The grid spacings used in FEA modeling.  
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spacings and compared to confirm that 
further refinement the mesh results in 
minimal changes in the results. Mesh was 
classified as “grid independent” if the 
results varied by less than 5%. The grid 
dependence study was performed for the 
enclosure design with a wall thickness of 
0.5 inches since the most deflection will be 
observed in this case and will require the 
most refined grid.  
Finite Element Analysis 
 The Ansys Static Structural module 
was utilized to setup the finite element 
solver. The finite element analysis was performed using cell cast acrylic and Type 1 PVC. The 
Cell cast Acrylic was modeled using a density of 1185 
𝑘𝑔
𝑚3
, a poisson’s ratio of 0.37, and a Young’s 
modulus of 3.05 GPa. Type 1 PVC was modeled using a density of 1400 
𝑘𝑔
𝑚3
, a poisson’s ratio of 
0.41, and a Young’s modulus of 2.90 GPa. Load and boundary conditions were imposed to 
simulate pressurization of the enclosure at the systolic and diastolic pressures of 300 mmHg and 
negative 200 mmHg, respectively. The part was fixed in three dimensional space by imposing two 
sets of boundary conditions. The back outside corners of the enclosure were fixed in the x and y 
directions since they will experience minimal deformations in those directions during 
pressurization.(Figure 2.10) The sealing face was fixed in the z direction since the clamping of 
the two halves of the enclosure together will only allow for very little deformation in this direction 
Figure 2.8: Meshes of the large half of the 
enclosure. Top: Course Grid.  Bottom: Fine Grid 
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since the clamping bolts will take the load 
of pressurization in the z direction at this 
face.(Figure 2.11) The Ansys Mechanical 
finite element solver was run and results 
were output for post processing.  
Post Processing 
 The Ansys Results module was 
utilized to estimate the total stroke volume 
loss due to enclosure flexure. Clip planes 
were used to reduce the deformed surface 
mesh to the inside faces of each enclosure 
half as seen in Figures 2.12 and 2.13. 
Clipping of the mesh resulted in extra 
surfaces near inlet/outlet port holes. 
However any mesh displacement on these 
holes will be offset to some extent by the 
lack of mesh on the face of port holes, and 
will provide sufficiently accurate results 
for the purpose of choosing a proper wall 
thickness for the enclosure design. The 
area weighted integral of mesh 
deformation was calculated over the clipped surface mesh to yield an estimate of the change in 
volume of the inside of each enclosure half. The summation of the volume change of each 
Figure 2.9:  Meshes of the Small half of the 
enclosure. Top: Course Grid.  Bottom: Fine Grid 
Figure 2.10:  Constrained corners of the large 
enclosure half. 
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enclosure half yielded the total volume 
change for the enclosure at the given 
pressure. This procedure was performed at 
the diastolic pressure of negative 200 
mmHg and the systolic pressure of positive 
300 mmHg. The absolute value of change 
in enclosure volume for systolic and 
diastolic cases were summed to yield the 
total stroke volume loss due to enclosure 
flexure at a given wall thickness.  
Final Design FEA  
 After finding an appropriate wall 
thickness through the use of finite element 
analysis a final enclosure design was 
produced in Solidworks. As can be seen in 
Figures 2.14 and 2.15, the final design 
integrated the device holding/ anti-
shunting region of the enclosure into the 
wall to increase wall thickness without 
adding material costs and to reduce 
machining costs. Prior to machining, the 
above finite element analysis methods 
were utilized to produce a final estimate of total stroke volume loss.  
Figure 2.11:  Constrained face of the large 
enclosure half. 
Figure 2.12:  Clipped surfaces used in post 
processing for the large enclosure half. 
Figure 2.13:  Clipped surfaces used in post 
processing for the small enclosure half. 
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2.2.3 CCSD Enclosure Benchtop Testing 
 After fabrication of the CCSD 
enclosure it was tested for total stroke 
volume loss. All ports were clamped off 
with the exception of the two de-
airing/pressure monitoring luer lock ports. 
The enclosure was bolted together and de-
aired through the two luer lock ports. A 
syringe pump () filled with saline was 
attached to one enclosure luer port, and a 
Transpac IV pressure transducer (ICU 
Medical Inc, San Clemente, CA) was 
attached to the other luer lock port. A 
Biopac MP150 data acquisition system 
(Biopac Systems Inc, Goleta, CA) was 
used to record pressure inside the enclosure in real time. A syringe pump (New Era Pump Systems 
Inc, Farmingdale, NY) was used to inject fluid volume into the enclosure in small increments 
resulting in incremental pressure increases in the enclosure.  Once a pressure of positive 300 
mmHg was obtained the volume injected into the enclosure was recorded. This procedure was 
repeated with the syringe pump withdrawing fluid from the enclosure rather than injecting in order 
to obtain a negative pressure of 200 mmHg. Equation 2.1 was utilized to correct for small 
deviations from the target pressures. 
     𝑉𝑐𝑜𝑟 = 𝑉𝑖𝑛𝑗 ∗
𝑃𝑡𝑎𝑟
𝑃𝑖𝑛𝑗
,                                       (2.1) 
Figure 2.14:  Large Half of the final CCSD 
enclosure design. 
Figure 2.15:  Large Half of the final CCSD 
enclosure design. 
50 
 
where Vcor is the corrected volume injected, Vinj is the actual volume injected during the 
experiment, Ptar is the target pressure for the experiment, and Pinj is the actual pressure attained 
during the experiment. For example, an actual pressure and injected volume of 279.2 mmHg and 
2.60 mL, respectively, the corrected volume was 2.62 mL. The corrected volume injected to 
increase the pressure to 300 mmHg and the corrected volume withdrawn to decrease the pressure 
to negative 200 mmHg were summed to yield a total stroke volume loss due to enclosure flexure. 
The enclosure was disassembled, reassembled, and tested three times (n=3). 
2.2.4 CCSD Valve Description and Fabrication 
 The first feasibility prototype of the CCSD used external ball valves located outside of the 
CCSD enclosure to maintain uni-directional flow. However, these valves are designed for non-
medical use and would likely cause damage to the blood and result in thrombus and subsequent 
emboli shedding in the valve. Additionally, these external valves add to system complexity and 
bulk. As a result, more biocompatible valves were desired that would integrate into the gas 
exchange unit’s blood inlet and outlet conduits. In order to allow efficient pumping and blood 
damage these valves needed to have a resistance below 1 mmHg/(L/min) and a regurgitant fraction 
below 10%.  
 The flexible housing of the gas exchanger was composed of Biospan polyurethane (DSM, 
Exton, PA), and the valves were fabricated from the same material. A tri-leaflet design was chosen 
to partially mimic the mitral valve of the heart. Previous attempts of fabricating polymeric trileaflet 
heart valves have been largely unsuccessful because they utilized either single sheets of polymer 
folded and sutured into a mitral valve like configuration or individual pieces of polymer sutured 
onto a ring to form valve leaflets. Repeated cycling of sutured polymers eventually leads to tearing 
at or near the sutures.  
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 The valve ring and leaflet for the CCSD valve are molded as a single piece of polyurethane 
to enhance durability of the valve. A detailed description of the fabrication process can be seen in 
Appendix A. A basic description of the valve fabrication process are as follows. A Teflon mold 
of the valve is dipped into Biospan polyurethane and placed on a rotisserie for drying. After at 
least 2 hours of drying, the valve is re-dipped and dried multiple times to attain the desired valve 
leaflet thickness. The seams between the leaves are then cut to form three separate leaves. The 
valve is then epoxied into either the CCSD blood inlet or outlet conduit for CCSD system testing 
or into a separate Biospan tube for in vitro valve testing. The outside of the valve is reinforced 
with a polycarbonate or PVC tube to prevent valve collapse during application of negative 
pressures.  
2.2.5 CCSD Valve Benchtop Testing  
 Prior to testing the CCSD system with integrated Biospan trileaflet valves, valves of 
different diameters and leaflet thicknesses were tested for optimal resistance and regurgitation 
characteristics. Valves were fabricated with diameters of 0.688, 1, 1.125, and 1.25 inches and 
leaflet thicknesses of approximately 0.040 and 0.060 inches. The 0.688 inch diameter was also 
manufactured with a leaflet thickness of 0.020 inches. Each of these valves was tested in a test 
circuit consisting of a pulsatile pump, an industrial ball valve, a valve to be tested, and a 
reservoir.(Figure 2.16) The circuit was filled with glycerol having a viscosity of 3.0 cP to simulate 
blood. Transpac IV pressure transducers were attached immediately before and after the valve to 
measure pressure drop, and a 5/8 inch PXL tubing flow probe (Transonic Systems Inc, Ithaca, NY) 
was placed upstream of the valve to measure volume flow rate. Pressure and flow data was 
acquired using a Biopac MP150 data acquisition system. 
 After circuit assembly the valves were tested at a variety of flowrates, pump cycle rates, 
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and systolic to diastolic ratios by altering the settings on the Harvard pulsatile pump. Each valve 
design was tested with three valves (n=3) at flowrates of 3 and 5 L/min, pump cycle rates of 80 
and 100 bpm, and a % systolic time of 33%. Data from the flow probe and pressure transducers 
were analyzed to yield resistance through the valve and regurgitant fraction of the valve. Raw data 
from five cycles of the pump were manually segregated from the data set and used in subsequent 
calculations. Resistance of the valve was calculated using Equation 2.2. 
𝑅𝑒𝑠 =
𝑃𝑝𝑜𝑠𝑡−𝑃𝑝𝑜𝑠𝑡
𝑄?̇?
     (2.2) 
Where Res is the valve resistance, Ppost is the time averaged post valve pressure during forward 
flow, Ppre is the time averaged pre valve pressure during forward flow, and Qf is the time averaged 
flowrate during forward flow. Regurgitant fraction of the valve was calculated from Equation 2.3.  
𝑅𝐹 =
𝑄?̇?
𝑄?̇?
       (2.3) 
Figure 2.16:  CCSD valve in vitro testing circuit. 
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Where RF is the regurgitant fraction, Q̇r is the time averaged reversed flowrate, and Q̇t is the time 
averaged flowrate for all flow directions. 
2.2.6 CCSD System In vitro Fluid Dynamics Testing 
 After finalizing the valve size of the CCSD system, the gas exchange device was fabricated 
and the system was assembled for initial in vitro fluid dynamics testing to characterize the 
regurgitant fraction of the system, pumping flowrate capabilities, and enclosure pressures. The in 
vitro testing of the CCSD was performed in three stages. In the first stage the first prototyped 
CCSD systems utilizing 0.040” leaflet thickness valves were tested for regurgitant fraction and 
enclosure driving pressures. In the second stage of the testing the CCSD was fabricated with 
thicker 0.060” leaflet valves and tested with the same end goals as stage 1 since the 0.040” leaflet 
valves were not sufficiently stiff.  
 In the third stage of testing, multiple priming methods were employed with the goal of 
reducing the magnitude of negative pressures inside the enclosure during pumping of the CCSD. 
These priming methods were performed to pre-stretch the housing of the CCSD gas exchanger and 
increase the amount of time in the 
unfurling stage of the housing. As 
the housing of the CCSD and similar 
cTAL gas exchangers are filled with 
fluid their expansion undergoes two 
phases; unfurling and stretching. In 
the unfurling stage where the 
housing is expanding with little 
stretching, the housing is very 
Figure 2.17:  Compliance of the cTAL with high 
pressure representing the stretching phase and low 
pressure representing the unfurling stage. (8)  
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compliant with large changes in volume occurring with little change in pressure.(Figure 2.17) (9)  
However, once the housing unfurls completely it enters the stretching phase where any increases 
in volume are due to low compliance housing stretching and are in turn accompanied by large 
changes in pressure.(Figure 2.17) (9) In the altered priming methods maximizing the time in the 
unfurling stage has the potential to reduce the amount of work performed by the pump to pull fluid 
into the gas exchanger housing, thereby reducing negative enclosure pressures. 
CCSD System Fabrication 
 The gas exchanger was fabricated using methods described in Appendix B. A basic outline 
of the process are as follows. The flexible housing of the gas exchanger was dip cast in Biospan 
polyurethane in a series of layers to build up a wall thickness. A fiber bundle composed of 
Membrana 300 micron outside diameter microporous polypropylene fibers (Membrana GmbH, 
Wuppertal, Germany) was wound around a polycarbonate core. The bundle and housing were 
centrifuge potted together using polyurethane. The potted section was partially sliced off to open 
the lumen of the gas exchange fibers, and acrylic gas caps were attached to serve as gas distribution 
manifolds. The trileaflet valves were epoxied into the inside of the blood inlet and outlet conduits. 
A stiff reinforcement tube was epoxied onto the outside of the blood inlet and outlet conduits to 
prevent valve performance losses from crushing of the conduits. The gas exchanger was inserted 
into the rigid acrylic enclosure and all tubing was secured to the enclosure’s integrated connectors 
with zip ties. Outside of the enclosure, the blood inlet and outlet conduits were gradually stepped 
down in diameter until the final tubing size of 3/8 inch inner diameter tubing was attained. 
CCSD System In vitro Experimental Setup 
 The in vitro testing setup (Figure 2.18) consisted of the CCSD assembly, a Harvard 
pulsatile pump for controlling CCSD pumping, a glycerol reservoir, and optional cannulas (32/40 
55 
 
Fr). Initial tests of the CCSD system in Stage 1 did not utilize cannulas with cannulas being added 
in later experiments to simulate in vivo tests. The gas exchange unit and blood conduits were 
primed with a 3.0 cP glycerol solution to simulate blood, and the enclosure and pulsatile pump 
were primed with water as the pumping fluid medium. Pressure transducers were connected on the 
enclosure pressure port to measure enclosure pressure, and immediately before and after the CCSD 
gas exchanger to measure inlet and outlet conduit pressures. A 5/8 inch PXL tubing flow probe 
was attached downstream of the gas exchanger to measure flowrate and regurgitant fraction. All 
data was recorded with a MP150 Biopac data acquisition system and analyzed in Microsoft Excel 
(Microsoft, Redmond, WA). The pulsatile pump was used to control the pumping rate, systolic to 
diastolic ratio, and volume flowrate. The reservoir was placed at different levels to simulate 
different positioning of the device relative to the patient. The controls on the pulsatile pump were 
adjusted to attain the target flow conditions. If significant amounts of air were pulled into the 
system as flowrate increased, the device was de-aired in preparation for the next test condition. 
Regurgitant fraction was calculated from Equation 2.3. 
CCSD System Priming 
 During priming of the CCSD, in the stage 1 and stage 2 in vitro testing of the CCSD system, 
the CCSD was primed as follows. First the gas exchanger unit was placed into the CCSD enclosure 
Figure 2.18:  The CCSD system in vitro testing circuit. 
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with the blood conduits facing vertically and filled with glycerol up until the first step down in 
tubing size. Gas bubbles were removed from the device and the tubing was clamped before 
returning the device to the horizontal position. The enclosure was then sealed and the pump head 
was returned to its fully retracted position. The enclosure, pump tubing, and pump head were filled 
with water and de-aired. The second tubing connection of the pulsatile pump was unused, so tubing 
was attached and clamped off to prevent any flow through this connection. The remaining blood 
conduit tubing was filled with glycerol, inserted to the glycerol reservoir, and the blood conduit 
tubing clamps were removed. 
  In stage 3 in vitro testing of the CCSD system, six priming methods were employed in an 
attempt to increase the amount of time in the housing unfurling stage and reduce the magnitude of 
internal negative pressures in the CCSD enclosure. Of these 6 methods, the method resulting in 
the lowest magnitudes of negative enclosure pressure is presented. The gas exchanger was placed 
with the blood conduits facing vertically and filled with glycerol up until the first step down in 
tubing size. Gas bubbles were removed from the device and the tubing was clamped before 
returning the device to the horizontal position. The enclosure was then sealed in preparation for 
enclosure priming. The stroke volume setting of the pulsatile pump was set to its 100% position 
and the piston head was retracted to its fully retracted position. A hand pump sphygmomanometer 
Table 2.2:  The testing conditions for Stage 1 in vitro CCSD pumping experiments. 
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(Welch Allyn, Skaneateles, NY) was attached to the blood inlet conduit and was used to pressurize 
the gas exchanger to 20 mmHg. The enclosure and pump head were primed with water and de-
aired before removing the sphygmomanometer. The remaining blood conduit tubing and cannulas 
were primed with glycerol and inserted into the glycerol reservoir. Lastly, the blood conduits were 
then unclamped to complete priming.  
CCSD System In vitro Test Conditions 
 During Stage 1, the CCSD system with 0.040” leaflet valves was tested without cannulas 
at the conditions listed in Table 2.2. When the glycerol reservoir was in its raised position the 
reservoir was raised so that the surface level of the glycerol was 30.2 inches higher than the center 
of the gas exchanger to simulate use with the CCSD on a low cart bedside to a patient. When the 
reservoir was not in its raised position the glycerol surface was 3.7 inches higher than the center 
of the gas exchanger to simulate the system used at bed level. During Stage 2, the CCSD system 
Table 2.3:  The testing conditions for Stage 2 in vitro CCSD pumping experiments. 
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with 0.060” leaflet valves was tested with and without cannulas at the conditions listed in Table 
2.3.  During Stage 3, the CCSD system with 0.060” leaftlet valves and an altered priming method 
was tested with cannulas at the conditions listed in Table 2.4.  
2.3 Results 
2.3.1 CCSD Enclosure Modeling 
 The CCSD enclosure was modeled using finite element analysis to determine the wall 
thickness necessary to reduce stroke volume losses due to enclosure flexure to below 10 mL. A 
sample band plot of mesh deformation (Figure 2.19) shows that the largest areas of enclosure 
deformation occurred at the sealing edges of the long sidewalls of the large enclosure half. A plot 
of total stroke volume as a function of wall thickness for acrylic and PVC enclosures can be seen 
in Figure 2.20. As the wall thickness increases above 1 inch, the volume losses reduce 
exponentially to a point were further increases in wall thickness yield only small changes in stroke 
volume loss. The stiffer acrylic enclosure yielded slightly lower total stroke volume losses when 
compared to the PVC enclosures. The final enclosure design had a side wall thickness of 1.125 
inches and was machined from acrylic. The final enclosure design yielded a total stroke volume 
loss of 5.84 mL predicted by finite element analysis.  
2.3.2 CCSD Enclosure Benchtop Testing 
 Benchtop testing of the final machined enclosure was performed to attain the actual 
Table 2.4:  The testing conditions for Stage 3 in vitro CCSD pumping experiments. 
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physical losses of 
volume during CCSD 
operation. The volume 
loss due to enclosure 
flexure for systole, 
diastole, and the entire 
stroke can be seen in 
Table 2.5. The total 
stroke volume loss 
due to enclosure 
flexure for the final 
machined enclosure 
was 4.707 ± 0.257 mL.  
2.3.3 CCSD Valve 
Benchtop Testing  
 The CCSD 
valves were tested in a 
benchtop system to 
characterize the regurgitation and resistance of valves with diameters ranging from 0.688 to 1.25 
inches and leaflet thicknesses ranging from 0.020 to 0.060 inches. The only diameter valve tested 
with a leaflet thickness of 0.020 inches was the 0.688 diameter valve since it was not robust enough 
to prevent complete valve leaflet reversal and subsequent large regurgitant fractions. When valve 
leaflet reversal occurred cavitation occurred at the valve and gas bubbles were generated in the 
Figure 2.19:  Displacement band plots.  Top: Large enclosure half.  
Bottom: Small enclosure half. 
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glycerol solution. The valves were 
fabricated and tested in the 
following order: 0.688 inch 
diameter, 1 inch diameter, 1.25 inch 
diameter and 1.125 inch diameter.  
The valve resistance as a function of 
valve diameter for flowrates of 3 and 
5 L/min can be seen in Figures 2.21 
and 2.22, respectively, for pulse 
rates of 80 and 100 bpm, and leaflet thicknesses of 0.040 and 0.060 inches. The regurgitant fraction 
as a function of valve diameter for flowrates of 3 and 5 L/min can be seen in Figures 2.23 and 
2.24, respectively, for pulse rates of 80 and 100 bpm, and leaflet thicknesses of 0.040 and 0.060 
inches.  
2.3.4 CCSD System In Vitro Fluid Dynamics Testing  
 The attained flowrate, attained pulse rate, regurgitant fraction, peak positive enclosure 
pressure and peak negative enclosure pressure are summarized in Table 2.6 for all stage 1 in vitro 
testing conditions using a valve leaflet thickness of 0.040.” In general magnitudes of peak pressure 
increased with increasing flowrate and pulse rate, and regurgitant fraction increased with 
increasing flowrate. Raising the reservoir raised the magnitude of the peak positive enclosure 
Figure 2.20:  Total flexural stroke loss for pvc and 
acrylic enclosures as a function of wall thickness. 
Table 2.5:  Flexural stroke volume losses during in vitro testing of the final enclosure design.  
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pressure but lowered the magnitude 
of the peak negative pressure. High 
regurgitant fractions and large 
magnitude enclosure pressure 
magnitudes were seen at all test 
conditions with 2 L/min glycerol 
flow rates. As the stroke volume 
was adjusted upwards to move from 
2 L/min to 4 L/min of glycerol 
flowrate, complete valve reversal 
occurred resulting in high 
regurgitant fractions, a drop in 
flowrate, and cavitation around the 
valves. The high regurgitant 
fractions and high magnitude peak 
pressures are evident in Figures 
2.25 and 2.26 for the 2 L/min, 80 
bpm and the 4 L/min, 100 bpm non-
raised reservoir cases, respectively.  
 In Stage 2 of the in vitro testing of the CCSD system, the gas exchangers were built with 
thicker valves that had a leaflet thickness of 0.060 inches. The attained flowrate, attained pulse 
rate, regurgitant fraction, peak positive enclosure pressure and peak negative enclosure pressure 
are summarized in Table 2.7 for all stage 2 in vitro testing conditions The first round of tests 
Figure 2.21:  CCSD valve in vitro testing resistance 
results at 3 L/min glycerol flowrate. 
Figure 2.22:  CCSD valve in vitro testing resistance 
fraction results at 5 L/min glycerol flowrate. 
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utilizing no cannulas, a raised 
reservoir, and a % systolic time of 
33% were successful in attaining 
flowrates of 4 L/min without 
significant valve reversal. As can be 
seen in Tables 2.6 and 2.7, the 
thicker valved stage 2 CCSD 
outperformed the thinner valved 
counterpart from stage 1 testing in 
all areas. For comparison to the 
stage 1 CCSD with thinner leaflet 
valves seen in Figure 2.26, pressure 
and volume flowrate graphs for the 
stage 2, non-raised, no cannula, 4 
L/min, 100 bpm case can be seen in 
Figure 2.27. However, upon 
increasing glycerol flowrates up to 4 
L/min, large amounts of gas were pulled from the gas side into the glycerol side of the gas 
exchanger. Concurrently, the gas caps of the CCSD filled with glycerol. Despite this, all target 
flowrates and pulse rates were attained for all tests at 4 L/min flowrate.  
 After making a comparison between results with CCSD devices using 0.040” and 0.060” 
thick valves using no cannulas, cannulas were added to simulate in vivo use of the entire CCSD 
system.  As can be seen in Table 2.9, the regurgitant fraction increased with increasing flowrate 
Figure 2.23:  CCSD valve in vitro testing regurgitant 
fraction results at 3 L/min glycerol flowrate. 
Figure 2.24:  CCSD valve in vitro testing regurgitant 
fraction results at 5 L/min glycerol flowrate. 
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and increasing pulse rate. The magnitudes of peak negative and peak positive enclosure pressures 
increased with increasing flowrate. 
When comparing the 33% to 50% 
systolic time cases, the latter had higher 
regurgitant fractions, higher peak 
enclosure pressure, and lower 
magnitude peak negative enclosure 
pressures at equivalent testing 
conditions. As with stage 2 cases with 
no cannulas, the all of the stage 2 cases 
with cannulas had a pulling of air from 
the gas side of the system to the blood 
side of the system when increasing to 4 
L/min glycerol flowrate.  
 In stage 3 in vitro testing of the 
CCSD system, six priming methods 
Table 2.6:  Stage 1 in vitro CCSD pumping test results.  
 
Figure 2.25:  In vitro traces for stage 1, 2 L/min, 80 
bpm test.  Top: Pressures. Bottom: Flowrate. 
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were explored to reduce the magnitude 
of negative pressures exerted on the gas 
exchanger. The prime condition with 
the lowest magnitude negative 
pressures is presented. The regurgitant 
fraction, attained flowrate, attained 
pulse rate, peak positive systolic 
pressure, and peak negative diastolic 
pressure for the stage 3 tests are listed in 
Table 2.8. In general, the regurgitant 
fraction, peak positive enclosure 
pressure, and magnitude of peak 
negative pressure increased with 
increasing flowrate. When comparing 
the results from this stage 3 prime 
condition (Test Conditions 1-4) to the equivalent stage 2 results from Table 2.7 (Test Conditions 
13-16), it is evident that the magnitudes of peak negative and positive pressures are lower for the 
stage 3 priming method. Additionally the regurgitant fraction is lower for all stage 3 test conditions 
with the exception of the 4 L/min, maximum pulse rate case. As with stage 2 testing, in stage 3 
testing air was pulled to the blood side of the device and glycerol was pulled to the air side of the 
device when increasing from 2 L/min to 4 L/min glycerol flowrate.  
2.4 Discussion 
2.4.1 CCSD Enclosure 
Figure 2.26:  In vitro traces for stage 1, 4 L/min, 
100 bpm test.  Top: Pressures. Bottom: Flowrate. 
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 The early CCSD prototype suffered from inefficiencies caused by flexing of the enclosure 
that acts as a pressurization chamber. A new CCSD enclosure was designed to reduce stroke 
volume losses to less than 10 mL when the enclosure is cycled from -200 mmHg to 300 mmHg. 
Finite element analysis of an initial design with varying wall thicknesses yielded Figure 2.20, 
where the plot shows the stroke volume loss as a function of wall thickness for acrylic and PVC 
enclosures. As the wall thickness increases there is an exponential decrease in stroke volume. 
Above a wall thickness of 1 inch the benefit of adding more thickness is minimal in terms of stroke 
volume, so a final wall thickness of 0.125 inches was chosen. The final enclosure included a more 
integrated gas exchanger holder that reduced machining costs and thickened the back wall of the 
enclosure. Finite element analysis estimates of the stroke volume loss was fairly close to the actual 
benchtop testing of the device where the finite element analysis yielded a stroke volume loss of 
5.84 mL and the benchtop testing yielded a stroke volume loss of 4.71 mL. The newly designed 
Table 2.7:  Stage 2 in vitro CCSD pumping test results.  
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enclosure allowed the second 
generation CCSD system to operate 
more efficiently than the first 
generation.  
2.4.2 CCSD Valves 
 The first generation CCSD 
device utilized external ball valves 
designed for industrial applications. 
These valves add components and 
prime volume to system, and likely 
would not have had the 
biocompatibility necessary for long 
term use with blood. In order to reduce 
separate components and prime 
volume, it was desired that the valves be 
integrated into the blood inlet and outlet conduits of the CCSD gas exchanger. In an attempt to 
create a more biocompatible valve than a tilting disc or bi-leaflet mechanical valve, a polymeric 
trileaflet valve was designed. This trileaflet valve was fabricated in a single piece since other 
Figure 2.27:  In vitro traces for stage 2, 4 L/min, 
100 bpm test.  Top: Pressures. Bottom: Flowrate. 
Table 2.8:  Stage 3 in vitro CCSD pumping test results. 
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attempts of creating polymeric valves failed at seams created when fabricating the part from 
multiple components. The biospan polyurethane that was used for the construction of the gas 
exchanger housing proved to be durable in the limited time windows when the valve was used in 
the in vitro testing. Further accelerated longevity testing would be needed to confirm the safety of 
these single piece polymeric valves.  
 Valves with diameters ranging from 0.688 inches to 1.25 inches and leaflet thicknesses 
ranging from 0.020 inches to 0.060 inches were fabricated and tested for optimal resistance and 
regurgitant fraction characteristics. It was desired that the valves have a regurgitant fraction less 
than 0.10 and a resistance less than 2 mmHg/(L/min) per valve at flowrates up to 5 L/min. 
Resistance tended to decrease with increasing valve diameter and increase with increasing valve 
thickness. Counterintuitively, as the stroke volume was decreased by raising pulse rate, there was 
a non-significant trend for the resistance of the valves to be slightly higher. This may have been 
due to the larger amount of time spent with the valve open in relation to the time spent in the 
opening/closing phase of valve cycling for the larger stroke volume cases. This would yield smaller 
energy losses due to valve opening and closing for a given amount of fluid traveling through the 
valve. Regurgitant fraction followed the opposite course, where the regurgitant fraction tended to 
increase with increasing valve diameter and decrease with increasing leaflet thickness. 
 Also apparent when inspecting the graphs of resistance and regurgitant fraction is deviation 
from the linear trends for the 1.125 inch diameter valves when increasing valve diameter. The error 
bars resulting from the 1.125 inch diameter valves tended to be smaller than the other valve 
diameters at a leaflet thickness of 0.040 inches. These deviations can be attributed to the fact that 
the 1.125 inch valve was the last valve size to be fabricated and tested. The valves were all hand 
dipped and during the course of manufacturing the different sized valves, the processed slowly 
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evolved to create more uniform valves. The 1.125 inch valves were not only more uniform, but 
slightly stiffer, resulting in elevated resistances and decreased regurgitant fractions. 
 The 1.125 inch diameter, 0.040 inch leaflet thickness valve was chosen to be used in the 
CCSD gas exchanger for its balance of regurgitant fraction and valve resistance. The regurgitant 
fraction was well within the target of less than 0.10, and the resistance was only slightly higher 
than the target of 2 mmHg/(L/min) per valve. However, when the valves were used in the full 
CCSD system, the valves exhibited large reguritant fractions from valve reversal. This indicates 
that the valve in vitro testing circuit was not an accurate representation of the forces the valves 
would encounter in the CCSD system. An improvement of the in vitro valve testing system would 
be to use two polymeric valves in the system rather than a ball valve and polymeric valve. 
Additionally, a resistance element, such as a Hoffman clamp, could be added upstream of the inlet 
valve and downstream of the outlet valve being tested in order to simulate the resistance of the 
tubing and cannulas of the CCSD system. Ultimately a 1.125 inch diameter, 0.060 inch leaflet 
thickness valve was utilized in the final CCSD system to reduce regurgitant fractions. These valves 
performed well, although their resistance exceeds the original target. Computational fluid structure 
interaction simulations, in vitro flow visualization studies, and/or in vivo biocompatibility studies 
would be needed to confirm biocompatibility of the valves. 
2.4.3 CCSD System Pumping 
 During stage 1 in vitro testing of the CCSD system with 0.040 inch leaflet thickness valves 
and no cannulas there were significant problems with valve regurgitation. At 2 L/min of flowrate 
the system was yielding regurgitant fractions between 0.126 and 0.248. Additionally, peak 
pressure magnitudes were higher than expected for these cases. When increasing the stroke volume 
to attain the 4 L/min flowrate condition the regurgitation increased greatly until complete valve 
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reversal was visually seen. Once valve reversal occurred, the flowrate dropped significantly and 
the target flowrate of 4 L/min was not able to be attained for both pulse rates. Additionally, 
cavitation occurred at the valves during reversal and gas built up inside the gas exchanger housing. 
The addition of high resistance cannulas to the system would have diminished the performance of 
the system. As a result, gas exchangers with a thicker 0.060 inch leaflet valve were manufactured 
for the second stage of CCSD system in vitro testing. 
 For comparison to stage 1 testing, stage 2 testing was started first without cannulas, with a 
raised reservoir, and % systolic time ratio of 33%. In stage 2 testing the regurgitant fractions and 
peak pressure magnitudes were lower at all flow conditions compared. However, as the stroke 
volume was increased to accommodate 4 L/min of flow, large amounts of gas was pulled into the 
blood side of the gas exchanger despite no gas being flowed through the gas side of the gas 
exchanger. This occurred with all devices tested at all flow conditions targeted at 4 L/min of flow 
including % systolic times of 33% and 50%, and pulse rates of 100 bpm and the maximum pulse 
rate produced by the pump. Upon de-priming the CCSD enclosure and removing the gas exchanger 
it was observed that the gas caps of the device and the gas lines were filled with large amounts of 
glycerol solution. This indicates a blowout in the potting material, gas and glycerol leakage across 
the porous wall of the hollow fibers, and/or hollow fiber rupture that allow gas to travel to the 
blood side the gas exchanger and glycerol to travel from the blood side to the gas side of the gas 
exchanger. All conditions occur as a result of the high magnitude negative pressures generated 
within the CCSD enclosure and gas exchanger. Additionally, high magnitude positive pressures 
can lead to blowout of the potting material.  
 When comparing the same test conditions in Stage 2 with a raised reservoir for 33% and 
50% systolic times, it can be seen that there were increases in the magnitude of peak positive 
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pressures and decreases in the magnitude of peak negative pressures when switching to % systolic 
time of 50%. At 4 L/min and 100 bpm, the peak positive pressure was increased by 54 mmHg and 
the peak negative pressure was reduced by 53 mmHg. At 4 L/min and the maximum pulse rate, 
the peak positive pressure was increased by 52 mmHg and the peak negative pressure was reduced 
by 46 mmHg. However, gas leakage was seen at all test conditions, and peak negative pressures 
were around negative 200 mmHg.    
 The stage 3 testing focused on reducing the peak negative pressure magnitudes in the gas 
exchanger, by attempting to improve the priming method of the gas exchanger. Since the housing 
is much more compliant in its unfurling stage rather than in its pure stretching stage, the pre-
stretching could reduce negative pressures by allowing the gas exchanger to operate more in the 
unfurling stage rather than in the stretching phase. At 4 L/min, 100 bpm and 4 L/min with the 
maximum pulse rate the improved priming method reduced the peak negative pressures by 67 
mmHg and 40 mmHg, respectively. However, there was still air pulled into the blood side of the 
gas exchanger and the enclosure pressures still ranged close to negative 200 mmHg. Based on 
Stage 2 testing, a % systolic time of 50% would likely reduce the magnitude of negative peak 
pressures, but not to a large enough extent as to yield a device safe from air embolism. 
 After testing the CCSD system during stage 3 the project was abandoned for safety 
concerns and a reduced benefit in comparison to ECMO. In the past five years, ECMO has 
improved to a point where circuits have been miniaturized and patients are starting to ambulate 
while being treated with ECMO. As a result, one of the major advantages of the CCSD system 
where the patient could ambulate to some extent while receiving therapy has been eliminated. 
Additionally, these smaller ECMO circuits won’t lose as much heat as their predecessors and safe 
fiber based heat exchangers are integrated into ECMO gas exchangers. With the improvement of 
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ECMO technologies, the only real advantage of the CCSD is the pulsatility of the flow regime. 
However, the theoretical improved perfusion will only be seen if the device is used in a veno-
arterial configuration. In recent years treatments have shifted more from veno-arterial treatment to 
veno-venous treatment, which results in a smaller potential patient pool for the CCSD. Lastly, 
there are safety concerns with air embolism. The risk of air embolism stemming from gas pulled 
from the fiber during diastole could be reduced by applying a negative pressure on the gas outlet, 
but this increases the pressure gradient between the blood and gas phase during systole, increasing 
the risk of rupturing the potting material. Additionally, these tests were performed with some of 
the largest cannulas available in order to reduce cannula resistance. In actual clinical use, the 
device would likely be paired with smaller single lumen or dual lumen cannulas for many patients. 
This would result in larger resistances, larger magnitude enclosure pressures, and more air 
embolism risk.  
 Overall the enhanced risk and small cohort of patients that could be treated with the 
technology outweighs the benefits of pulsatile perfusion and the system should not be pursued 
further. However, the one piece polymeric valves could be viable replacements for more traditional 
mechanical heart valves. The benefits of pulsatile perfusion may also be integrated into ECMO by 
utilizing varying rotational speeds in ECMO pumps(14-16) or pump replacement with piston 
pumps similar to pulsatile flow ventricular assist devices Both of these methods of inducing 
pulsatility to the flow regime eliminate negative pressures on the fiber bundle of the exchanger 
thereby reducing air embolism risk.  
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Chapter 3: Compliant Thoracic Artificial Lung 
3.1 Introduction  
Each year in the United States approximately 127,000 people die from chronic respiratory 
disease including COPD, IPF, and CF.(1) The only long term cure for these patients is lung 
transplantation, although only about 1800 lung transplants are performed each year due to donor 
organ shortages.(2) Extracorporeal membrane oxygenation (ECMO) can be used as a bridge to 
lung transplantation for some patients. However as discussed in Chapter 1, ECMO offers limited 
patient ambulation (3-6) and biocompatibility issues lead to patient deterioration over time.(4, 7-
13)  Chief amongst these is significant blood damage and activation that necessitates blood product 
transfusion.(7-9) Additionally, the number of patients bridged to transplantation using any method 
is limited by the scarcity of donor lungs. The compliant Thoracic Artificial Lung (cTAL) is thus 
needed as a possible bridge to transplantation or destination therapy. 
The cTAL has an advantage over ECMO as a bridge to transplantation and destination 
therapy due to its simple, pumpless system and low resistance. The cTAL should produce lower 
blood damage and be more portable than an ECMO system since it does not utilize a pump to 
maintain blood flow.(14, 15) Additionally, the cTAL in particular has a very low resistance, which 
should reduce the shear on the blood leading to less blood damage and clot inducing platelet 
activation.(15) 
Past studies of the compliant Thoracic Artificial Lung (cTAL) have characterized the 
impedance and gas exchange capabilities in an in vitro setting, and the cTAL’s effects on 
physiology in acute in vivo experiments.(14-16) The cTAL has excellent gas exchange capabilities,  
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with the rated flow exceeding 7 L/min of blood flow.(15) The cTAL has the lowest impedance and 
in turn resistance attributes of current artificial lungs.(15) The resistance of the cTAL is 
approximately 0.5 mmHg/(L/min), which is less than half the resistance of the next lowest 
resistance gas exchanger, the MC3 Biolung.(15, 17, 18) Furthermore, the zeroth order impedance 
modulus decreases with stroke volume and the first order impedance modulus has minimal 
increases with stroke volume in pulsatile flow.(15) The favorable resistance and impedance moduli 
are attributable to the cTAL’s gradual tapering blood inlet and outlet manifolds, the large frontal 
area of the device, and the compliant housing.(15) This housing design maximizes spatial and 
temporal uniformity of blood flow through the fiber bundle in an effort to reduce the blood flow 
resistance, improve gas exchange efficiency, and limit coagulation.(15)  
 When attached in a PA-LA configuration in parallel with the native lungs the low 0.5 
mmHg/(L/min) resistance of the cTAL has the ability to unload the right heart in patients with 
pulmonary hypertension.(14) Short term in vivo studies have also shown that minimal degradations 
in the cardiac function occur with up to 90% of the cardiac output delivered to the cTAL, even 
under simulated exercise conditions.(14) The present study aims to assess the cTAL’s efficacy as 
a bridge to lung transplantation and destination therapy device by testing the long term function 
and biocompatibility of the uncoated cTAL for 14 day periods. In particular, this study seeks to 
examine if the device can maintain the gas exchange and resistance characteristics demonstrated 
during short-term in vitro and in vivo studies while maintaining normal animal physiology. 
3.2 Methods  
3.2.1 cTAL System Description 
  The cTAL is a hollow-fiber membrane artificial lung with a compliant housing previously 
described by Schewe et al.(14-16) As can be seen in Figure 3.1, the device consists of a compliant 
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housing with tapering blood inlet and outlet manifolds, a gas exchange fiber bundle potted into the 
compliant housing, and acrylic gas caps used to distribute the sweep gas to the hollow fibers.(19) 
The gas exchange membrane has 2.4 m2 of surface area consisting of microporous polypropylene 
fibers (Membrana, Charlotte, NC). The compliant housing is fabricated from Biospan 
polyurethane (DSM PTG, Berkeley, CA). In addition to the gas exchanger, a cage was 
manufactured to protect the cTAL’s compliant housing and eliminate any shunt flow that could 
occur around the fiber bundle while allowing for housing expansion and contraction. The first 
version, used in Sheep 1 (Figure 3.2), clamped the sides of the cTAL fiber bundle with high 
pressure. The second version, used in all subsequent sheep, held the cTAL with minimal pressure 
placed on the fiber bundle. (Figure 3.3) These holders were very large so as to provide flexibility 
to adaptation in research use. However, the commercial holder would be a more compact and 
durable two piece molded housing. In order to divert pulmonary blood flow to and from the cTAL, 
custom blood inflow and outflow conduits where manufactured. These conduits (Figure 3.4) 
Figure 3.1: An assembled cTAL consisting of a compliant housing, fiber bundle, and gas 
caps. Adapted from (19) 
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consisted of six inches of 5/8” ID 
tygon tubing bonded to 18 mm dacron 
vascular grafts (Maquet Getinge, 
Wayne, NJ, or Terumo 
Cardiovascular, Ann Arbor, MI) using 
previously published methods (see 
Appendix C for full detail).(20)  
3.2.2 Surgery 
The cTAL was attached to five 
sheep weighing 60-65 kg. All sheep 
received humane care in compliance 
with the Guide for the Care and Use of 
Laboratory Animals, and all methods 
were approved by the University of 
Michigan Committee for the Use and 
Care of Animals. Sheep were given 
transdermal fentanyl (100 µg/hour) 24 
hours prior to surgery, and surgical 
anesthesia was induced with propofol 
(400-600 mg, IV). The sheep were 
intubated, mechanically ventilated, 
and a plane of anesthesia was 
maintained with 1-5% isoflurane. An 
 
Figure 3.2: The cTAL bundle clamped in the first 
generation device holder. 
 
Figure 3.3: The cTAL gas caps clamped in the 
second generation device holder. 
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orogastric tube was placed to prevent abdominal distension. A carotid arterial line was placed for 
monitoring mean arterial pressure (MAP), heart rate (HR), and arterial pO2, pCO2, pH, and 
hemoglobin (Hb). A venous line was placed in the jugular vein for monitoring central venous 
pressure and administering fluids and medications.  
A left thoracotomy was performed. Nafcillin (1000 mg, IV), gentamicin (120 mg, IV), 
heparin (5000-8000 Units, IV) buprenorphine (0.6 mg) and flunixin (60 mg, IV) were 
administered. The outlet and inlet graft conduits were attached to the LA and PA, respectively, via 
end-to-side anastomoses and tunneled through the sixth intercostal space. A flow probe 
(Transonic, Ithaca, NY) was placed around the main trunk of the PA, proximal to the conduit, to 
measure cardiac output and its cable was tunneled through the sheep’s back. Ventral and dorsal 
chest tubes (n=4) or a single ventral chest tube (n=1, Sheep 1) were placed. Initially, the inlet and 
outlet grafts were connected via 5/8” PVC tubing to maintain graft patency while awaiting sheep 
recovery and cTAL attachment. A tubing flow probe (Transonic, Ithaca NY) was placed on this 
shunt and blood flow was limited to 1 L/min using a Hoffman clamp. A heparin drip was supplied 
to the distal end of the inlet conduit with the goal of maintaining a systemic activated clotting time 
Figure 3.4: The graft used to attach the cTAL to the vasculature. 
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(ACT) between 200-280 s. The sheep was then recovered according to previous methods and 
moved to a custom-built cage (Figure 3.5) that allowed all activity except turning around.(17) In 
Sheep 2-4 the cTAL was attached the morning following surgery. In Sheep 1 the cTAL was 
attached 6 hours after surgery, and in Sheep 5 the cTAL was attached 2 mornings after the surgery 
due to limited surgical staff availability. The sheep were awake, and ate and drank freely during 
the 14 days of cTAL support.  
3.2.3 cTAL Attachment 
Prior to attachment the cTAL was primed with 1.3 L of lactated Ringer’s solution, 50 mL 
albumin (25% solution), 6000 units heparin, and 500 mg methylprednisolone. Heparin (5000-8000 
Figure 3.5: A sheep in a custom stanchion cage during a 14 day cTAL experiment.  
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Units) and methylprednisolone (500 mg) were also administered intravenously immediately prior 
to attachment to prevent clotting and inflammatory reactions to device attachment, respectively. 
The inlet and outlet conduits of the cTAL were clamped, the cTAL as was then inserted into its 
protective holder, and these were inserted into a camera bag customized to hold the cTAL onto the 
sheep while providing an additional layer of protection.(Figure 3.5) After cTAL preparation, the 
shunt tube was removed and the cTAL was attached using sterile technique without sedation. A 
sweep gas of 100% O2 was attached to the cTAL gas inlet at a rate of 5 L/min, a vacuum was 
established at the gas outlet to maintain gas inlet pressure between negative 15-30 mmHg, and 
blood flow was initiated through the device. The vacuum was applied to the gas outlet of the device 
to prevent air embolism that results from bulk flow of sweep gas through the porous polypropylene 
fibers when sweep gas pressures exceed blood pressures inside the device. Due to the excessive 
CO2 transfer in the cTAL, CO2 (6.9+/-0.3%) was blended into the sweep gas to maintain normal 
arterial pCO2 and respiratory rate.  
3.2.4 Animal Management 
All animals were administered nafcillin (500 mg IV) every six hours and gentamicin (120 
mg IV) every eight hours for three days or as needed. Pain management was accomplished through 
buprenorphine (0.6 mg, IM) every four to six hours and flunixin (60 mg, IV) every twelve hours 
or toradol (60 mg, IM or IV) every six hours. Analgesic dosages and schedules were adjusted as 
needed. In order to reduce the effects of pulmonary edema and hemodilution, Furosemide (40 mg, 
IV) was administered every 12 hours from device attachment to day 7 and day 9 for Sheep 4 and 
5, respectively. Heparin was administered as a continuous infusion to maintain a targeted systemic 
ACT between 200-280 sec. Fluids and electrolytes were administered as needed to maintain 
normal physiology. Animals had access to food and water ad libitum. Sheep 2 received 10 mg of 
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Diazapam during an episode of restlessness. After the episode subsided, the sheep was 
administered with 12 mg of Fumazenil to reverse the effects of the Diazapam. Sheep 2 also was 
administered several doses of atropine and epinephrine as rescue medications during acute 
bradycardic arrhythmias. Lastly, sheep 4 received a transfusion on day 6 to correct a low 
hemoglobin, but lysed the transfusion over the following days due to a lack of blood type matching.  
If elevated body temperature (>104°F) was observed a bacterial culture was submitted for 
analysis. After 14 days, animals were euthanized using sodium pentobarbital (16 mL, IV), and 
necropsied. The pulmonary artery, left atrium, and detached inlet and outlet grafts were inspected 
for gross thrombus formation. The heart, kidneys, and liver were inspected for signs of gross 
infarct. The lungs were visually inspected for atelectasis and pulmonary edema.  
3.2.5 Data Collection and Analysis 
Arterial Hb, pO2, and pCO2 were measured using a blood gas analyzer (Radiometer, West 
Lake, OH) every one to six hours as needed. ACT was measured using a whole blood coagulation 
system (Hemochron, Edison, NJ) every one to six hours as needed. Blood chemistry panels 
including aspartate aminotransferase (AST), alanine transaminase (ALT), blood urea nitrogen 
(BUN), and creatinine were run upon intake into animal housing and approximately every other 
day following surgery. White blood cell (WBC) and platelet counts (Plt) were run upon intake into 
animal housing and approximately every other day following. No blood chemistry panels, WBC 
counts, or platelet counts were performed on the weekend due to closure of diagnostic facilities on 
the weekend.  In order to account for hemodilution and blood loss, the WBC and Plt counts were 
normalized to the pre-device hemoglobin for each individual sheep according to Equation 1.1 
   𝑋𝑛𝑜𝑟𝑚 = 𝑋 ∗
𝐻𝑏𝑃𝐷
𝐻𝑏
  (1.1) 
where Xnorm is the normalized value, X is the measured value at any given time, Hb is the 
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hemoglobin at that same time, and HbPD is the pre-device hemoglobin. MAP was recorded hourly 
from the patient monitor (Marquette Electronics, Milwaukee, WI). The HR was recorded daily 
with a Biopac MP150 data acquisition system (Biopac Systems, Goleta, CA) (Sheep 2-5) or hourly 
with the patient monitor (Sheep 1). The cTAL flowrate was recorded hourly from the ultrasonic 
flow meter (Transonic, Ithaca, NY). The cTAL oxygen transfer rate (VO2) was calculated from 
inlet and outlet blood gas measurements and cTAL flow rate twice a day using Equation 1.2 
      𝑉𝑂2 = ?̇? ∗ ((𝑃𝑂2𝑂𝑢𝑡 − 𝑃𝑂2𝐼𝑛) + 1.34 ∗ 𝐻𝑏 ∗ (𝑆𝑂2𝑂𝑢𝑡 − 𝑆𝑂2𝐼𝑛))      (1.2) 
where Q̇ is the blood flowrate through the device, PO2Out is the partial pressure of oxygen in the 
outlet blood sample, PO2In is the partial pressure of oxygen in the inlet blood sample, 1.34 is the 
amount of oxygen that can be dissolved in 1 gram of hemoglobin with units mLO2/ghb, Hb is the 
hemoglobin level, SO2Out is the hemoglobin oxygen saturation in the outlet blood sample, and SO2In 
is the hemoglobin oxygen saturation in the inlet blood sample. The device blood flow resistance 
was calculated in the standard fashion from inlet and outlet blood pressures and cTAL flow rate 
recorded with the Biopac MP150 data acquisition system according to Equation 1.3 
         𝑅 =
𝑃𝐼𝑛−𝑃𝑂𝑢𝑡
?̇?
          (1.3) 
where R is the cTAL resistance, PIn is the cTAL inlet blood pressure, POut is the cTAL outlet blood 
pressure, and Q̇ is the cTAL blood flowrate. 
 Data represented as “pre-device” (PD) has been averaged from data taken over the six hours 
leading up to device attachment, and data represented as “baseline” (BL) is averaged over the six 
hours following device attachment. All other data is averaged over 24 hour periods after device 
attachment. The one exception to this are the clinical veterinary labs (AST, ALT, BUN, Creatinine, 
WBC, and Plt). These baseline samples were measured at intake and averaged over 3 day periods 
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after device attachment. Exceptions are; Sheep 2 had no intake labs and due to complications and 
animal unrest post attachment Sheep 4 had a BL VO2 taken at 7 hours post device attachment. 
Statistical comparisons utilized data from baseline (BL) through fourteen days. Comparisons were 
performed with SPSS (SPSS, Chicago, IL) using a linear mixed model with the sheep number as 
the subject variable and time as the fixed, repeated measure variable. Post-hoc analysis using a 
Bonferroni-corrected confidence interval was employed to compare all variables to baseline data 
to examine changes with time.  
3.3 Results  
 Three of the five sheep survived the entire 14 day experiment, and no device exchanges 
were performed. Sheep 2 was euthanized on day 6 due to a bradycardic arrhythmia that was evident 
prior to device attachment but worsened thereafter. Sheep 2 also developed a rear limb palsy 
following administration of Diazapam and a long period of sitting on the rear limb, although this 
did not contribute to early euthanasia. Sheep 5 was euthanized on day 11 after a blood conduit 
tubing connection failed. 
3.3.1 Sheep Physiology: 
 General animal physiology 
was largely normal and unchanged 
throughout the experiment. The 
MAP was 84±12.8 mmHg prior to 
attachment, 90±8.4 mmHg at 
baseline, and averaged 103±0.8 
mmHg thereafter (Figure 3.6), 
with no statistically significant Figure 3.6: The mean arterial pressure and heart rate as 
a function of experimental time. 
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comparisons to baseline (p=0.24).  
The HR was 141±17.3 bpm prior to 
attachment, 130±10.1 bpm at 
baseline, and averaged 124±5.0 
bpm thereafter (Figure 3.6), with 
no statistically significant 
comparisons to baseline  (p=0.37). 
Arterial PCO2 was 33±1.0 mmHg 
prior to cTAL attachment, 32±0.8 
mmHg at baseline, and averaged 
40±0.4 mmHg thereafter (Figure 
3.7). The PCO2 was statistically 
higher than baseline on Day 6 
(p=0.02). Arterial PO2 was 65±4 
mmHg prior to cTAL attachment 
due to the presence of the shunt, 
138±13 mmHg at baseline, and 
averaged 130±1.1 mmHg thereafter 
(Figure 3.7). Pre-device PO2 was 
significantly lower than BL (p=0.01), but PO2 was not statistically different from baseline 
thereafter (p=0.99).  
3.3.2 Hematology 
 Neither ACT, normalized WBC, nor normalized platelet counts (p=0.99, p=0.27, and 
Figure 3.7: The arterial oxygen and carbon dioxide 
partial pressures as a function of experimental time. 
Figure 3.8: The blood hemoglobin level and activated 
clotting time as a function of experimental time. 
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p=0.75, respectively) varied 
significantly from baseline. The 
hemoglobin was 10.3±0.4 g/dL 
prior to cTAL attachment, 8.9±0.6 
g/dL at baseline, and averaged 
9.0±0.1 g/dL thereafter (Figure 
3.8). The drop in hemoglobin from 
pre-device attachment to baseline 
was the only statistically significant 
comparison to baseline (p=0.01). 
The ACT was 211±7.3 sec prior to 
cTAL attachment, 310±71 sec at 
baseline, and averaged 238±2.1 
g/dL thereafter (Figure 3.8). The 
normalized WBC count was 
6.2±0.5 k/μL at baseline, trended 
upward throughout the experiment 
with an average of 6.8±0.6 k/μL 
over the course of the entire experiment with the count reaching a mamximum of 12.9±2.68 k/μL 
in the day 13-14 period (Figure 3.9). Despite this, WBC counts did not vary significantly from 
baseline (p=0.27). Bacterial cultures were analyzed from Sheep 3, 4, and 5 due to elevated body 
temperatures 5 days before surgery, Day 8, and Day 9, respectively. All culture results were 
negative for both aerobic and anaerobic bacterial growth. Normalized platelet counts were 281±36 
Figure 3.9: The hemoglobin normalized white blood 
cell and platelet counts function of experimental time. 
Figure 3.10: The cTAL flowrate and resistance as a 
function of experimental time. 
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k/μL at baseline, dropped to 185±25 k/µL after device attachment, and averaged 346±81 k/μ 
thereafter (Figure 3.9).  
3.3.3 Device Function  
The cTAL functioned without any statistically significant changes in device flowrate, 
resistance, and VO2 when comparing to baseline(p=0.68, p=0.99, and p=0.27, respectively). Blood 
flow through the cTAL was 3.46±0.15 L/min at baseline and averaged 3.18±0.05 L/min throughout 
the experiment (Figure 3.10). cTAL resistance had a baseline of 0.99±0.07 mmHg/L/min and 
averaged 1.04±0.05 mmHg/L/min over the course of the experiment (Figure 3.10). In sheep 3, the 
cTAL resistance increased over days 12- 14 despite minimal visual thrombus formation in this 
device (Figure 3.11), possibly due to a faulty stop-cock with significant thrombus formation or a 
failed pressure transducer. Additionally, this cTAL did not have substantial decrease in flowrate 
with an average of 3.48 L/min for days 1-11 and 3.40 L/min days 12-14, suggesting faulty  
Figure 3.11: The clot formation in the cTAL’s removed from all sheep surviving 14 days. A: 
The top views of the fiber bundles. B: The side views of the fiber bundles. 
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resistance measurement over this 
period. cTAL VO2 was 206±27 
mL/min at baseline and averaged 
180±8 mL/min over the course of 
the experiment (Figure 3.12).  At 
approximately day 7, plasma 
leakage was observed in the gas 
outlet of the cTAL for most of the 
sheep. However, periodic increases 
in gas flow rates to clear plasma 
preserved gas exchange.  
 Devices that were attached 
to 14 day survivors had varying 
amounts of thrombus formation 
depending on which device holder 
was employed (Figure 3.11). The 
device from Sheep 1 employed the 
first generation holder and had 
gross thrombus formation on the 
sides of the device where the holder 
clamped on the fiber bundle. The 
devices from sheep 3 and sheep 4 
employed the second generation 
Figure 3.12: The cTAL VO2 and flowrate as a function 
of experimental time. 
Figure 3.13: The cTAL removed from Sheep 4 after 14 
days. A: Non-taped side. B: Taped side. 
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device holder and had very little 
thrombus formation. The majority 
of the bundles were clear of 
significant thrombus formation, 
with a small section of thrombus at 
device corners and thrombus 
formation on the side of the cTAL 
bundle stemming from a section of 
double sided tape used during 
device fabrication (Figure 3.11 B 
and Figure 3.12 B). The effect of 
the tape on thrombus formation can 
be seen in Figure 3.13 showing the 
thrombus formation in the non-
taped and taped sides of the fiber 
bundle from Sheep 4.  
3.3.4 Organ Function 
 Neither BUN, creatinine, 
ALT nor AST varied significantly 
from baseline (p=0.99, p=0.36, p=0.27, and p=0.51, respectively). The baseline BUN and 
creatinine were 11.5±2.3 mg/dL and 0.77±0.06 mg/dL, respectively and averaged 11.9±0.9 mg/dL 
and 0.91±0.09 mg/dL, respectively thereafter (Figure 3.14). Liver enzymes increased immediately 
after surgery, but fell thereafter and stayed within normal ranges. However, at day 13-14 there was 
Figure 3.14: The kidney function markers BUN and 
creatinine as a function of experimental time. 
Figure 3.15: The liver function markers ALT and AST 
as a function of experimental time. 
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a non-significant increase in the AST due to reduced sheep numbers coupled with an increase in 
one sheep. Of the sheep that were euthanized early the AST levels prior to euthanization were 
undetectable and 73 prior to euthanication for Sheep 2 and 5, respectively. The baseline ALT and 
AST were 23±3.6 U/L and 86±8.5 U/L, respectively and averaged 62±19.3 U/L and 211±34 U/L, 
respectively thereafter (Figure 3.15). Sheep 2 had an elevated AST of 450 prior to euthanization. 
3.3.5 Necropsy 
Gross inspections of the organs during necropsy were largely unremarkable with the 
exception of the lungs. The lungs of the sheep typically exhibited pulmonary edema throughout 
the lung, and atelectasis in the upper lobes and in the areas around the chest tubes and blood 
conduits. Also noted during the necropsy were visual signs of infection around the graft site of 
Sheep 4 due to inadequate tissue in-growth to seal the chest wall.  
3.4 Discussion   
The purpose of these studies was to determine if an uncoated cTAL could maintain the gas 
exchange and resistance characteristics demonstrated during short-term in vitro and in vivo studies 
while maintaining normal animal physiology for a period of 14 days. Overall, the cTAL 
demonstrated that it has the capability to be used for at least two weeks without any anticoagulant  
coatings, and likely longer with more sophisticated biomaterials approaches. The device 
maintained a low, constant resistance while supporting normal blood gases. Animal physiology 
was, in general, normal with initial changes due to the effect of surgery and a trend back towards 
normal values thereafter, with the exception of slightly elevated AST levels in one sheep, and 
atelectasis and edema in the lungs of the necropsied sheep.  
 Even though the cTAL doesn’t utilize anti-coagulant coatings, there wasn’t a significant 
increase in resistance over 14 days. There was a consistent upward spike in device resistance after 
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one day but resistance returned to baseline values thereafter. This likely reflects some initial, 
transient protein or cellular binding that then resolves. After 14 days, gross visual thrombus 
formation in the cTAL was minimal in all devices except the device attached to Sheep 1. In this 
sheep the device was primed and placed tightly within its holder, which led to stasis regions and 
clot formation on the sides of the fiber bundle. The remaining devices utilizing a less compressive 
holder had almost no gross thrombus formation in the entirety of the bundle with the exception of 
some thrombus formation stemming from a piece of tape used during device fabrication on the one 
side of the fiber bundle. Elimination of this tape is a minor alteration and should reduce the 
thrombus formation. Despite minimal clot formation, the resistance of the device attached to Sheep 
3 apparently tripled over days 11-14. This was perplexing due to the minimal gross thrombus 
formation (Figure 3.12) and no reduction in the blood flow rate through the device. It is possible 
that the source of error was one of the stopcocks exhibiting back-bleeding and clotting or a faulty 
pressure transducer, but this is unknown.  
Previous in vitro and acute in vivo experiments demonstrated a consistent resistance of 
approximately 0.5 mmHg/(L/min) (14-16), however the resistance started at 1 mmHg/(L/min) in 
this study. The higher resistance seen here may be due to different positioning of the device. In the 
short-term in vivo studies, the device was in its ideal positioning, sitting flat on the animal. In these 
long-term studies, the device was placed on its side at the animals flank. This can cause lower 
pressure and housing collapse in the superior regions of the device, and may limit blood flow 
through these regions. In theory, this could cause both increased resistance as well as stasis and 
coagulation in those regions. However, there was no noticeable difference in clot formation 
between the upper and lower regions of the device. Even when the device is poorly positioned on 
the animal, the resistance of the cTAL is lower than healthy normal lungs and the least resistive 
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commercially available device, the iLA membrane oxygenator with 6 mmHg/(L/min) 
resistance.(21, 22) 
 Overall, the cTAL proved more biocompatible than similar devices. The uncoated MC3 
Biolung on average failed from clot formation within 7 days(18), while the anticoagulant coated 
iLA membrane oxygenator in a PA-LA configuration lasts 14-21 days before replacement is 
required.(23-26) The uncoated cTAL would have functioned well beyond 14 days, and the 
application of anti-thrombogenic coatings could potentially extend the functional lifespan into the 
range of a few months.  
 Gas exchange through the cTAL was maintained over 14 days despite some problems with 
plasma leakage. This is true, in part, because the cTAL’s rated flow exceeds 7 L/min, and blood 
flow rates averaged 3.46 L/min. Thus, a considerable decrement of performance would have been 
necessary to see reduced gas exchange. When performance did degrade to a point of reduced gas 
exchange, the plasma was cleared from the fibers by increasing the sweep gas flowrate to 10 L/min 
for a period of time. Plasma leakage was observed because the cTAL was constructed with porous 
polypropylene fibers. Polypropylene fibers were used since nonporous polymethylpentene fibers 
offer limited choices of fiber diameters, and it was believed prior to this study that plasma leakage 
was not a problem in sheep. For clinical prototypes, PDMS coated polypropylene fibers or solid 
silicone fibers will be necessary.(27-30)  
 Animal physiology was largely normal over the course of the experiment. The heart rate, 
MAP, and arterial blood gasses normalized after device attachment. The kidneys of the animals 
were functioning normally throughout the experiment with only slight fluctuations in BUN and 
creatinine. The liver enzyme values showed some dysfunction post surgery, but the values trended 
back down to normal levels throughout the experiment. One exception was a non-significant 
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increase in the AST level on the last two day period of the experiment. This was largely the effect 
of the euthanization of two sheep (Sheep 2 and 5) with lower AST concentrations and an AST 
increase in one animal (Sheep 3). Sheep 2, that encountered limb palsy, was administered with 
Diazepam, Fumazenil, atropine, and epinephrine, and was euthanized on Day 5 due to a 
bradycardic arrhythmia. In the 24 hours prior to ethanization this sheep showed liver dysfunction 
with elevated ALT and an undetectable AST. Gross inspection of the organs at necropsy revealed 
no signs of major infarct or other deraignment with the exception of atelectasis and edema 
throughout the lungs. The atelectasis and edema likely resulted from a low respiratory drive 
brought on by too much carbon dioxide removal in the system.  
Hematologically, the physiology was affected by the hemodilution of device attachment, 
but hematological values stayed consistent or rebounded the longer the cTAL was attached. 
Following device attachment and initial hemodilution, hemoglobin levels remained relatviely 
consistent with some non-significant decrease with time, and platelet counts trended back to 
normal. However, increased experimental repetitions may have yielded a statistically significant 
decrease in hemoglobin levels in part due to the large number of blood samples taken over the 
course of the experiment.  The overall white blood cell count did not vary significantly over the 
course of the experiment. The WBC count for Sheep 1 and 3 increased steadily throughout the 
experiment indicating possible infection. However, Sheep 3, 4, and 5 were all cultured for bacteria 
and had negative cultures. The effects of hemodilution were offset by the minimal blood product 
consumption by the device, evidenced by the stable hemoglobin and normal platelet countsin the 
later course of the experiment. In clinical use, patients treated with the cTAL may need an initial 
transfusion of packed red blood cells after device attachment, but should not need any further 
transfusions over the remainder of the treatment with the cTAL. This is in contrast to ECMO where 
93 
 
reported blood product median daily transfusions can range from 0.16 to 2 units per day for red 
blood cell transfusions and from 0 to 3 units per day for platelet transfusions.(8, 31) These 
transfusion requirements can be particularly high for patients with significant pulmonary 
hypertension or other conditions that necessitate the utilization of the higher operating pressure 
VA ECMO configuration.(9) The prime volume of the cTAL and resulting hemodilution can be 
reduced by shrinking the overall size of the device. This is feasible since the cTAL is currently 
overdesigned in terms of gas exchange, and the fiber bundle frontal area and path length could 
both be reduced simultaneously to maintain low resistance. 
The ultimate goal for the cTAL will be its use as a long term bridge to lung transplantation 
and destination therapy. In order to progress the cTAL towards this goal, the device will be reduced 
in size and prime volume, utilize a solid walled fiber to reduce plasma leakage and air embolism 
risk, and anticoagulant coatings will be applied to all surfaces of the device. The cTAL’s superior 
fluid dynamic design coupled with these coatings could allow the functional lifetime of a single 
device to be on the order of months. Utilizing periodic device replacement, cTAL treatment could 
be used for years in a patient as a destination therapy. The lack of blood damage and need for 
continuing blood transfusions further indicates the cTAL’s potential use as a destination therapy.   
 The 14 day long term efficacy experiments of the uncoated cTAL demonstrated the 
device’s ability to support a patient for a period of weeks without major thrombus format ion and 
subsequent device failure.  The cTAL was able to maintain gas exchange performance despite the 
incidence of plasma leakage. During the period of cTAL attachment there were no major 
physiological derangements and the device consumed very little in terms of blood products. Even 
without anti-coagulant coatings, the cTAL could have functioned beyond the current 14 day 
experimental time, and continued improvements of the device including these coatings would 
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allow it to serve as a destination therapy.  
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Chapter 4: Pulmonary Assist Device Computational Modeling and Design 
4.1 Introduction 
 In the United States there are over 12 million patients with chronic lung diseases that are 
fatal without lung transplantation.(1) However, there are less than 2,000 lung transplantations 
performed each year in the United States.(2) These transplants account for a fraction of a percent 
of patients who need treatment. The device described here, the pulmonary assist device (PAD), is 
designed both as a bridge to lung transplantation as well as a destination therapy device for the 
millions of patients who have no chance of receiving a donor lung.  
 Current gas exchangers are large devices with high resistances and large blood contacting 
surface areas. Modern adult gas exchangers for use in ECMO and AVCO2R have gas exchange 
surface areas that range from 1.1 m2 to 2.5 m2.(3, 4) While they are very efficient in gas exchange, 
their large blood contacting surface area and high resistances (lowest available, 5-6 
mmHg/(L/min))(5, 6) have negative effects on biocompatibility.(7, 8) When used in pumped 
configurations the high resistance of the device leads to higher blood pump speeds and, in turn, 
blood damage and activation.(7) The higher pump speeds combined with large blood contacting 
surface areas also result in greater incidence of clot formation and a limitation of two to three 
weeks of device longevity despite anti-coagulant coatings and systemic heparinization(7, 9).  
 In addition to biocompatibility issues, current gas exchangers are limited in their long term 
use by their portability. These devices and their associated pumps and circuits are very large and 
confine patients to the ICU. Advances in ECMO miniaturization have allowed for limited 
ambulation, but these patients need a team to assist in their walking.(10-12) Thus, regular patient-  
99 
 
initiated exercise is not an option, and they are not able to return home or to regular patient rooms 
during treatment. As a result, there is a need for a smaller, more portable device and ECMO system.  
4.1.1 Design Goals 
 As a long term support device, our goal is to design a PAD that is compact for ease of 
transportation in the hospital or at home and modular for flexibility to the needs of the patient. 
Modularity will allow for one or two module configurations as dictated by respiratory needs and/or 
the need for unloading of the heart in a pulmonary AV attachment. Additionally, the PAD was 
designed with the goal of achieving a clot free lifespan of months so that treatment can continue 
for years with preventative device change-outs. In order to satisfy these needs, the pulmonary assist 
device was designed to be used in one or two gas exchanger module configurations operating in 
either a pumped or pumpless manner with a variety of vascular attachment mode possibilities.  
Design goals for gas exchange capabilities of the PAD were developed through discussion with 
our clinical collaborator, Dr. Matthew Bacchetta. He expressed that most patients can be 
effectively treated with partial oxygen exchange support. It was desired that the device be able to 
oxygenate venous blood to 95% saturation with a flowrate of 1.25 L/min through each module. 
This would allow for up to 2.5 L/min of blood flowrate when used in a two module configuration. 
The PAD was also designed to remove at least 50 mL/min of carbon dioxide per module with 5 
L/min of sweep gas flowrate through each module. The Novalung has a resistance of 5-6 
mmHg/(L/min),(5, 6) and was not able to provide sufficient unloading of the right heart in 
pulmonary hypertension patients.(13-16) The resistance of the PAD should have a resistance 
similar to that of a healthy natural lung when placed in a two module parallel configuration. A 
target single module resistance less than 2.5 mmHg/(L/min) would result in a parallel two module 
resistance of 1.25 mmHg. Lastly, the device must be small enough to be used with a patient in a 
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home setting, preferably worn on a belt. 
 The first stage of the design of the pulmonary assist device was devoted to determining a 
compact fiber bundle geometry meeting the gas exchange and resistance goals. This fiber bundle 
design was performed using semi-empirical computational methods that rely on data from similar, 
previously tested fiber bundles. These computational methods were performed in Matlab (The 
Mathworks Inc, Natick, MA) and outlined in the early part of the chapter.  
 The second stage of computational modeling focused on the design of the housing around 
the fiber bundle geometry chosen in the first stage of design. With an initial port configuration and 
bundle design, computational fluid dynamics simulations were performed for several housing 
geometries similar to the cTAL tested in the previous chapter with the goal of choosing an inlet 
and outlet configuration that is the most compact and avoids clot promoting regions of blood stasis 
and recirculation. In regions of blood stasis and recirculation, pro-coagulant molecules that are 
generated from blood contact with artificial surfaces are able to build up and induce clot formation 
within the gas exchanger. Clot formation leads to an increase in device resistance, reduced gas 
exchange, and increased risk of thromboembolism. No quantifiable rules exist for an acceptable 
degree of recirculation or minimum blood flow velocity. Thus, care will be taken to minimize 
recirculation and statis while not making dramatic changes to the overall device concept.  
4.2 Methods 
4.2.1 Computational Bundle Modeling 
 Custom Matlab code was written to choose the appropriately sized fiber bundle for the 
PAD. Design curves were created to characterize the bundle aspect ratio, oxygen exchange, and 
bundle resistance as a function of fiber surface area and bundle blood flow frontal area. Design 
curves of carbon dioxide exchange were produced as a function of surface area and sweep gas 
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flowrate. A flowchart of the computational modeling procedure can be seen in Figure 4.1. 
Bundle Dimensions and Aspect Ratio  
 Bundle dimensions (Figure 4.2) were calculated from a range of fiber bundle surface areas 
between 0.1 and 0.5 m2 with a step size of 0.1 m2, and bundle blood flow path frontal areas between 
20 and 50 cm2 with a step size of 0.1 cm2. The rolling of a fiber bundle creates a radius at either 
end of the fiber bundle (Figure 4.2.A) that would affect overall surface area of the device and 
therefore gas exchange. However, the prediction of the exact size of a rolled fiber bundle is subject 
to variability and difficult to model accurately, so for the purposes of computational modeling of 
the bundle in Matlab, the bundle was modeled as a rectangular prism.(Figure 4.2.B)  
 With known frontal and surface areas, the bundle dimension of height or path length was 
calculated using fiber and fiber mat geometries and Equation 4.1 as detailed in Appendix D. 
           𝑃𝐿 =
(Φ𝑓+𝑔𝑎𝑝)∗𝑆𝐴∗cos 𝜃
𝜋∗Φ𝑓∗𝐹𝐴∗𝑠𝑝𝑎𝑐𝑖𝑛𝑔
                   (4.1) 
Figure 4.1: The flowchart of bundle design computational modeling in Matlab. 
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where PL is the bundle 
path length, Φf is the 
diameter of a single fiber, 
w is the width of the fiber 
bundle, gap is the 
distance between layers 
of fiber mat, spacing is 
the density of fiber 
packing in the fiber mat 
expressed as the number 
of fibers per unit length, 
and θ is the distortion 
angle that the angled fiber 
of the fiber mat makes 
with the axis across the width of the fiber bundle as shown in Figure 4.3. Since Equation 4.1 only 
requires frontal area and none of the other Matlab analyses in subsequent sections require specific 
bundle width or length values, the frontal area of the bundle is assumed to be square for simplicity. 
However, the actual constructed bundle can be any ratio of width to length so long as it meets the 
frontal area and surface area specifications.  
 After the path lengths were known the bundle aspect ratio was calculated for each 
combination of frontal and surface area, according to Equation 4.2  
           𝐴𝑅 =
√𝐹𝐴
𝑃𝐿
                     (4.2) 
in which AR is the aspect ratio and FA is the frontal area. The aspect ratio is important for the 
Figure 4.2: The dimensions of the fiber bundles for: A a curved 
fiber bundle.  B a rectangular fiber bundle. 
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overall design for several reasons. First, although the modeling is performed on idealized, 
rectangular fiber bundles, the rolled bundles have curvature at the ends of the bundle that results 
in a variation of path length that can effect gas exchange and bundle resistance. Second, a bundle 
with low aspect ratio is difficult to manufacture since it is close to circular.  
Bundle Resistance 
 Once the dimensions of the fiber bundle were output, the resistance of the bundle could be 
estimated using a Darcy law porous media model according to Equation 4.3  
      𝑘𝑝 =
𝑄∗𝜇∗𝑃𝐿
𝐹𝐴∗Δ𝑃
         (4.3) 
where kp is the permeability, μ is the dynamic viscosity, and ΔP is the pressure drop across the 
fiber bundle. A permeability of 2.81e-9 m2 was obtained from experimental data from an early 
cTAL prototype with a similar fiber bundle to the PAD fiber bundle.(17) Equation 4.3 was 
rearranged to yield Equation 4.4 
Figure 4.3: A single layer of fibers with the distortion angle labeled. 
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Δ𝑃
𝑄
=
𝜇∗𝑃𝐿
𝐹𝐴∗𝑘𝑝
         (4.4) 
The left hand side of Equation 4.4 is equal to the resistance of the fiber bundle, R, so Equation 
4.4 reduces to Equation 4.5 
            𝑅 =
𝜇∗𝑃𝐿
𝐹𝐴∗𝑘𝑝
          (4.5) 
The dynamic viscosity of blood was calculated according to Equation 4.6 
     𝜇 = (2.205𝑒 − 5) ∗ 𝑒[
1965
273.15+𝑇
+(2.31∗𝐻)]
        (4.6) 
where μ is the dynamic viscosity of blood in Poise, T is the Temperature in degrees Celsius, and 
H is the fractional hematocrit.(18) The resistances were calculated and plotted for all frontal area 
and surface area combinations. 
Oxygen Exchange Theory 
 Previous studies of gas exchangers have utilized heat exchange theory from shell and tube 
heat exchangers to model the oxygen exchange in medical gas exchangers.(18-21) The gas 
exchange fiber bundle of a medical gas exchanger is very similar to a crossflow shell and tube heat 
exchanger, but instead of transferring heat to a fluid it transfers oxygen to a fluid removes carbon 
dioxide from the fluid. However, the interactions of oxygen and carbon dioxide in the blood are 
much more complex than the interaction of heat with a fluid in a heat exchanger. When oxygen 
and carbon dioxide are exchanged with the blood, they are not merely dissolved. The oxygen both 
dissolves in the blood and chemically binds with hemoglobin. Carbon dioxide is dissolved in the 
blood and becomes sequestered as bicarbonate in the blood. Furthermore, carbon dioxide exchange 
is typically limited by the sweep gas flowrate, so heat exchanger theory typically isn’t used for 
modeling. The exchange of oxygen is highly dependent on the blood flow in the gas exchanger 
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and can still be modeled using heat exchange theory, but with adaptations to account for uptake of 
oxygen by hemoglobin.(18-21) 
 The crossflow shell and tube heat exchanger heat exchange theory can be adapted to the 
oxygen exchange of a medical gas exchanger as described by previous studies. Dimensionless 
analysis of tube banks in both heat exchange theory adapted for mass transfer, and mass transfer 
theory yields a model of mass transfer in a fiber bundle described by the Reynolds number, the 
Stanton number, and the Schmidt number according to Equations 4.7-4.9   
𝑁𝑆𝑡 =
𝐾𝐿
𝑣
          (4.7) 
            𝑁𝑆𝑐 =
𝜇
𝜌∗𝐷𝑒𝑓𝑓
         (4.8) 
     𝑓(𝑁𝑅𝑒) =  𝑁𝑆𝑡 ∗ 𝑁𝑆𝑐
2
3⁄  .       (4.9) 
The NSt is the mass transfer Stanton number expressed as the ratio of mass flux to the mass flux 
capacity of the fluid flow. The NSc is the Schmidt number, which is the gas exchange equivalent 
of the Prandtl number. It is expressed as the ratio of momentum transport to diffusive transport in 
which KL is the local mass transfer coefficient of oxygen from the gas exchange fiber, v is the 
velocity of the blood, Deff is the effective diffusivity of oxygen in blood, μ is the dynamic viscosity 
of blood, and ρ is the density of blood.(18) Combining Equations 4.7-4.9 yields Equation 4.10 
            𝑓(𝑁𝑅𝑒) =  
𝐾𝐿
𝑣
∗ (
𝜇
𝜌∗𝐷𝑒𝑓𝑓
)
2
3⁄       (4.10) 
 Low Reynolds numbers heat exchanger experiments yielded a power law relationship for 
the Reynolds number function leading to Equation 4.11 
        Φ ∗ 𝑁𝑅𝑒
−𝑚 =  
𝐾𝐿
𝑣
∗ (
𝜇
𝜌∗𝐷𝑒𝑓𝑓
)
2
3⁄       (4.11) 
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where m and Φ are dimensionless constants derived from experimental data for a given gas 
exchanger fiber mat and bundle. With further manipulation this equation becomes the basis for 
being able to predict the oxygen exchange performance of varying sized fiber bundles within a gas 
exchanger.(18) The m and Φ values were derived from experimental data and then fed back into 
this equation to predict the oxygen exchange for a differently sized fiber bundle. Equation 4.12 
gives the velocity of flow through the porous media composed of the fibers of the gas exchange 
fiber bundle 
             𝑣 =  
𝑄𝑏
𝑝𝑜𝑟∗𝐴𝑓
       (4.12) 
where Qb is the bulk blood flowrate through the fiber bundle, por is the porosity of the fiber bundle, 
and Af is the frontal area of the fiber bundle that the blood flows through. The porosity of the fiber 
bundle, which is the ratio of void volume to total volume around a fiber, can be solved using 
Equation 4.13 
          por =  1 −
𝜋∗Φ𝑓∗𝑠𝑝𝑎𝑐𝑖𝑛𝑔
4
      (4.13) 
Inserting Equation 4.12 into Equation 4.11 yields Equation 4.14. 
        Φ ∗ 𝑁𝑅𝑒
−𝑚 =  
𝐾𝐿∗𝑝𝑜𝑟∗𝐴𝑓
𝑄𝑏
∗ (
𝜇
𝜌∗𝐷𝑒𝑓𝑓
)
2
3⁄     (4.14) 
 With the goal of further refining Equation 4.14, the local mass transfer coefficient of 
oxygen in blood for the gas exchanger, KL, is derived using a balance of the mass transfer rate 
between the gas exchanger and the uptake of oxygen by the blood. The local rate of mass transfer 
along an increment of the path length of the fiber bundle, ṁbundle, has been shown to follow 
Equation 4.15 (18) 
   ?̇?𝑏𝑢𝑛𝑑𝑙𝑒 =  𝐾𝐿 ∗ 𝑑𝑆𝐴 ∗ (𝐶𝑂2𝑓 − 𝐶𝑂2𝑏)     (4.15) 
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where dSA is the incremental surface area contained in an incremental distance dx into the fiber 
bundle, CO2f is the concentration of oxygen at the outer diameter of the fiber and CO2b is the 
concentration of oxygen in the bulk flow of blood. The incremental surface area contained in dx 
can be restated as a function of dx using fiber geometry and Equation 4.16 
          𝑑𝑆𝐴 =  
4∗(1−𝑝𝑜𝑟)∗𝐴𝑓
Φ𝑓
∗ 𝑑𝑥      (4.16) 
where Φf is the outside diameter of the fiber and dx is the incremental distance into the fiber bundle 
perpendicular to the frontal area. The difference in concentration of oxygen in the blood at the 
fiber outer surface and the bulk flow can be related to the partial pressure of oxygen dissolved in 
the blood according to Equation 4.17 (18) 
       𝐶𝑂2𝑓 − 𝐶𝑂2𝑏 =  𝑘𝑊𝐵 ∗ (𝑃𝑂2𝑔 − 𝑃𝑂2𝑏)        (4.17) 
where kWB is the solubility of oxygen in whole blood, PO2g is the partial pressure of oxygen in the 
sweep gas, and PO2b is the partial pressure of oxygen dissolved in the bulk flow of blood. 
Equations 4.16 and 4.17 can be inserted into Equation 4.15 to yield Equation 4.18 
    ?̇?𝑏𝑢𝑛𝑑𝑙𝑒 =  𝐾𝐿 ∗
4∗(1−𝑝𝑜𝑟)∗𝐴𝑓
Φ𝑓
∗ 𝑘𝑊𝐵 ∗ (𝑃𝑂2𝑔 − 𝑃𝑂2𝑏) ∗ 𝑑𝑥   (4.18) 
 The mass transfer rate of oxygen taken up by the blood, ṁblood, can be calculated with 
Equation 4.19 
     ?̇?𝑏𝑙𝑜𝑜𝑑 = ?̇?𝑏𝑙𝑜𝑜𝑑𝑏 + ?̇?𝑏𝑙𝑜𝑜𝑑𝑑       (4.19) 
where ṁbloodb is the mass transfer rate of oxygen taken up by the blood in the form of oxygen bound 
to hemoglobin and ṁbloodd is the mass transfer rate of oxygen taken up by the blood in the form of 
oxygen dissolved in the blood. ṁbloodb has been shown previously to follow Equation 4.20 (18) 
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          ?̇?𝑏𝑙𝑜𝑜𝑑𝑏 = 𝑄𝑏 ∗ 𝑘𝑊𝐵 ∗
𝑑𝑃𝑂2
𝑑𝑥
∗ 𝑑𝑥      (4.20) 
where PO2 is the partial pressure of oxygen dissolved in the blood and Qb is the blood flowrate. 
ṁbloodb has been shown previously to follow Equation 4.21 (18) 
          ?̇?𝑏𝑙𝑜𝑜𝑑𝑑 = 𝑄𝑏 ∗ 1.34 ∗ 𝐶ℎ𝑏 ∗
𝑑𝑆
𝑑𝑥
∗ 𝑑𝑥     (4.21) 
where 1.34 is the amount of oxygen that can be dissolved in 1 gram of hemoglobin with units 
mLO2/ghb, Chb is the hemoglobin concentration in blood, and S is the oxyhemoglobin saturation. 
Equations 4.20 and 4.21 can be inserted into Equation 4.19 and rearranged to yield Equation 
4.22 
   ?̇?𝑏𝑙𝑜𝑜𝑑 = (1 + 1.34 ∗
𝐶ℎ𝑏
𝑘𝑊𝐵
∗
𝑑𝑆
𝑑𝑃𝑂2
) ∗ 𝑘𝑊𝐵 ∗ 𝑄𝑏 ∗
𝑑𝑃𝑂2
𝑑𝑥
∗ 𝑑𝑥   (4.22) 
Since the amount of oxygen given off by the gas exchanger is equal to the amount of 
oxygen taken up by the blood, ṁbundle is equal to ṁblood. The right hand sides of Equations 4.18 
and 4.22 can then be equated to create Equation 4.23 
𝐾𝐿 ∗
4 ∗ (1 − 𝑝𝑜𝑟) ∗ 𝐴𝑓
Φ𝑓
∗ 𝑘𝑊𝐵 ∗ (𝑃𝑂2𝑔 − 𝑃𝑂2𝑏) ∗ 𝑑𝑥 = 
  [1 + (1.34 ∗
𝐶ℎ𝑏
𝑘𝑊𝐵
∗
𝑑𝑆
𝑑𝑃𝑂2
)] ∗ 𝑘𝑊𝐵 ∗ 𝑄𝑏 ∗
𝑑𝑃𝑂2
𝑑𝑥
∗ 𝑑𝑥               (4.23) 
Simplifying Equation 4.23 and solving for KL yields Equation 4.24 
     𝐾𝐿 =  
𝑄𝑏∗Φ𝑓
4∗(1−𝑝𝑜𝑟)∗𝐴𝑓
∗ 
1+𝜆(𝑃)
𝑃𝑔−𝑃
∗
𝑑𝑃𝑂2
𝑑𝑥
       (4.24) 
where λ(PO2) is a sink term that takes into account oxygen uptake by hemoglobin with λ(P) 
following Equation 4.25 
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         𝜆(𝑃𝑂2) = 1.34 ∗
𝐶ℎ𝑏
𝑘𝑊𝐵
∗
𝑑𝑆
𝑑𝑃𝑂2
       (4.25) 
where the oxyhemoglobin saturation, S, can be derived from Equation 4.26 
       𝑆 =
(
𝑃𝑂2
𝑃50
)𝑛𝑟𝑏𝑐
1+(
𝑃𝑂2
𝑃50
)𝑛𝑟𝑏𝑐
       (4.26) 
where nrbc is the Hill parameter which for bovine blood is equal to 2.85 and human blood is equal 
to 2.7, and P50 is the partial pressure of oxygen dissolved in blood in mmHg when the hemoglobin 
is 50% saturated.(18, 21) Equation 4.26 can be differentiated and combined with Equation 4.25 
combined to yield Equation 4.27 
    𝜆(𝑃𝑂2) = 1.34 ∗
𝐶ℎ𝑏
𝑘𝑊𝐵
∗ (
𝑃𝑂2
𝑃50
)
𝑛𝑟𝑏𝑐−1
∗
𝑛
𝑃50
∗
1
[1+(
𝑃𝑂2
𝑃50
)
𝑛𝑟𝑏𝑐
]2
    (4.27) 
P50 can be found using Equations 4.28 and 4.29 for bovine and human blood, respectively (18) 
         𝑃50𝑏𝑜𝑣𝑖𝑛𝑒 = 29.0 ∗ 10
{[0.41∗(7.4−𝑝𝐻)]−[0.024∗(37−𝑇)]}     (4.28) 
         𝑃50ℎ𝑢𝑚𝑎𝑛 = 26.6 ∗ 10
{[0.48∗(7.4−𝑝𝐻)]−[0.024∗(37−𝑇)]}    (4.29) 
where T is the temperature in degrees Celsius. The solubility of oxygen in whole blood, kWB, can 
be calculated using Equations 4.30-4.32.(18, 21)  
           𝑘𝑐 = (4.658𝑒 − 5) ∗ 1.01
(37−𝑇)      (4.30) 
           𝑘𝑝 = (2.855𝑒 − 5) ∗ 1.01
(37−𝑇)      (4.31) 
          𝑘𝑊𝐵 = (𝑘𝑐 ∗ 𝐻) + [𝑘𝑝 ∗ (1 − 𝐻)]     (4.32) 
where kc is the solubility of oxygen in the cellular component of blood in mLO2/(mLblood*mmHg), 
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kc is the solubility of oxygen in the plasma component of blood in mLO2/(mLblood*mmHg), kWB is 
the solubility of oxygen in whole blood in mLO2/(mLblood*mmHg), and H is the fractional 
hematocrit. The effective diffusivity that takes into account reactions between oxygen and 
hemoglobin can be found using Equation 4.33 (18, 21) 
            𝐷𝑒𝑓𝑓 =
𝐷𝑊𝐵
1+𝜆(𝑃𝑂2)
        (4.33) 
where DWB is the diffusivity of oxygen in whole blood. The diffusivity of oxygen in whole blood 
can be calculated using Equations 4.34-4.40 
        𝐷𝑐 = (0.76𝑒 − 5) ∗ 1.025
(𝑇−25)                (4.34) 
       𝐷𝑝 = (1.62𝑒 − 5) ∗ 1.025
(𝑇−25)     (4.35) 
              𝑁 =
𝑘𝑐∗𝐷𝑐
𝑘𝑝∗𝐷𝑝
         (4.36) 
  𝛽 =
(𝑁−1)
3
∗ {
2
1+[(𝑁−1)∗(
𝑚𝑟𝑏𝑐
2
)]
+
1
1+[(𝑁−1)∗(1−𝑚𝑟𝑏𝑐)]
}     (4.37) 
            𝜒 =
1−[𝑁∗(1−𝛽)]
𝑁−1−𝛽
        (4.38) 
             𝐺 =
𝐻∗(𝑁−1)
𝑁+𝜒
        (4.39) 
             𝐷𝑊𝐵 =
𝐷𝑝∗𝑘𝑝∗[1+(𝐺∗𝜒)]
𝑘𝑊𝐵∗(1−𝐺)
      (4.40) 
where Dc is the diffusivity of oxygen in the cellular component of blood in cm
2/sec, Dp is the 
diffusivity of oxygen in the plasma component of blood in cm2/sec, DWB is the diffusivity of 
oxygen in whole blood in cm2/sec; N, β, G, and χ are intermediary constants included for ease of 
calculation, and mrbc is the aspect of ratio of a red blood cell, assumed to be 0.283.(18, 21) 
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Equations 4.14, 4.24, and 4.33 can be combined to form Equation 4.41 
     Φ ∗ 𝑁𝑅𝑒
−𝑚 =  
𝑄𝑏∗Φ𝑓
4∗(1−𝑝𝑜𝑟)∗𝐴𝑓
∗ 
1+𝜆(𝑃)
𝑃𝑂2𝑔
−𝑃𝑂2𝑏
∗
𝑑𝑃𝑂2
𝑑𝑥
∗𝑝𝑜𝑟∗𝐴𝑓
𝑄𝑏
∗ (
𝜇
𝜌∗
𝐷𝑊𝐵
1+𝜆(𝑃)
 
)
2
3⁄    (4.41) 
which can be simplified to Equation 4.42 
           Φ ∗ 𝑁𝑅𝑒
−𝑚 =  
Φ𝑓∗𝑝𝑜𝑟
4∗(1−𝑝𝑜𝑟)
∗ (
𝜇
𝜌∗𝐷𝑊𝐵
)
2
3⁄
∗
(1+𝜆(𝑃𝑂2))
5
3⁄
(𝑃𝑂2𝑔−𝑃𝑂2𝑏)
∗
𝑑𝑃𝑂2
𝑑𝑥
   (4.42) 
However according to Vaslef, the right hand side of Equation 4.42 does not take into account 
variation in the capacity of the blood entering the device to take up oxygen, so it is divided by the 
oxygen binding capacity term, (1+λ(P)), to yield Equation 4.43 (18) 
         Φ ∗ 𝑁𝑅𝑒
−𝑚 =  
Φ𝑓∗𝑝𝑜𝑟
4∗(1−𝑝𝑜𝑟)
∗ (
𝜇
𝜌∗𝐷𝑊𝐵
)
2
3⁄
∗
(1+𝜆(𝑃𝑂2))
2
3⁄
(𝑃𝑂2𝑔−𝑃𝑂2𝑏)
∗
𝑑𝑃𝑂2
𝑑𝑥
   (4.43) 
Oxygen Exchange Bundle Modeling  
 The above previously studied oxygen exchange theory was used to computationally 
produce oxygen exchange design curves for a variety of fiber bundle geometries using the venous 
blood conditions as follows; temperature = 37˚C, hematocrit = 40%, hemoglobin concentration = 
13.3 g/dL, oxygen saturation = 65%, and pH = 7.4. Gas exchange constants m=0.214 and Φ=0.82 
from previous cTAL testing were used in oxygen modeling.(17) Bundle dimensions produced as 
described in previous sections were used in combination with Equation 4.43 to predict PAD 
oxygen exchange. Since Equation 4.43 represents local oxygen exchange in a small portion of the 
path length of the fiber bundle the equation was manipulated to model the entire fiber bundle. 
Rearranging Equation 4.43 to solve for 
𝑑𝑃
𝑑𝑥
 yields Equation 4.44 (21) 
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𝑑𝑃𝑂2
𝑑𝑥
=  Φ ∗ 𝑁𝑅𝑒
−𝑚 ∗
4∗(1−𝑝𝑜𝑟)
Φ𝑓∗𝑝𝑜𝑟
∗ (
𝜌∗𝐷𝑊𝐵
𝜇
)
2
3⁄
∗
(𝑃𝑂2𝑔−𝑃𝑂2𝑏)
(1+𝜆(𝑃𝑂2))
2
3⁄
   (4.44) 
The Reynolds number for the fiber bundle is represented by Equation 4.45 
     𝑁𝑅𝑒 =  
𝑄𝑏∗Φ𝑓∗𝜌
(1−𝑝𝑜𝑟)∗𝐴𝑓∗𝜇
      (4.45) 
Equation 4.45 was inserted into Equation 4.44 and Equation 4.44 was simplified to yield 
Equation 4.46  
𝑑𝑃𝑂2
𝑑𝑥
=  Φ ∗ (
𝑄𝑏 ∗ Φ𝑓 ∗ 𝜌
(1 − 𝑝𝑜𝑟) ∗ 𝐴𝑓 ∗ 𝜇
)
−𝑚
∗
4 ∗ (1 − 𝑝𝑜𝑟)
Φ𝑓 ∗ 𝑝𝑜𝑟
∗ (
𝜌 ∗ 𝐷𝑊𝐵
𝜇
)
2
3⁄
∗ 
               
(𝑃𝑂2𝑔−𝑃𝑂2𝑏)
(1+𝜆(𝑃𝑂2))
2
3⁄
                  (4.46) 
A forward differencing numerical scheme was utilized to solve Equation 4.46 for the change in 
partial pressure of oxygen in the blood from the bundle inlet to the bundle outlet, ΔPO2, using 
Equation 4.47.  
 𝛥𝑃𝑂2 = 𝛥𝑥 ∗  Φ ∗ (
𝑄𝑏∗Φ𝑓∗𝜌
(1−𝑝𝑜𝑟)∗𝐴𝑓∗𝜇
)
−𝑚
∗
4∗(1−𝑝𝑜𝑟)
Φ𝑓∗𝑝𝑜𝑟
∗ (
𝜌∗𝐷𝑊𝐵
𝜇
)
2
3⁄
∗ 
        
(𝑃𝑂2𝑔−𝑃𝑂2𝑏(𝑥))
(1+𝜆(𝑃𝑂2(𝑥)))
2
3⁄
      (4.47) 
Where Δx is a small change of the distance into the fiber bundle (1e-6 m) and PL is the path length 
of the fiber bundle. For the initial partial pressure of oxygen at the inlet of the bundle, the pressure 
was set to the partial pressure of oxygen in the inlet blood. In an iterative manner Equation 4.47 
was stepped by Δx and solved for ΔPO2. At each step the output ΔPO2 was added to PO2(x) to 
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increase the starting partial pressure of oxygen in the blood as the forward differencing is marched 
through the fiber bundle path length. Once the upper x bound of the forward differencing 
corresponding to the outlet of the fiber bundle is reached, the partial pressure of oxygen was output 
as PO2Out. PO2Out was inserted into Equation 4.26 to output the outlet hemoglobin oxygen 
saturation, SOut. Lastly the rate of oxygen exchange, VO2, was calculated and output using 
Equation 4.48 
     𝑉𝑂2 = 𝑄𝑏 ∗ {[𝑘𝑊𝐵 ∗ (𝑃𝑂2𝐼𝑛 − 𝑃𝑂2𝑂𝑢𝑡)] + 
    [1.34 ∗ 𝐶ℎ𝑏 ∗ (𝑆𝑂𝑢𝑡 − 𝑆𝐼𝑛)]}     (4.48) 
where PO2In is the partial pressure of oxygen in the inlet blood, Sin is the oxyhemoglobin saturation 
in the inlet blood, and 1.34 is the amount of oxygen that can be dissolved in 1 gram of hemoglobin 
with units mLO2/ghb. VO2 and Sout were plotted as a function of bundle frontal and surface area.  
Carbon Dioxide Exchange 
According to Federspiel, et al the amount of carbon dioxide exchanged by a gas exchanger 
can be modeled based on a gas transfer constant and the gas flowrate due to the fact that the 
concentration gradient of carbon dioxide and the blood is very low, ~40 mmHg.(22) This low 
concentration gradient means that any buildup of carbon dioxide on the gas side of a gas exchange 
fiber results in a reduced ability to remove additional CO2. Additionally, carbon dioxide diffuses 
quickly in the blood due to its high solubility. Therefore, removal of CO2 buildup on the gas side 
of a fiber is greatly affected by the sweep gas flowrate, and can be modeled with Equation 4.49  
       𝑉𝐶𝑂2 = 𝐾𝐶𝑂2 ∗ 𝐴𝑠 ∗ (𝑃𝐶𝑂2𝑏
̅̅ ̅̅ ̅̅ ̅ − 𝑃𝐶𝑂2𝑔
̅̅ ̅̅ ̅̅ ̅)      (4.49) 
where VCO2 is the rate of carbon dioxide removal from the blood, KCO2 is the mass transfer 
coefficient of a gas exchanger, As is the surface area of a gas exchanger, P̅CO2b is the average partial 
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pressure of carbon dioxide dissolved in the blood within the gas exchanger, and P̅CO2g is the average 
partial pressure of carbon dioxide in the sweep gas within the gas exchanger.(22) P̅CO2g can be 
approximated by using the average between the partial pressure of carbon dioxide entering the gas 
exchanger in the sweep gas and the partial pressure of carbon dioxide leaving the gas exchanger 
in the sweep gas according to Equation 4.50 (22) 
       𝑃𝐶𝑂2𝑔
̅̅ ̅̅ ̅̅ ̅ =
𝑃𝐶𝑂2𝑜+𝑃𝐶𝑂2𝑖
2
       (4.50) 
In most instances, 100% oxygen is used as the inlet sweep gas, so PCO2i will be equal to zero which 
reduces the equation down to Equation 4.51 
           𝑃𝐶𝑂2𝑔
̅̅ ̅̅ ̅̅ ̅ =
𝑃𝐶𝑂2𝑜
2
      (4.51) 
Substituting Equation 4.51 into Equation 4.49 yields Equation 4.52 
          𝑉𝐶𝑂2 = 𝐾𝐶𝑂2 ∗ 𝐴𝑠 ∗ (𝑃𝐶𝑂2𝑏
̅̅ ̅̅ ̅̅ ̅ −
𝑃𝐶𝑂2𝑜
2
)    (4.52) 
 The carbon dioxide exchange from the sweep gas can also be calculated with a mass 
balance according to Equation 4.53 (22) 
          𝑉𝐶𝑂2 =  𝑄𝑔 ∗
𝑃𝐶𝑂2𝑜−𝑃𝐶𝑂2𝑖
𝑃𝑔
     (4.53) 
Once again the inlet sweep gas is 100% oxygen so Equation 4.53 will simplify to Equation 4.54 
        𝑉𝐶𝑂2 =  𝑄𝑔 ∗
𝑃𝐶𝑂2𝑜
𝑃𝑔
      (4.54) 
 Since the rate of carbon dioxide to the sweep gas is equal to the rate of carbon dioxide 
transferred from the blood by the gas exchanger Equations 4.52 and 4.54 can be set equal to one 
another yielding Equation 4.55 
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         𝐾𝐶𝑂2 ∗ 𝐴𝑠 ∗ (𝑃𝐶𝑂2𝑏
̅̅ ̅̅ ̅̅ ̅ −
𝑃𝐶𝑂2𝑜
2
) =  𝑄𝑔 ∗
𝑃𝐶𝑂2𝑜
𝑃𝑔
    (4.55) 
Solving for PCO2o and simplifying yields Equation 4.56 
        𝑃𝐶𝑂2𝑜 =
𝐾𝐶𝑂2∗𝐴𝑠∗𝑃𝑔∗𝑃𝐶𝑂2𝑏
̅̅ ̅̅ ̅̅ ̅̅ ̅
𝑄𝑔+(
1
2
∗𝐾𝐶𝑂2∗𝐴𝑠∗𝑃𝑔)
     (4.56) 
Substituting Equation 4.56 back into Equation 4.52 and simplifying yields Equation 4.57 
        𝑉𝐶𝑂2 =
2∗𝐾𝐶𝑂2∗𝐴𝑠∗𝑄𝑔∗𝑃𝐶𝑂2𝑏
̅̅ ̅̅ ̅̅ ̅̅ ̅
(2∗𝑄𝑔)+(𝐾𝐶𝑂2∗𝐴𝑠∗𝑃𝑔)
     (4.57) 
 Matlab code was generated to predict VCO2 from Equation 4.57. P̅CO2b was assumed to 
be 40 mmHg for separate plots. Unpublished data from the early cTAL prototype in Cook et al, 
resulted in a KCO2 of 4.61 mLCO2/(min*mmHg).(17) Equation 4.54 was used to calculate VCO2 at 
sweep gas flowrates from 0 to 5 L/min and a blood flowrate of 1.25 L/min. VCO2 was plotted as a 
function of sweep gas flowrate and device surface area. Refer to Appendix E for all Matlab code. 
4.2.2 Computational Fluid Dynamics Modeling: 
 Computational Fluid Dynamics (CFD) was utilized to investigate the flow patterns and 
device resistance of the PAD. Drafting of the PAD fluid and fiber bundle domains was completed 
using Solidworks 2015 (Dassault Systems, Velizy-Villacoublay Cedexx, France). CFD modeling 
was performed using the ANSYS Workbench 14.5 package (ANSYS Inc., Canonsburg, PA).  
Domain Drafting 
 The CAD for the PAD computational simulations consisted of three domains; the housing 
inlet fluid domain, the fiber bundle porous media domain, and the housing outlet fluid domain. 
(Figure 4.4) These domains were drafted as a multibody part and imported into ANSYS using a 
direct export from Solidworks. This automatically sews the shared faces of all of the domains, so 
that a conformal mesh was produced. The fiber bundle geometry includes an additional face at the 
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front and rear of the 
device where the fiber 
bundle curvature meets 
the housings.(Figure 4.5) 
These faces were created 
for three reasons: 1) the 
fiber bundle is 
compressed slightly 
when meeting up the 
housing to prevent 
shunting of blood around 
the fiber bundle, 2) the 
mesh is more difficult to 
refine without highly 
skewed elements at these 
bundle-housing 
interfaces if a tangential 
bundle geometry is used, 
and 3) where the fiber 
bundle meets the housing 
a single fiber contacts the 
housing and acts as a face. These faces were added and sized at 0.008 inches to approximate the 
thickness of a single fiber.  
 
Figure 4.4: The domains modeled in the CFD analyses. 
 
Figure 4.5: A zoomed in image of the domains modeled in the 
CFD analyses with one of the flat faces labeled that was added to 
the fiber bundle where the fiber bundle meets the housing. 
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Mesh Generation 
 After domain drafting 
an ANSYS workbench Fluent 
fluid flow analysis system 
was created. The ANSYS 
Meshing module was utilized 
to produce the finite volume 
discretized mesh using free 
meshing scheme with 
refinement zones where 
complex fluid dynamics were 
expected. The mesh was 
refined in the blood inlet 
region (Figure 4.6) and at the 
interface faces between the 
bundle and housing at the 
front and rear of the fiber 
bundle.(Figure 4.7) Mesh sizings were repeatedly halved during the grid dependence study. Mesh 
global settings and refinement settings for the grid dependence study are shown in Table 4.1. A 
Figure 4.6: The inlet region of mesh refinement. 
Figure 4.7: The bundle-housing interface area of mesh 
refinement. 
Table 4.1: The mesh sizing settings for the grid dependence study of the PAD CFD.
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sample mesh can be seen in Figure 4.8.  
Model Parameters  
 The housing inlet and outlet fluid domains were modeled as a Newtonian fluid with a 
density of 1040 kg/m3 and a dynamic viscosity of 3.0 cP to simulate blood. However, blood is non-
Newtonian so the computational model will vary to some degree from in vivo fluid dynamics. The 
bundle domain was modeled as a Darcy porous media. The Darcy porous media model in Ansys 
incorporates two input parameters; the bundle porosity and the viscous resistance coefficient, 
CRvisc. As discussed in the computational bundle design section, the porosity of the bundle was 
obtained using Equation 4.15 coupled with fiber mat physical dimensions, diameter and spacing. 
The calculated permeability of a similar fiber mat, 2.81e-9 m2, was converted to the viscous 
 
Figure 4.8: A mesh used in the CFD analysis of the PAD. 
Table 4.2: Blood flow characteristics as a function of blood flowrate and inlet dimensions.
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resistance coefficient for input into the porous media definition in Ansys Fluent using Equation 
4.58  
             𝐶𝑅𝑣𝑖𝑠𝑐 =
1
𝑘𝑝
        (4.58)  
Boundary Conditions  
 The blood inlet was modeled with a uniform blood inlet velocity specified in Table 4.2 to 
simulate a blood volume flowrate of 1.25 L/min for PAD’s with inlet diameters of 3/8 and 1/2 inches 
and inlet/outlet tapering angles of 30 and 45 degrees.(Figure 4.9) The blood outlet was modeled 
as an outflow with a constant pressure of 8 mmHg to simulate a mean left atrial pressure if the 
device is attached in a pump controlled pulmonary artery to left atrium.(Figure 4.10) A no-slip 
boundary condition was 
imposed at all walls where the 
fluid meets the housing, 
including the regions within 
the fiber bundle.  
Convergence Monitoring 
 Convergence monitors 
were imposed to iterate the 
computation until crucial 
output parameters converged. 
The solution was deemed to 
be “converged” if all 
monitored output parameters 
for a given iteration varied by 
Figure 4.9: A top view of the PAD with inlet angle labeled. 
Figure 4.10: The inlet and outlet boundary condition 
locations used in the PAD CFD. 
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less than or equal to 0.2% 
from the previous 15 
iterations. The first 20 
iterations were ignored to 
eliminate false convergence 
from the imposed 
initialization. Area weighted 
averaged pressure and 
velocity at the inlet and outlet 
face of the fluid domain were monitored to ensure that a converged device flow resistance was 
achieved. The area weighted average velocity component in the y direction (front to back on the 
bundle) and the area weighted average velocity component in the z direction (along the pathlength 
of the bundle) were monitored on the top surface of the fiber bundle on the inlet half of the device 
since flow patterns will vary greatly in the inlet half of the device and were used for design 
comparisons.(Figure 4.11) The area averaged velocity component in the x-direction was not 
monitored since the flow patterns are largely symmetric in this direction.  
Numerical Solver Scheme 
 Fluent’s pressure based steady flow solver in double precision was utilized to calculate the 
finite volume solution of the fluid dynamics within the PAD. Peak Reynolds numbers dictated 
modeling in the laminar regime. (Table 4.2) The pressure-velocity coupling of the solver was set 
to “SIMPLE”, the spatial discretization gradient was set to Least Squares Cell Based, the spatial 
discretization pressure was set to PRESTO!, and the special discretization Momentum was set to 
Second Order Upwind. Solution stability was maintained with the following under-relaxation 
 
Figure 4.11: The top surfaces of the fiber bundle (highlighted 
in bright green) used in convergence monitoring of the PAD 
CFD. 
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factors; Pressure = 0.3, Density = 1, Body Forces = 1, and Momentum = 0.5. The solution was 
initialized with a standard initialization outlet gauge pressure of 8 mmHg and outlet normal 
velocity equal to the velocity set at the inlet boundary condition. 
Fluid Mechanics Post Processing  
 All post processing for the final mesh and grid dependence study was performed using 
Ansys CFD-Post. In order to assess the performance of the PAD, numerical data investigating 
gross properties and graphical data to visualize fluid flows were analyzed. Numerically, area 
weighted averages were taken of pressure and velocity at the blood inlet, blood outlet, bundle top 
surface, and bundle bottom surface. These were then used to calculate the overall device resistance 
and component resistances.    
 Contour and vector plots were produced on preexisting device surfaces as well as user 
defined surfaces at specific regions in the device. A contour plot of velocity was produced on the 
existing top surface of the fiber bundle. Two horizontal user defined planes parallel to the top 
surface of the fiber bundle (xy-plane) were created for velocity contour and vector plots at key 
Figure 4.12: The horizontal domain slices used to create vector and contour plots. 
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locations in the inlet half of the 
fluid domain. The horizontal 
planes referred to as “bundle-
housing slice,” and “inlet slice” in 
the vertical direction (z-direction) 
align with the point where the 
fiber bundle first contacts the 
housing and the midpoint of the 
blood inlet conduit, 
respectively.(Figure 4.12) Two 
vertical user defined planes 
parallel to the side face of the 
fiber bundle (yz-plane) were 
created. The vertical planes 
referred to as “quarter slice” and 
“mid slice” in the horizontal direction across the width of the fiber bundle (x-direction) align with 
the point one quarter across the fiber bundle and with the point halfway across the fiber bundle, 
respectively.(Figure 4.13) All user defined surfaces were used for producing velocity vector plots. 
In addition to vector and contour plots, streamlines were produced from 1000 points on the inlet 
blood conduit face. All velocity contour plots were inspected for areas of stasis. Velocity vectors 
and streamlines were inspected for areas of recirculation.  
Grid Dependence Study 
 A grid dependence study was performed to ensure that the volume discretized grid spacing 
Figure 4.13: The vertical domain slices used to create 
vector and contour plots. 
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was refined sufficiently to produce 
results that do not change 
significantly with further grid 
refinement. This was achieved by 
progressively halving the grid 
spacing until results varied by less 
than 5% between spacings. Area 
weighted averages of fluid inlet 
and outlet velocities and pressures 
and the calculated resistance were 
included in the grid dependence 
study. Area weighted averages of 
the velocity component in the y 
direction (front to back on the 
bundle) of velocity and velocity 
component in the z direction (side 
to side on the bundle) were 
calculated for the grid dependence 
study at the inlet slice and bundle-
housing slice.  
4.3 Results 
4.3.1 Computational Bundle Modeling  
 Bundle computational modeling was performed to design the PAD’s bundle. As can be 
Figure 4.14: A plot of bundle path length as a function 
of frontal area for a range of bundle surface areas. 
Figure 4.15: A plot of bundle resistance as a function of 
frontal area for a range of bundle surface areas. 
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seen in Figure 4.14, the path length 
of the bundles decreased as the 
frontal area was increased for a 
given surface area, and at a fixed 
frontal area the path length 
increased with increasing surface 
area. The resistance also decreased 
with increasing frontal area at a 
fixed surface area but to a greater 
extent than path length, as can be 
seen in Figure 4.15. The resistance 
also increased with increasing 
surface area at a fixed frontal area.  
 The carbon dioxide 
removal by the PAD, VCO2, can be 
seen in Figure 4.16. At all surface 
areas, the VCO2 asymptotically 
increases towards a maximum as 
sweep gas flowrate is increased, 
and this asymptotic value increases 
with surface area. The oxygen 
exchange, VO2, can be seen in Figure 4.17. Increasing the frontal area while keeping surface area 
fixed decreases the oxygen exchange, and increasing the surface area while keeping the frontal 
Figure 4.16: A plot of carbon dioxide exchange as a 
function of sweep gas flowrate for a range of bundle 
surface areas while utilizing a single PAD module. 
Figure 4.17: A plot of oxygen exchange as a function of 
frontal area for a range of bundle surface areas when the 
blood hemoglobin level is 12 g/dL. 
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area fixed increases the oxygen 
exchange. The outlet hemoglobin 
oxygen saturations can be seen in 
Figure 4.18. The general trend was 
for outlet saturations to decrease 
with increasing frontal area and 
increase with increasing surface 
area.  
4.3.2 Computational Fluid 
Dynamics Modeling  
 The CFD simulation results 
were analyzed in both a quantitative and qualitative manner. From a quantitative standpoint, 
bundle resistance, inlet manifold resistance, outlet manifold resistance, and total resistance were 
organized into Table 4.3 for all housing designs. As would be expected the bundle resistances 
were similar amongst all housing designs with bundle resistances ranging from 0.666 to 0.677 
mmHg/(L/min). The resistances of the remaining components and in turn overall resistance varied 
between designs, most drastically between blood conduit diameters. The predicted resistances 
were dominated by the bundle resistance, followed by the outlet manifold resistance, and lastly the 
inlet manifold resistance.  
Figure 4.18: A plot of outlet oxygen saturation as a 
function of frontal area for a range of bundle surface 
areas when the blood hemoglobin level is 12 g/dL. 
Table 4.3: Blood flow characteristics as a function of blood flowrate and inlet dimensions.
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 In a qualitative 
manner, streamlines and 
velocity vector plots were 
inspected for areas of 
recirculation, and band 
plots of velocity were 
inspected for regions of 
stasis. When inspecting 
the streamlines for all of 
the housing geometries 
(Figure 4.19) the most 
distinguishing feature of 
the flow patterns was 
fluid jetting from the 
device inlet. This jetting 
effect resulted in fluid impacting the rear of the device and recirculating in two recirculations that 
spanned from the rear to the front of the device. These recirculations were also evident in the 
velocity vector plots of the inlet slice for all housing geometries.(Figure 4.20) When inspecting 
the velocity vectors of the vertical midslice, further small recirculations were evident in all housing 
geometries.(Figure 4.21) These recirculations reside at the rear and front of the fiber bundle on 
the inlet half of the device. The vertical quarter slices also exhibited the rear recirculations seen in 
the midslices.(Figure 4.22) The frontal recirculations reside further back on the bundle in the 
quarter slice in comparison to the mid slice. In all cases the fiber bundle evens out flow on the 
Figure 4.19:Streamline plots. Top: 0.375” conduit, 45˚ taper. 
Bottom: 0.5” conduit, 45˚ taper. 
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outlet half of the device.  
 When inspecting 
the band plots of velocity 
the main areas of stasis 
were at the center of the 
recirculations in the inlet 
half of the device for all 
designs.(Figure 4.23) 
Additionally, high 
velocities were evident in 
the center of the housing 
where the jetting fluid 
impacts the fiber bundle.   
4.4 Discussion  
4.4.1 Computational 
Bundle Modeling  
 The bundle computational modeling was used to design the fiber bundle used in the 
pulmonary assist device. Due to the non-linearity between frontal area and bundle resistance 
additional functionality gains from reducing resistance through increased frontal area level off with 
frontal areas exceeding 35-40 cm2 depending on bundle surface area. Increasing frontal area 
beyond these values would add to device size and prime volume, and decrease gas exchange. 
However, all predicted bundle resistances were close to five times lower than the overall device 
resistance goal.  
Figure 4.20: Velocity Vector plots, inlet slice. Top: 0.375” 
conduit, 45˚ taper. Bottom: 0.5” conduit, 45˚ taper. 
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  In choosing a fiber 
bundle sizing based on 
oxygen exchange, a more 
stringent outlet saturation 
of 98% was chosen to 
allow for errors in the 
computational models. 
The gas exchange 
constants, m and Φ, used 
from an early cTAL 
prototype were expected 
to overestimate gas 
exchange since the outlet 
saturations produced 
during in vitro testing of 
this device never dropped to 98% or lower. The outlet hemoglobin saturations for the 0.1 and 0.2 
m2 surface area bundles are inadequate at all frontal areas modeled. The 0.3, 0.4, and 0.5 m2 surface 
area bundles produce 98% saturations at frontal areas below 25.2, 36.3, and 48.2 cm2, respectively.  
 The carbon dioxide exchange for the PAD ranged from inadequate to more than adequate. 
The goal for CO2 exchange was at least 50 mL/min of carbon dioxide exchange with up to 5 L/min 
of total sweep gas at a blood flowrate of 1.25 L/min/module. Any surface area above 0.3 m2 would 
provide adequate CO2 exchange for the PAD when increasing the sweep gas flowrate to 5 L/min. 
For surface areas 0.4 m2 and above target carbon dioxide transfer could be achieved with sweep 
Figure 4.21: Velocity Vector plots, mid slice. Top: 0.375” 
conduit, 45˚ taper. Bottom: 0.5” conduit, 45˚ taper. 
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gas flowrates of 1.5 
L/min, reducing the 
demands on oxygen 
concentrators or oxygen 
tanks.  
 The aspect ratio of 
the bundle, which is 
essentially a measure of 
the amount of curvature in 
the rolled fiber bundle, 
was a minor decision 
making variable in 
comparison to gas 
exchange and resistance. 
However, it was desired 
to have a fiber bundle with an aspect ratio close to that of the previously tested cTAL (2.7) for ease 
of manufacture and to reduce the effect of the curved regions of the fiber bundle on gas exchange. 
Bundles with surface areas below 0.3 m2 had aspect ratios at least that of the cTAL for all 
investigated frontal areas. However, for surface areas of 0.3 m2 and greater, frontal areas in the 30-
40 cm2 range are needed to achieve aspect ratios as large as the cTAL. 
 In the final bundle design the bundle resistance, aspect ratio, carbon dioxide exchange, and 
oxygen exchange were taken into account. The carbon dioxide and oxygen exchange requirements 
of the PAD eliminate all devices with surface areas less than 0.3 m2. At a surface area of 0.3 m2 
Figure 4.22: Velocity Vector plots, quarter slice. Top: 0.375” 
conduit, 45˚ taper. Bottom: 0.5” conduit, 45˚ taper. 
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oxygen exchange 
requirements would 
dictate a frontal area less 
than 25.2 cm2 while the 
resistance and aspect ratio 
requirements would 
dictate a frontal area in 
the 30-40 cm2 range. 
Additionally, the carbon 
dioxide exchange 
capabilities of the 0.3 m2 
surface area device would 
be barely adequate. As a 
result, the PAD bundle 
surface areas were 
narrowed down to 0.4 and 0.5 m2.  
 When investigating the gas exchange capabilities of the 0.4 m2 device the carbon dioxide 
removal requirements should be met at low sweep gas flowrates and the oxygen exchange 
requirements would be met with a frontal area less than 36.3 cm2. Using a cTAL aspect ratio the 
frontal area would be 35.9 cm2 and the bundle resistance would be 0.79 mmHg/(L/min).  
 When investigating the gas exchange capabilities of the 0.5 m2 device the carbon dioxide 
removal requirements should be met at low sweep gas flowrates and the oxygen exchange 
requirements would be met with a frontal area less than 48.2 cm2 of frontal area. Using a cTAL 
Figure 4.23: Velocity Band Plots, bundle top. Top: 0.375” 
conduit, 45˚ taper. Bottom: 0.5” conduit, 45˚ taper. 
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aspect ratio the frontal area would be 41.6 cm2 and the bundle resistance would be 0.74 
mmHg/(L/min). 
 Between these two surface areas, the smaller surface area should result in a lower 
resistance, increased aspect ratio, and reduced prime volume and physical size of the device at a 
given frontal area. Additionally, the smaller surface area device does not have as much surface 
area to react with the blood and induce clot formation. However, the gas exchange capabilities of 
the larger surface area device are greater at a given frontal area. When taking into account the 
aspect ratio of the two surface area bundles, the 0.5 m2 device would need to be a little larger in 
all directions, but would have similar resistance to the 0.4 m2 device at the aspect ratio of the 
cTAL. Ultimately, the 0.4 m2 fiber bundle was chosen since it had a smaller volume and a smaller 
blood contacting surface area. A frontal area of 35 cm2 was chosen since it should meet all design 
requirements.  
 The bundle with a surface area of 0.4 m2 and frontal area of 35 cm2 was further refined to 
increase the aspect ratio. The fiber bundle was increased in length from 5.9 cm to 7 cm increasing 
the aspect ratio from 2.6 to 3.1. The final fiber bundle design of 0.4 m2 surface area and 5 cm wide 
by 7 cm long frontal area was used in subsequent CFD simulations and in vitro testing of the PAD. 
4.4.2 Computational Fluid Dynamics Modeling 
 The computational simulations for all designs were distinguished by a low predicted 
resistance in all cases, but also large levels of recirculations due to jetting of the fluid from the 
blood inlet conduit. The areas of recirculation existed in all inlet designs, but were slightly less 
severe in the 0.5” inlet diameter cases. Additionally, the resistance was lower for the 0.5” inlet 
diameter cases. However, in both inlet diameters this level of recirculation will not be acceptable 
for the PAD to serve as a long term support device, as clot will inevitably form relatively quickly 
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in all of these devices. When comparing 45˚ and 30˚ designs of the same inlet diameter, there was 
little difference between designs. 
 The 0.5” conduit devices have the disadvantage that a majority of current oxygenators, 
cannulas, and pump heads are designed for use with 0.375” diameter tubing. As a result if a 0.5” 
diameter blood conduit were used, tubing sizes from cannulas and pump heads will need to be 
stepped up in size upstream of the device and then back down in size downstream of the device. 
This will result in more connection points where failure can occur, greater heat loss from the 
circuit, increased prime volume, increased system complexity, and increased bulk. Additionally, 
there would likely be market resistance to changing to a non-standard size ECMO tubing. 
 Since all of the housing designs suffered from large areas of recirculations, major design 
modifications will need to be made to the device for in vivo testing. Initial prototypes of the PAD 
were produced from these computational simulations to provide a baseline for gas exchange and 
future computational modeling. The 0.5” blood conduit device exhibited slightly improved 
resistance and flow patterns over the 0.375” blood conduit device, but the non-standard tubing size 
was a major disadvantage. Ultimately, the 0.375” blood conduit PAD was chosen since it utilizes 
a more standard 0.375” tubing size and will serve as a better baseline of comparison for the 
redesigned PAD.  
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Chapter 5: Pulmonary Assist Device In vitro Testing 
5.1 Introduction 
 The computational modeling of the PAD predicted a device with a resistance of 1.50 
mmHg/(L/min), and 98% oxyhemoglobin saturation when processing 1.25 L/min of blood. In vitro 
testing was carried out to characterize the actual gas exchange and resistance performance of 
prototype devices. The in vitro resistance was compared to the resistance predicted by the 
computational modeling to validate or invalidate the computational fluid dynamics model. The in 
vitro gas exchange results were used to both compare to modeling results as well develop more 
effective dimensionless constants for that model. The gas exchange constants used in the modeling 
(1) are expected to be at least somewhat inaccurate in that they were derived from experiments 
where the gas exchanger was never challenged enough to produce accurate constants. In those 
experiments, the outlet oxygen saturation never dropped to 98%.(1) The PAD gas exchange 
experiments performed here were designed to challenge the device to a greater extent and thus 
should yield more accurate constants. 
5.2 Methods 
5.2.1 In vitro Test Device Prototyping 
 Five prototype PAD devices were fabricated for testing in in vitro gas exchange and 
resistance experiments. Detailed specifications on the fabrication process can be seen in the 
appendix. A basic outline of the fabrication process is outlined as follows. First a fiber bundle core 
was cut using a laser cutter (Trotec Laser, Inc, Canton, MI). Then the fiber was attached to the 
core using a small amount of Wacker Elastosil RT625 PDMS (Wacker Chemie AG, Germany) in  
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a region where the fiber is not exposed to blood. The bundle was then rolled a given number of 
turns and measured until the final bundle dimensions were obtained. The loose end of the fiber 
was then attached to the main fiber bundle using a small amount of PDMS in a region where the 
fiber is not contacted by blood. The bundle was completed by painting a small amount of PDMS 
onto the ends of the fibers to secure the layers of the bundle to each other. A housing was fabricated 
from ABS using a 3-D printer. The porosity of the 3-D printed housings resulting in fluid leakage 
through the housing. Multiple coating methods on the inside and outside of the device housing 
were employed to eliminate the leakage. (Table 5.1) The external epoxy coating was applied by 
spreading marine grade epoxy on all surfaces not enclosed by the gas caps of the assembly. The 
internal PVC coating was applied by painting PVC dissolved in cyclohexanone on all internal 
surfaces not in contact with potting material. As the cyclohexanone evaporated, PVC was left 
behind on all coated surfaces. Internal silicone coating was applied by painting Med-6019 silicone 
(Nusil Technology LLC, Carpinteria, CA) onto all internal surfaces not in contact with potting 
material. The fiber bundle was inserted into the housing, and the housing was glued together with 
PDMS. The ends of the fiber bundle were encased in polyurethane (“potted”) using a centrifuge 
separate the blood and gas space of the device. The potted region of the bundle was cut to expose 
the lumen of the fibers. The outside of the housing was coated with epoxy to further seal the 
housing, and gas caps were attached to the device using silicone RTV.  
5.2.2 In vitro Gas Exchange Testing 
Table 5.1: The coating methods employed to prevent leakage during PAD testing. 
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 The oxygen and 
carbon dioxide exchange 
capabilities of the 
pulmonary assist device 
were tested in an in vitro 
testing circuit seen in 
Figure 5.1. The circuit is 
composed of two main 
branches separated by 
tubing clamps: a 
conditioning 
recirculation circuit 
shown in blue and a 
device testing circuit 
shown in blue and red. Approximately 4 gallons of fresh bovine blood was anticoagulated 
immediately on collection with 180,000 units of heparin and 64 mg of sodium citrate dehydrate 
(Sigma Aldrich, St. Louis, MO). The conditioning circuit was primed with carbon dioxide for ease 
of bubble removal. The bovine blood was inserted into the feed reservoir common to both branches 
of the circuit and the reservoir was sealed. Blood was recirculated through the conditioning circuit 
with a centrifugal pump (Terumo Cardiovascular, Ann Arbor, MI or Medtronic, Minneapolis, MN) 
at flowrates ranging from 2.5 to 3 L/min per conditioning gas exchanger. The clamped off device 
testing circuit was primed first with carbon dioxide at a flowrate of 5 L/min for a minimum of 2 
minutes, and then saline to ensure that the test device was free from air bubbles.  
 
Figure 5.1: The in vitro gas exchange circuit comprised of a 
conditioning branch and a test branch separated by tubing clamps. 
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Blood Conditioning  
 Within the conditioning circuit, two to 
three gas exchangers (Terumo Cardiovascular, 
Ann Arbor, MI or Maquet, Germany) were used 
to continuously condition the blood gasses and 
blood temperature to AAMI specifications, as 
listed in Table 5.2. The sweep gas was balanced with a blend of nitrogen, oxygen, and carbon 
dioxide to condition the blood gasses. The hemoglobin was adjusted down to AAMI specifications 
by saline addition, and the base excess was adjusted by the addition of sodium bicarbonate. Blood 
gas samples were drawn and tested with a blood gas analyzer (Radiometer, Denmark) 
approximately every 10-30 minutes to obtain the status of the blood conditioning, and the 
temperature was monitored with a temperature probe (YSI, Yellow Springs, OH) and monitor 
(YSI, Yellow Springs, OH or Seabrook Medical Systems, Inc, Cincinnati, OH). Once the blood 
was conditioned to AAMI standards, a two point calibration was performed on the blood gas 
analyzer to ensure measurement accuracy, and a new blood gas sample was drawn and tested to 
confirm appropriate blood conditioning before commencing the experimental run. 
PAD Testing 
 After the blood was conditioned, the pump was stopped, the conditioning circuit was 
clamped off, and the test circuit was unclamped. The pump was then restarted and blood was 
pumped through the PAD and into a waste reservoir. The blood supply reservoir contained a 
polyethylene expansion bag connected to an opening on the lid of the reservoir. This provided a 
barrier between the conditioned blood and the atmosphere to prevent gas exchange within the 
reservoir while limiting pressure changes in the reservoir. The pump flowrate was measured using 
Table 5.2: AAMI blood conditioning 
specifications. 
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a 3/16” PXL tubing flow 
probe and associated 
TS410 flowmeter 
(Transonic, Ithaca, NY) 
and was set to the target 
blood flowrates (Table 
5.3). Concurrently, sweep gas containing pure oxygen was supplied to the gas inlet of the PAD at 
a flowrate twice that of the target blood flowrate. One minute was allowed between the start of 
blood pump adjustment and sample taking to allow for full saline and blood clearance from the 
PAD. Table 5.3 shows the target blood and sweep gas flowrates tested and the order in which they 
were tested. At each condition, blood samples were drawn in duplicate from the blood inlet and 
outlet of the PAD and analyzed in a blood gas analyzer. A sweep gas sample was also drawn in 
duplicate and analyzed with a blood gas analyzer to measure the carbon dioxide content for carbon 
dioxide exchange calculations. Following sampling, the pump was adjusted to the next flowrate 
with one minute between start of adjustment and the next round of sampling, and the process was 
repeated for all test conditions.  
Gas Exchange Calculation  
 All duplicate blood and sweep gas samples were first averaged for calculation purposes. 
The outlet blood oxygen saturations were calculated from the pH and partial pressure of oxygen 
in the outlet blood according to Equations 4.22 and 4.24. The outlet saturation was then plotted 
as a function of blood flowrate. The oxygen transfer rate V̇O2 in mL/min was calculated using 
Equations 4.45 and 4.26-4.28. The volume rate of carbon dioxide exchange (V̇CO2) in mL/min 
was calculated from the sweep gas outlet sample using Equation 5.1 
Table 5.3: The blood and gas flowrate conditions for PAD 
testing. 
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     𝑉𝐶𝑂2
̇ =  𝑄𝑔 ∗ 𝐶𝐶𝑂2         (5.1) 
where Qg is the sweep gas flowrate through the device in mL/min, CCO2 is the fractional 
concentration of carbon dioxide in the sweep gas outlet. The V̇O2 and V̇CO2 were graphed to assess 
gas exchange performance. 
Experimental Oxygen Exchange Constants Calculation 
 The experimental data from the PAD testing was used to calculate new gas exchange 
constants, m and Φ, for future fiber bundle modeling. According to previous gas exchange theory 
for artificial lungs the gas exchange characteristics can be modeled locally using Equation 4.39, 
re-written below for convenience.(2-6) 
        Φ ∗ 𝑁𝑅𝑒
−𝑚 =  
Φ𝑓∗𝑝𝑜𝑟
4∗(1−𝑝𝑜𝑟)
∗ (
𝜇
𝜌∗𝐷𝑊𝐵
)
2
3⁄
∗
(1+𝜆(𝑃𝑂2))
2
3⁄
(𝑃𝑔−𝑃𝑂2)
∗
𝑑𝑃𝑂2
𝑑𝑥
   (4.39) 
In the case of experimental data, the path length of the fiber and the inlet and outlet partial pressures 
of oxygen in the blood are known, but m and Φ as well as the distribution of the partial pressure 
change of oxygen within the fiber bundle are not known. The global solution to Equation 4.39 
can be obtained by integration yielding Equation 5.2.(6) 
                                Φ ∗ 𝑁𝑅𝑒
−𝑚 =  
Φ𝑓∗𝑝𝑜𝑟
4∗(1−𝑝𝑜𝑟)
∗ (
𝜇
𝜌∗𝐷𝑊𝐵
)
2
3⁄
∗ 
                                    
1
𝑃𝐿
∗ ∫
(1+𝜆(𝑃𝑂2))
2
3⁄
(𝑃𝑔−𝑃𝑂2)
∗
𝑑𝑃𝑂2
𝑑𝑥
𝑃𝐿
0
𝑑𝑥      (5.2) 
Which can be simplified and rearranged to form Equation 5.3 that utilizes the known inlet and 
outlet partial pressures of oxygen from experimental data for the integration.(6) 
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Φ ∗ 𝑁𝑅𝑒
−𝑚 =  
Φ𝑓 ∗ 𝑝𝑜𝑟
4 ∗ (1 − 𝑝𝑜𝑟)
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)
2
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∗ 
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𝑃𝑂2𝐼𝑛
𝑑𝑃𝑂2        (5.3) 
The right hand side of Equation 5.3 was calculated using a trapezoidal numerical integration with 
a 1 pascal step size for all flowrates tested with the PAD. The Reynolds number was calculated for 
all flowrates using Equation 4.41, re-written below for convenience.(3-6) 
     𝑁𝑅𝑒 =  
𝑄𝑏∗Φ𝑓∗𝜌
(1−𝑝𝑜𝑟)∗𝐴𝑓∗𝜇
       (4.41)  
All data was combined into a single data set and a log-log plot with Reynolds number on the x-
axis and the right hand side of Equation 5.2 on the y-axis was then produced. A power law fit was 
performed on the data in excel, yielding values of m and Φ.  
5.2.3 In Vitro Resistance Testing and Computational Model Validation: 
 The computational model validation testing was performed by comparing in vitro 
resistance measurements to the resistance predicted by the computational fluid dynamics. In vitro 
resistance testing was performed by measuring the pressure drop from the PAD blood inlet to the 
blood outlet while pumping at a known flowrate. The in vitro resistance test circuit can be seen in 
Figure 5.2.  The flowrate provided by the pump was measured by a tubing flow probe and 
associated flow meter, and was recoded using a Biopac data acquisition system.(Biopac Systems, 
Inc, Goleta, CA) The pressure drop was recorded by placing tubing T-connectors upstream of the 
PAD blood inlet and downstream of the blood outlet to create pseudo-manometers. As the pressure 
increases in the blood conduits the fluid rises according to a gravitational pressure head equal to 
the pressure inside the blood conduits. The difference in fluid heights were measured with a 
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caliper, and the pressure drop was calculated using Equation 5.4 
       ∆𝑃 =  𝜌 ∗ 𝑔 ∗ ∆ℎ         (5.4) 
where ΔP is the pressure drop from the blood inlet to blood outlet, ρ is the measured fluid density, 
g is the gravitational acceleration, and Δh is the height difference between fluid heights in the 
vertical fluid column tubes. The total resistance, Rt, for the PAD and tubing between the T-
connectors and device was calculated from Equation 5.5 
          𝑅𝑡 =  
∆𝑃
𝑄
          (5.5) 
where ΔP is the pressure drop from the inlet to outlet T connector and Q is the fluid flowrate 
through into the PAD. The resistance of the conduits between the T-connectors and the PAD, RC, 
was calculated as laminar flow through a pipe according to Equation 5.6 
     𝑅𝑐 =  
128∗(𝐿𝑖𝑛+𝐿𝑜𝑢𝑡)∗𝑄∗𝜇
𝜋∗𝐷𝑐
4         (5.6) 
where Lin is the distance between the inlet conduit and the inlet T-connector, Lout is the distance 
 
Figure 5.2: The in vitro resistance testing circuit with the fluid column height difference 
labeled with Δh.  
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between the outlet conduit and the outlet T-connector, Q is the fluid flowrate, μ is the dynamic 
viscosity, and Dc is the inside diameter of the blood conduits. Since the resistances of the PAD and 
conduits are in series with each other, the resistance of the PAD, RPAD, was calculated as the blood 
conduit resistance subtracted from the total resistance in Equation 5.7  
            𝑅𝑃𝐴𝐷 =  𝑅𝑡 − 𝑅𝑐          (5.7) 
Combining Equations 5.3-5.7 yielded the final equation for the resistance of the PAD, Equation 
5.8 
    𝑅𝑃𝐴𝐷 =  
𝜌∗𝑔∗ℎ
𝑄
−
128∗(𝐿𝑖𝑛+𝐿𝑜𝑢𝑡)∗𝑄∗𝜇
𝜋∗𝐷𝑐
4        (5.8)  
 This experiment was performed (n=4) using glycerol with a dynamic viscosity of 3.0 cP 
and a density of 1068 kg/m3 to simulate blood by matching the Reynolds number of blood in the 
PAD within 3%. At a flowrate of 1.25 L/min, the Reynolds number of the glycerol in the fiber 
bundle and blood inlet conduit during in vitro testing were 1.59 and 992, respectively. At a flowrate 
of 1.25 L/min, the Reynolds number of blood in the fiber bundle and blood inlet conduit would be 
1.55 and 965, respectively. The resistance was calculated at flowrates of 0.5, 0.75, 1, 1.25, 1.5, 
1.75, and 2 L/min and were graphed as a function of flowrate. The flowrate of 1.25 L/min was 
used to compare to the computational model.  
5.3 Results 
5.3.1 In Vitro Gas Exchange Testing 
 There was a range in oxygen exchange capabilities between the individual prototypes tested 
as can be seen in Figures 5.3 and 5.4. The outlet hemoglobin oxygen saturation levels were 
relatively high among PADs 3, 4, and 6. PADs 7 and 8 had considerably lower outlet saturations. 
In all cases, the outlet saturations decreased with increasing blood flowrate. The amount of oxygen 
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exchanged, VO2, also varied greatly between devices. The VO2 for PADs 3 and 4 were higher than 
the other devices, exceeding 90 mL/min at a blood flowrate of 2.5 L/min. The VO2 for PADs 7 
and 8 was considerably lower, close to half the VO2 of PADs 3 and 4. PAD 6 had VO2s in between 
the two other groups of devices. In all cases the VO2 increased with increasing blood flowrate as 
would be expected.  
 As can be seen in Figure 5.5, the carbon dioxide exchange, VCO2, followed similar 
patterns where the carbon dioxide exchange was highest for PADs 3 and 4, and lowest for PADs 
7 and 8. Once again PAD 6 performed in between the two groups, but had only slightly better 
performance than PADs 7 and 8. The CO2 exchange increased with increasing sweep gas flowrate. 
 For future gas exchange modeling the oxygen exchange modeling constants, m and Φ, were 
Figure 5.3: The outlet hemoglobin oxygen saturation as a function of blood flowrate. 
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calculated for all PADs grouped together, and for PADs 3, 4, and 6 grouped together. The log-log 
graph of the right hand sides of Equation 5.3 on the y axis and Equation 4.41 on the x axis can 
be seen in Figure 5.6 for all PADs tested. When grouping all devices together the m and Φ, were 
0.718 and 0.4636R2 (R2 = 0.71). When grouping PADs 3, 4, and 6 together the m and Φ, were 
0.654 and 0.5409, respectively (R2 = 0.89). 
5.3.2 In Vitro Resistance Testing and Computational Model Validation 
 When pumping glycerol through the PAD, the resistance of the device increased in a linear 
manner as can be seen in Figure 5.7. The linear fit of the data yields Equation 5.9, and has a R2 
of 0.974. 
𝑅𝑃𝐴𝐷𝑔 = (0.8758 ∗ 𝑄) + 2.3405      (5.9)  
Figure 5.4: The oxygen exchange as a function of blood flowrate. 
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where RPADg is the resistance of the PAD in mmHg/(L/min) using glycerol and Q is the glycerol 
flowrate in L. At 1.25 L/min, the in vitro testing of the PAD yielded a resistance of 3.650±0.004 
mmHg/(L/min) while the computational simulations predicted a resistance of 1.498 
mmHg/(L/min). 
5.4 Discussion 
5.4.1 In vitro Gas Exchange Testing 
 The prototype PADs did not meet performance goals in terms of oxygen exchange with the 
device saturating outlet blood to less than 95% at all blood flowrates above 0.5 L/min. Most notable 
was that PADs 7 and 8, that were prototyped in a single batch, performed significantly worse than 
the other three devices. Post experiment, gas resistance testing was performed to quantify the 
opposition to sweep gas flow. Comparison of gas resistance testing results is an indirect method 
Figure 5.5: The carbon dioxide exchange as a function of sweep gas flowrate. 
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for measuring the relative amount of unplugged fibers of a device in relation to other devices. In 
these tests, PADs 7 and 8 had an average gas flow resistance of 3.8 mmHg/(L/min)while PADs 3, 
4, and 5 had an average resistance 
of 1.3 mmHg/(L/min) at a sweep 
gas flowrate of 2.5 L/min, 
indicating plugging of the lumen of 
a large portion of fibers, leading to 
poor gas exchange. This plugging 
may be the result of fiber ends 
being open rather than sealed shut 
during the potting process, which 
Figure 5.6: The dimensionless oxygen exchange as a function of Reynolds number. 
Figure 5.7: The resistance of the PAD as a function of 
glycerol flowrate. 
148 
 
would allow potting material to build up significantly on the inside of the fibers. Another 
compounding factor that could decrease gas exchange would be a device being potted too deeply, 
which covers up a portion of the gas exchange surface. However, potting depth for the PAD can 
only be checked with a destructive measurement. Overall, the PAD’s fiber bundle will need to be 
redesigned for increased oxygen exchange using the new gas exchange constants derived from 
PAD’s 3,4, and 6, and fabrication methods will need to be improved to prevent future plugging of 
the fibers.  
 In terms of carbon dioxide exchange, the devices with the lowest gas resistance (PADs 3 
and 4) outperformed all other prototypes. In order to compare to the carbon dioxide exchange 
prediction predicted by the computational bundle modeling, the amount of carbon dioxide removed 
was compared at a blood flowrate of 1.25 L/min and gas flow rate of 2.5 L/min. At these flowrates 
the computational modeling predicted 57.6 mL/min carbon dioxide removal. Since the in vitro 
tests did not include this exact data point, the carbon dioxide exchange could be linearly 
interpolated between the 1 L/min blood flowrate-2 L/min gas flowrate and 2 L/min blood flowrate-
3 L/min gas flowrate cases to yield a carbon dioxide exchange for a blood flowrate of 1.25 L/min 
and a gas flowrate of 2.5 L/min. PADs 3 and 4 outperformed the computational modeling 
predictions with carbon dioxide removal of 74.5 and 71 mL/min, respectively. PADs 6, 7, and 8 
under performed with carbon dioxide removal of 41.5, 32.5, and 35.5 mL/min. A more in depth 
analysis of carbon dioxide transfer will be needed where blood flowrate is held constant at 1.25 
L/min and the sweep gas flowrate is varied from 1 L/min up to 5 L/min. However, the future 
surface area increases needed to accomplish oxygen exchange goals should result in a PAD that 
will exceed performance goals for CO2 at any reasonable gas flow resistance. 
5.4.2 In Vitro Resistance Testing and Computational Model Validation 
149 
 
 The in vitro resistance testing of the PAD resulted in a resistance of 3.650 mmHg/(L/min) 
with a glycerol flowrate of 1.25 L/min. This single module resistance was lower than the lowest 
gas exchanger resistance on the market, the 5-6 mmHg/(L/min) resistance of the Novalung.(7-9) 
When two modules are placed in parallel, the combined resistance of the PADs is 1.825 
mmHg/(L/min). Although the single module resistance is low, it is more than twice the resistance 
predicted by the computational model, 1.498 mmHg/(L/min). The large discrepancy in resistance 
 
Figure 5.8: Velocity vector plots of the mid-slice. Top: Highlighting a region of fluid jet 
impact on the fiber bundle. Bottom:  Zooming in on this highlighted area. 
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between the computational model and in vitro results is problematic, since the flow patterns 
predicted by the model are not validated. Therefore, the CFD simulations may not provide suitable 
insight into the possible regions of clot inducing blood stasis and recirculation within the PAD. An 
improved CFD model is needed to investigate areas of stasis and recirculation and to redesign the 
PAD for improved fluid flow patterns in the device. 
 The discrepancy between the CFD predictions and in vitro testing likely results from the 
jetting fluid directly impacting the fiber bundle as it flows through the inlet half of the device. In 
the CFD simulation, the jetting fluid impacts the fiber bundle and the jet continues to flow against 
a low resistance fiber bundle to the back of the device as a result of the homogenous Darcy porous 
media model.(Figure 5.8) This reduces the validity of the computational model in two manners: 
(1) as the jet flows over the top of the fiber bundle it will be flowing over the top of a rough surface 
formed by the radii of the individual fibers, resulting in minor losses not predicted by the 
computational model, and (2) the geometry of the layers of fiber in the fiber bundle creates a very 
low permeability path in the direction of the jetting in comparison to the permeability used in the 
computational model.   
 As can be seen in Figure 5.9 
of two layers of fiber mat, as the jet 
enters from the y-direction and flows 
over the top of the fiber bundle it 
encounters the radii of each 
individual fiber in the mat. These 
repeated radii will impart drag and 
minor losses into the flow that will 
Figure 5.9: A two layer mat of fiber with orthogonal 
blood flow directions labeled. 
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not be captured by the porous media model used in these CFD simulations. Numerical data for a 
similar drag as a function of bundle porosity for similar fiber mats exists (5) and may be able to be 
integrated into the CFD model to more fully capture the interactions of the jetting fluid with the 
top of the fiber bundle.  
  The Darcy porous media model used in the CFD simulations models the fiber bundle as 
having a consistent permeability in three dimensions, as if the fiber bundle was a sponge with 
consistent pore size.(10) However, the fiber bundle is composed of a bank of fibers that has large 
geometric variation in three dimensions. An individual layer of fiber in orientated in an ordered 
fashion with a 15˚ offset. Layers are stacked in an alternating fashion to create a 30˚ offset between 
the fibers of alternating layers.(Figure 5.9) The orientation of the fiber arrays creates a 
permeability that varies in three dimensions depending on the flow direction in relation to the fiber 
bundle.  
 In the CFD modeling, the permeability was set according to the assumption that the flow 
through the fiber bundle is largely normal to the top face fiber bundle as can be seen in Figure 5.9 
as flow in the z-direction. However, in the inlet half of the device the direction of flow from the 
jet impacting the fiber bundle varies greatly from the normal direction (z-direction). (Figure 5.8) 
This jetting in the PAD will create flow that varies in all directions, so the fluid will experience 
very different permeabilities depending on the location in the x-y plane of the fiber bundle. As the 
flow progresses through the fiber bundle cases it will eventually normalize to the z-direction. 
However, until the point where the flow is normal to the fiber bundle top face, there will be error 
in the model.   
 An improved permeability model would vary the permeability in all three dimensions. The 
Ansys Fluent software used in CFD modeling has the capability for variation of permeability in 
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three directions. However, experimental derivation of permeability for a fiber bundle in three 
dimensions is not a simple process as fabrication and potting of a fiber bundle with flow coming 
purely from the x or y directions is difficult due to the potting process involved in the fabrication 
of a gas exchanger.  
 Overall, the resistance of the PAD is very low in comparison to commercially available gas 
exchangers, and when placed in a 2 module parallel configuration has a resistance approaching 
that of a healthy natural lung. However, this resistance did not meet the original design goal of 
having a single module resistance of 2.5 mmHg/(L/min). The resistance measured during in vitro 
experiments greatly exceeded the resistance predicted by the CFD analysis, necessitating an 
improvement of the computational model. Following computational model improvement, the PAD 
will need to be redesigned for improved gas exchange and coagulation avoiding blood flow 
patterns.  
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Chapter 6 Conclusion 
6.1 Conclusions 
 This work focused on the design and testing of three extracorporeal gas exchangers for 
treatment of acute and chronic respiratory failure; the compliant thoracic artificial lung (cTAL), 
the compact cardiopulmonary support device (CCSD), and the pulmonary assist device (PAD). 
The cTAL was tested for long term biocompatibility and device function in a 14 day in vivo 
experiment. Computational simulations and in vitro studies were utilized to design individual 
components of the CCSD. Following component design, the entire CCSD system was tested in 
vitro to characterize its pumping abilities. The PAD bundle size was designed using numerical 
modeling of gas exchange and bundle resistance. The PAD housing was designed using 
computational fluid dynamics simulations. In vitro tests were performed to characterize the actual 
gas exchange capabilities and resistance of the PAD. After preforming these studies, it can be 
concluded that: 
6.1.1 cTAL 
1) The cTAL is able to maintain functioning for 14 days without major clot formation, despite a 
lack of anti-coagulant coatings. The resistance of the cTAL’s did not significantly increase as a 
group over the course of the experiment, with only one device exhibiting an increase in resistance. 
However, this device had no visual signs of thrombus formation and resistance measurements may 
have been erroneous. 
2) In vivo resistance of the cTAL in the 14 day experiments (0.99 mmHg/(L/min)) was twice that 
of previous in vitro and acute in vivo experiments (0.51 mmHg/(L/min)). This occurred as a result  
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device positioning on the side of the fiber creating less favorable hydrostatic pressure on the 
compliant housing of the device during 14 day in vivo testing. In turn, the housing collapsed in the 
upper regions of the device, creating altered flow patterns. This resistance is still very low in 
comparison to any other gas exchange device and can provide unloading of the right heart. 
3) The cTAL caused very little dysfunction of the kidneys and liver. In the early post-operative 
time period there were changes in organ function markers due to surgical trauma, but they 
rebounded as the experiment progressed. 
4) Hematologically, the cTAL consumes very little in terms of blood products. Initially, there is a 
large hemodilatory affect from the large prime volume of the device, but hemoglobin counts 
decrease very little over the remainder of the experiment and platelet counts rebound to pre-device 
attachment levels. 
5) Excess clamping on the sides of the fiber bundle can induce stasis and subsequent clotting. Clot 
formation occurred at the fiber bundle of a device that utilized a holder with large clamping forces. 
In subsequent experiments this clot formation was eliminated by reducing clamping force. 
6) The polypropylene fibers of the cTAL allowed plasma leakage after 1 week, but periodic 
increases in sweep gas flowrate was able to effectively clear the plasma. 
6.1.2 CCSD 
1) The individual components of the CCSD perform very well. The enclosure flexure only leads 
to 4.7 mL of stroke loss as it is cycled from -200 mmHg to 300 mmHg. Valves with a leaflet 
thickness of 0.060” and a diameter of 1.125” are able to perform with low levels of backflow at 
flowrates of 4 L/min. 
2) The CCSD system is able to produce flowrates of 4 L/min. However, large magnitude negative 
pressures inside the enclosure induce gas leakage into the blood side of the device. 
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3) Negative enclosure pressures can be reduced by improved priming methods and a change in 
systolic time, but not to an extent that would alleviate risk of gas embolism in a patient. 
6.1.3 PAD 
1) Numerical modeling of the gas exchange and resistance of the fiber bundle predicted that a 
bundle frontal area of 35 cm2 and a surface area of 0.4 m2 would meet design goals. 
2)  CFD modeling predicted that resistance of the PAD will be 1.498 mmHg/(L/min) and 0.963 
mmHg/(L/min) for 0.375 inch and 0.5 inch diameter inlet housings, respectively. Inlet manifold 
angle had very little effect on resistance. Thus, all housing designs were predicted to meet design 
goals. The 45 degree inlet manifold was chosen for in vitro testing due to its more compact size 
when compared to the 30 degree inlet manifold angle.  
3) Large recirculations occurred in all housing designs as a result of fluid forming a jet as it flowed 
through the inlet manifold. The jetting fluid impacted the back of the housing and the fiber bundle. 
Thus, the housing of the PAD will need to be redesigned. 
4) The tubing size required for the 0.5” inlet diameter PAD is a non-standard size in the medical 
field, and would require new pump interfaces. Thus the 0.375” inlet diameter was chosen for in 
vitro testing.  
5) In vitro gas exchange testing yielded oxygen exchange performance well below design goals. 
However, two of the five PAD’s that were tested had a manufacturing defect that result in plugging 
of the gas exchange fibers. When excluding the defective devices, the oxygen exchange of the 
PAD was below the design goals, but not to as a great extent. 
6) In vitro resistance testing of the PAD yielded a resistance more than twice that predicted by the 
CFD simulations. As a result, the computational model was not able to be validated. 
7) In vitro resistance exceeded the design goal by 46%. As a result, the PAD must be redesigned 
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to decrease resistance. 
6.2 Limitations and Future Work 
 The CCSD was greatly limited by the magnitude of large pressures in the enclosure 
housing. These negative pressures resulted in gas being pulled from the gas side of the device to 
the blood side. In a patient, if the gas entered circulation it would lead to gas embolism and 
subsequent patient mortality and morbidity. This risk greatly outweighs any benefits of the CCSD 
system. Thus, the CCSD system should not be developed further. However, recent strides in 
ECMO pump technologies may allow for adoption of pulsatile flow in ECMO. 
 The 14 day in vivo cTAL experiments were largely limited by non-device complications 
that reduced animal numbers in the later stages of the experiment. One sheep was euthanized as a 
result of a bradycardic arrhythmia that progressively became more severe as experimental time 
increased. This arrhythmia was evident shortly after surgery and was likely the result of grafting 
directly onto the left atrium. In the future, the graft attachment will likely need to be improved to 
reduce complications.  
 From a device standpoint, the rapid prototyped connectors that connected the cTAL to the 
device failed catastrophically in two cases. In one case this resulted in the euthanization of an 
animal. In the other case the connector failed immediately after detaching the cTAL from the 
animal at the conclusion of the experiment. These connectors must be replaced with injection 
molded or machined polycarbonate connections prior to future long term in vivo studies. The large 
prime volume of the device led to initial hemodilution when the device was attached. Thus, the 
device will need to be decreased in size to reduce the prime volume of the device. This will be 
possible as the cTAL is overdesigned in terms of gas exchange performance. This re-design will 
also need to incorporate PDMS coated polypropylene gas exchange fibers to prevent future plasma 
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leakage issues. Despite no anti-coagulant coatings being applied to the cTAL and its circuitry, the 
cTAL remained relatively clot free for 14 days. In the future, anti-coagulant coatings should be 
applied to allow for an even greater device lifespan. Following anti-coagulant coating and prime 
volume reduction, the cTAL should be tested in two month in vivo biocompatibility studies to 
prove efficacy as a destination therapy device. 
 The PAD work was limited by the accuracy of the computational models used in its design. 
The CFD model was highly inaccurate in its prediction of the resistance of the device. This may 
be due in part to a fluid jet impacting the fiber bundle. The fiber bundle is not modeled in a way 
that takes into account minor losses from fluid moving over the top of the fiber radii on the top 
surface of the fiber bundle or the decreased permeability of the bundle in the direction of the jetting 
fluid flow. Future efforts will be needed to improve the validity of the computational modeling 
including the addition of directional permeability and minor losses on the top surface of the fiber 
bundle.  
 The in vitro gas exchange of the device was also lacking in comparison to the predictions 
of the numerical models. However, this was expected as the gas exchange constants used in the 
modeling were derived from past experiments that failed to challenge the tested gas exchangers. 
The new gas exchange constants derived from the current work should be used for future oxygen 
transfer modeling. In vitro gas exchange varied between devices due to a fabrication defect that 
resulted in plugging of the gas exchange fibers. Future fabrication techniques will need to improve 
the sealing of the fiber ends prior to potting, so as to avoid plugging during the potting process. 
Additionally, all future devices should be screened for a high gas resistance prior to in vitro and 
in vivo use to avoid gas exchange abnormalities.  
 From an overall device design standpoint, the housing and fiber bundle will need to be 
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redesigned to improve gas exchange, reduce resistance, and improve potential biocompatibility. 
The fiber bundle will need to be increased in path length and surface area to increase gas exchange 
capabilities. Concurrently, the frontal area must be increased to reduce the overall device 
resistance. Care will need to be taken to avoid designing a device too large for in home use. The 
housing will need to be redesigned to reduce the jetting that results in increased stasis regions, 
increased recirculation regions, and decreased computational model validity. As the recirculations 
are reduced, the PAD’s clotting potential should be reduced, and there may be some gains in gas 
exchange and resistance performance. Following a redesign of the PAD, future in vivo studies will 
be needed to test the biocompatibility of the PAD and its ability to serve as a destination therapy 
device. 
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Appendix A: CCSD Valve Fabrication 
A.1 Valve Dip Casting 
1. Perform all dip casting in the dipping hood/glove box heated to 120˚F with proper ventilation.  
2. Clean the delrin valve mold with isopropyl alcohol. 
3. Thread a section of threaded rod into the back of the mold to facilitate dipping and rotisserie 
attachment. (Figure A.1) 
4. Slowly insert valve mold into a vat of Biospan polyurethane dissolved in cyclohexanone, 
making sure to angle the valve so that one corner of mold dips in first. (Figure A.1) This will 
help avoid air pockets forming in the leaflet cavities.  
5. Slowly withdraw the valve mold, once again tilting it so that one corner is facing downward to 
avoid bubble formation. 
6. Keep the valve in angled and allow 
Biospan to drip off of this corner for 30 
seconds. 
7. After 30 seconds, slowly rotate the valve so 
that biospan drips off of the next corner, and 
let drip for 30 seconds. 
8. Rotate slowly to the last corner and let drip 
for 30 seconds. 
Figure A.1: A CCSD valve mold with attached 
threaded rod with the valve center tip and valve 
corner labeled. 
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9. Angle the valve so that the biospan drips 
off of the center point connecting all three 
valve leaflets. (Figure A.1) 
10. Drip for a final 30 seconds. 
11. Use a stainless steel dental pick to pop any 
bubbles that formed on the leaflet. 
12. Angle/rotate the valve mold so that 
biospan fills in the void from the bubble after 
popping.  
13. Following bubble popping and filling, 
angle the mold so that its axis is horizontal. 
14. Rotate the valve on its axis to evenly spread biospan over the valve leaflet faces. 
15. While continuing to rotate the valve, attach it to the rotisserie. (Figure A.2) 
16. Turn the rotisserie on to its slowest setting. 
17. Allow the valve to dry for 2 hours before the next dip. 
18. Turn off rotisserie and repeat the above dipping steps. 
19. Repeat the procedure until the desired number of coats have been obtained. 
20. After the last dip, allow the valve to dry over night. 
21. Remove mold from the dipping hood and insert into the drying oven inside the fume hood, 
with the oven temperature set to 120˚F. 
A.2 Valve Demolding 
1. Remove the valve mold from the oven. 
2. Set the valve mold into a beaker of water for at least an hour. 
Figure A.2: A CCSD valve mold attached to the 
rotisserie. 
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3. Starting from the back edge, roll the valve 
biospan over onto itself to form a folded-over 
lip of biospan. 
4. Pull this biospan lip towards the leaflets of 
the valve to remove the valve from the mold. 
5. Immediately flip the valve right-side-out. 
6. Rinse the valve with water and dry 
thoroughly. 
A.3 Valve Finishing 
1. Starting from the center leaflet joining tip, 
cut the seam between leaflets (3 in total).  Once a seam has been cut, cut just slightly further 
beyond the valve corner. (Figure A.3) 
2. Once all leaflets are feed from eachother, color the edges of the valves with a permanent 
marker to allow easy visualization of leaflet movements. 
3. Cut the excess valve tubing off, so that 
valves are approximately 1 inch long (Figure 
A.4) 
4. Sand the non-blood contacting surfaces of 
the valve with 220 grit sandpaper to ensure 
proper adhesion of polyurethane in the 
following steps. 
5. Use BJB polyurethane to glue valves into 
an outer biospan tube for valve testing or the 
Figure A.3: A CCSD valve with leaflets cut free 
labeled with the cutting seam and the distance to 
cut past the valve corner. 
Figure A.4: A cut to length CCSD valve with 
colored leaflet edges. 
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CCSD blood conduit for CCSD system 
testing.  When inserting into blood inlet and 
outlet conduits, ensure that one valve opens 
towards the fiber bundle and the other opens 
away from the fiber bundle. 
6. Use BJB polyurethane to glue a stiff plastic 
tube onto the outside of the biospan valve-
tube assembly.  This prevents valve collapse. 
(Figure A.5)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.5: A valve glued into a biospan tube 
with a rigid support tube. 
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Appendix B: Gas Exchanger Manufacture 
The manufacture of the PAD, cTAL, and CCSD are very similar with the exception of 
the housing construction, type of material used as potting, and the addition of valves into the 
CCSD blood conduits. The PAD manufacturing process is the most evolved, so the entire 
manufacturing process will be described in the most detail for the PAD with notes that designate 
major differences with CCSD and cTAL construction. The construction of the cTAL has been 
described previously in detail.(1) The CCSD construction is identical to cTAL construction with 
the exception of the addition of valves into the blood conduits according to procedure outlined in 
Appendix A.  
B.1 Fiber Bundle Rolling 
1. Cut a properly sized core from a 3/32 inch 
thick sheet of acrylic with a laser cutter. 
(Figure B.1) Note: Originally CCSD and 
cTAL cores were cut from polycarbonate 
sheet using a dremel tool.  However the PAD 
method is an improvement and should be 
followed for future cTAL and CCSD 
manufacture.   
2. Sand all surfaces of the acrylic core that are 
embedded in the potting material using 320  
Figure B.1: A PAD core drawing with all 
dimensions labeled in inches. 
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grit sand paper, making sure to remove all 
sharp edges. 
3. Wash cores thoroughly with water. 
4. Lightly wipe the cores with a Kim-wipe 
that has isopropyl alcohol on it.  Be careful to 
only use a small amount of alcohol on the 
Kim-wipe, as the alcohol will craze the 
acrylic core and weaken it. 
5. Prime all sanded surfaces with Nusil MED-
163 following manufacturer instructions. 
Note: This step is specific to potting with 
PDMS rather than polyurethane. 
6. Using a natural hair brush, apply a thin layer of PDMS to all surfaces in contact with the 
potting material. Note: This step is specific to potting with PDMS rather than polyurethane.  
7. Allow the PDMS to cure in an oven for at least 2 hours prior to handling. Note: This step is 
specific to potting with PDMS rather than polyurethane. 
8. Heat seal across the width of the fiber mat, and cut off the excess fiber mat. (Figure B.2)  
9. Attach the fiber mat to the core using a small amount of PDMS on the core where the potting 
material will later contact. Note: This step is specific to potting with PDMS rather than 
polyurethane. If potting with polyurethane, use polyurethane rather than PDMS for this step. In 
previous versions of the cTAL and CCSD, two sided tape was utilized.  However, the tape served 
as a nidus for clot formation and should not be used for future CCSDs and cTALs. 
Figure B.2: Heat sealing across the width of a 
fiber mat. 
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10. Place the fiber and core into the oven and allow it to cure for at least 4 hours prior to 
attempting to roll the fiber bundle. 
11. Lay clean plastic out on the benchtop and unroll the length of fiber that is attached to the core 
onto the benchtop. 
12. Measure out and mark the length of fiber that will result in the desired gas exchanger surface 
area. (140.893 inches of double layer fiber mat for the PAD) Note: This bundle sizing step and 
future bundle sizing quality control steps were only performed for the PAD, but would result in 
more consistent fiber bundles for cTALs and CCSDs. 
13. Flip the core over 51 times to roll the fiber bundle. Note: 58 times for the CCSD, 84 times for 
the cTAL 
14. Check that you are within one turn of the mark placed on the fiber that corresponds to the 
proper bundle surface area. Note: This bundle sizing quality control step was only performed for 
the PAD, but would result in more consistent fiber bundles for cTALs and CCSDs. 
15. Measure the thickness of the fiber bundle using a caliper without crushing down on the fiber 
bundle.  Use this measurement and core thickness to ensure that the spacing between layers of 
fiber is 5-20 micrometers. Note: This bundle sizing quality control step was only performed 
using a caliper for the PAD, but would result in more consistent fiber bundles for cTALs and 
CCSDs. 
16. Measure the bundle width to ensure that the bundle is 20-40 micrometers oversized from the 
width of the housing. Note: This bundle sizing quality control step was only performed for the 
PAD, but would result in more consistent fiber bundles for cTALs and CCSDs. 
17. If the fiber bundle is out of specification, re-roll the bundle until bundle sizing specifications 
are met. 
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18. Heat seal across the width of the fiber mat where it rolls over the side of the bundle at the end 
of the last flip. 
19. Cut the fiber along this heat seal. 
20. Apply a small amount of PDMS to the fiber bundle to connect this last flap of fiber to the 
fiber, while making sure to only apply PDMS to places that will be encapsulated during the 
potting process. Note: This step is specific to potting with PDMS rather than polyurethane. If 
potting with polyurethane, use polyurethane rather than PDMS for this step. In previous versions 
of the cTAL and CCSD, two sided tape was utilized.  However, the tape served as a nidus for clot 
formation and should not be used for future CCSDs and cTALs. 
21. Place the fiber bundle in the oven to allow the PDMS to cure for at least 2 hours before 
handling. 
22. Apply PDMS to the ends of the fibers on the fiber bundle to connect the layers of fiber to 
eachother. Note: This step is specific to potting with PDMS rather than polyurethane. If potting 
with polyurethane, heat seal the layers of fiber together with a hot plate. 
23. Place the fiber bundle in the oven to allow the PDMS to cure for at least 2 hours before 
handling. 
B.2 PAD Housing Preparation 
1. Sand all inside surfaces of the 3-D printed 
housing, surfaces coming on contact with 
potting material, and sealing faces between 
the two halves of the housing with 320 grit 
sand paper. (Figure B.3) 
Figure B.3: Sanding of the inside surfaces of the 
PAD housing. 
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2. Wash the housing with water and dry in the oven.  
3. Clean the housing with isopropyl alcohol. 
4. Prime all sanded surfaces with the exception of potting contacting surfaces and the sealing 
faces between the two housing halves with Nusil MED-163 primer according to manufacturer 
instructions. 
5. Prepare Nusil MED-6019 PDMS according to manufacturer instructions, and paint onto the 
primed surfaces of the housing. 
6. Place housing into the oven and allow to cure overnight. 
7. Prime all potting contacting surfaces with Nusil MED-163 primer according to manufacturer 
instructions. 
8. Prepare Wacker Chemie Elastosil RT625 PDMS according to manufacturer instructions, and 
paint onto the newly primed surfaces of the housing. 
9. Place housing into the oven and allow to cure overnight. 
10. Prime the sealing faces between the two housing halves with Nusil MED-163 primer 
according to manufacturer instructions. 
11. Prepare Wacker Chemie Elastosil RT625 PDMS according to manufacturer instructions, and 
paint onto the sealing faces of the housing, making sure to avoid excessive PDMS that could 
seap into the fiber bundle when the two halves of the housing are sandwiched together. 
12. Insert fiber bundle into one half of the housing. 
13. Carefully sandwich the two halves of the housing together to avoid PDMS flowing into the 
fiber bundle. 
14. Clamp the fiber bundle lightly with C-clamps. 
15. Place housing-fiber bundle assembly into the oven and allow to cure at least two hours. 
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B.3 Device Potting 
 Pot only according to current potting 
protocols, as the potting procedure is 
continuously improving and varies depending 
on equipment.  These steps are only meant to 
serve as a basic potting outline and is not as 
detailed as current lab potting protocols.  Only 
pot after being properly trained by current lab 
staff, and never pot alone. 
1. Clean all Teflon potting molds thoroughly. 
2. Secure the housing-fiber bundle assemblies 
in the potting fixture, and ensure that all bolts 
and nuts are properly tightened.  Apply low 
strength thread-locker to the proper bolts that connect the Teflon mold to the aluminum fixture.  
3. When inserting the housing fiber bundle assembly into the potting fixture ensure that the core 
of the fiber bundle slides into the slot in the Teflon mold. Note: This is only done in the new 
mold design of the PAD, but future CCSD and cTAL molds should incorporate a core slot to 
properly secure the fiber bundle during potting. (Figure B.4) 
4. When inserting the housing fiber bundle assembly into the potting fixture ensure that you 
allow for a small overflow gap between the mold and the housing. Note: This only applies to the 
solid housing PAD. (Figure B.5) 
5. Insert the potting fixtures into the centrifuge and secure to the centrifuge arm (one PAD on 
each end of the centrifuge arm, ensuring equal distance from the rotational axis). (Figure B.6) 
Figure B.4: A bare core being slid into the 
potting mold core slot. 
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6. Attach silicone tubing between the potting 
molds and the centrifuge potting boat.  
7. Follow the “Potting Safety Checklist” to 
prepare the centrifuge.  Also be prepared to 
hit the emergency stop button on the 
centrifuge.  Operate the centrifuge according 
to current lab safety protocols. 
8. Prepare the Wacker Chemie Elastosil 
RT625 PDMS according to manufacturer 
instructions and insert into the potting gun 
syringes. Note: The previous CCSD and cTAL 
used polyurethane potting material rather 
than PDMS.  Refer to previous polyurethane 
potting documents for detailed polyurethane preparation, centrifuge heating instructions, 
centrifuge speeds, and centrifugation timings. 
9. Turn on centrifuge and turn speed up to 707 rpms. 
10. Slowly inject PDMS into the potting boat. 
11. Turn on heat gun at highest settings. 
12. Monitor centrifuge temperature. 
13. Stay at this rotational speed until the time 
hits 24 minutes or the temperature reaches 
120˚F for at least 5 minutes, whichever occurs 
later. 
Figure B.5: A PAD housing inserted into a 
potting mold with the overflow gap labeled. 
Figure B.6: The PAD potting fixture attached to 
the centrifuge arm. 
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14. Turn down the centrifuge speed to approximately 200 rpm until the total centrifuging time 
reaches 1 hour. 
15. Monitor the temperature and ensure that it does not exceed 130˚F.  
16. At the end of the centrifuge cycle allow the molds to cool for 1 hour. 
17. Flip the fixtures around to pot the second side of the PADs. 
18. Clean out the potting boat, and remove all tubing and tubing connectors from the previously 
potted molds. 
19. Attach new silicone tubing to the un-potted molds and repeat the above procedure to pot the 
second side of the PADs. 
20.  Upon completion of the second round of potting, remove the fixtures from the centrifuge and 
insert into the oven to post cure the PDMS potting for at least a day. Note: This only applies to 
PDMS potting. 
21. De-mold the PADs and place back into the oven to post cure for at least 2 more days. Note: 
This only applies to PDMS potting. 
B.4 Device Cutting 
Follow all safety precautions and current lab safety protocols when cutting, since the 
cutting saw has the potential to severely injure you and others when used improperly. Cut only 
according to current cutting protocols, as the cutting procedure is continuously improving and 
varies depending on equipment.  Only senior staff are permitted to cut devices, and they are 
never permitted to cut alone.  
These steps are only meant to introduce the basic process with the purpose of describing 
the preparation of the PAD and give context to the discussions in the main dissertation body. 
1. Mark the potting material 3/8 of an inch from the housing on both potted sides. 
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2. Plug/cover the blood inlet and outlet conduits. 
3. Insert the PAD into the cutting fixture and secure properly. 
4. Follow current lab cutting safety protocols. 
5. Cut a thin slice of potting material away with the saw. 
6. Repeat cuts until you cut away your marking. 
7. Flip the device around and repeat the above procedure. 
8. Remove from the PAD from the cutting fixture. 
9. Inspect the last slice from each side of PAD by holding the slice up to the light to see if the 
lumen of the fibers are not plugged with potting material. 
10.  If plugging exists, cut further slices from the PAD and check again. 
B.5 Sealing the PAD Housing 
 The 3-D printed PAD housing is very porous, so it must be sealed after cutting the potted 
sections in order to prevent gasses from passing into the blood side of the housing and to prevent 
liquids from passing outside of the housing. 
1. Prepare a marine grade epoxy according to manufacturer instructions. 
2. Using a tongue depressor paint the entire outside of the PAD housing with epoxy with 
exception of the faces that come in contact with blood tubing and the gas caps. 
4. Allow the epoxy to dry in the fume hood according to manufacturer instructions. 
5. Apply a very thin layer of silicone RTV gasket maker to the remaining external surfaces of the 
PAD, making sure to thoroughly smooth out the silicone and force it into cracks with a gloved 
finger. 
6. Allow the silicone RTV to dry in the fume hood according to manufacturer instructions. 
B.6 Leak Testing the Potted Section 
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1. Fill the PAD with deionized water. 
2. Attach tubing to each blood conduit. 
3. Attach a barbed tubing connector with leur lock to each tube. 
4. Connect another section of tubing to the other end of barbed tubing connection. 
5. Fill all tubes and connectors with deionized water and clamp the terminal tubing ends with 
tubing clamps. 
6. Attach a pressure transducer to the leur lock on one barbed tubing connection, and attach a 
syringe filled with deionized water to the leur lock on the other barbed tubing connection. 
7. Inject fluid with the syringe to pressurize the PAD to 40 mmHg. 
8. Inspect the potted regions for leaks. 
9. If there are leaks, mark them for patching with a fine tipped permanent marker. 
10. Empty the PAD and dry the device with filtered air for at least 8 hours. 
11. Prepare the Wacker Chemie Elastosil RT625 PDMS according to manufacturer instructions. 
Note: The previous CCSD and cTAL used polyurethane potting material rather than PDMS.      
12. Apply a small dot of PDMS to the marked leaks using a blunt applicator needle. 
13. Place the PAD in the oven for at least one day to cure. 
14. Repeat the above procedure until the device is leak free. 
15. Log all leak testing and patching in lab leak testing binders. 
B.8 PAD Gas Cap Attachment 
1. Clean the gas caps with water if they are made from acrylic.  Use isopropyl alcohol if they are 
manufactured from polycarbonate, as polycarbonate resists crazing by isopropyl alcohol. 
2. Apply a thick layer of silicone RTV gasket maker to the PAD housing faces that interface with 
the gas caps. 
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3. Smooth this layer out with a gloved finger. 
4. Slide the gas cap onto the PAD housing gas cap shoulders. 
5. Apply a thick layer of silicone RTV bridging any gap between the PAD housing and gas cap. 
6. Force the silicone RTV into any gaps using a gloved finger, and smooth the silicone RTV out. 
7. Allow the silicone RTV to dry in the fume hood according to manufacturer instructions. 
B.9 PAD Gas Cap Leak Testing 
1. Attach tubing to the blood inlet and outlet conduits, and clamp these off with tubing clamps. 
2. Attach tubing to the gas inlet and outlets on the gas caps. 
3. Flow oxygen through the gas inlet at a rate of at least 3 L/min. 
4. Submerge the PAD in a bucket of water while making sure that the gas outlet does not become 
submerged. 
5. Inspect the seams between the gas caps and the housing for air leaks. 
6. If there is a leak, mark it with a permanent marker for later patching. 
7. Dry the device thoroughly before patching. 
8. Force silicone RTV into any leaking areas with a glove finger. 
9. Allow the silicone RTV to cure in the fume hood according to manufacturer instructions. 
10. Repeat the above procedure until no leaks are present. 
11. The PAD is not ready for in vitro testing.  However, the blood contacting surfaces should be 
rinsed with deionized water for a day before in vivo use. 
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Appendix C: Graft Assembly Fabrication 
C.1 Dacron Graft Preparation 
 Dacron grafts (Figure C.1) are typically coated with a gelatin coating during the 
manufacturing process. If this coating is not removed prior to graft insertion into the assembly 
tubing, the graft will separate from the tubing and cause a life threatening failure. 
1. Prepare a 5% bleach solution. 
2. Submerge grafts into bleach. 
3. Use a toothbrush to scrub the gelatin off of the 
graft. 
4. Rinse thoroughly with water and dry. 
5. If there is discoloration or stiffness in the valve, 
repeat the above process with a bleach 
concentration stepped up 5% until grafts are clean. 
C.2 Tubing Preparation 
 The tubing that the grafts slide into will need to be expanded in diameter to accommodate 
graft insertion.  If the tubes are under expanded, the graft will kink upon insertion and clot may 
form on the kink when used in vivo. If the tubes are over expanded, the graft-tubing connection 
will be weak and susceptible to separation. 
1. Heat the smallest diameter aluminum expansion rod with a heat gun. (Figure C.2) 
Figure C.1: A section of 18 mm Dacron 
graft material. 
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2. Inside of a fume hood, heat the final inch of an 8 
inch long piece of Tygon R-3603 tubing with a heat 
gun.  
3. During heating rotate the tubing in order to allow for even softening and avoidance of tubing 
burning. 
4. Once a small amount of smoke/vapor is emitted from the tubing, it is sufficiently heated. 
5. Slide the tubing onto the taper of the expansion rod, allowing for at least ½ inch of the tubing 
to be expanded for graft insertion. 
6. Wait for the rod and tubing to cool. 
7. Invert the tubing and pour isopropyl alcohol into the tubing. 
8. Over top of a sink push forwards, and then pull backwards on the tubing to free it from the 
expansion rod. 
9.  Carefully insert a bare graft into the expansion of the tubing. 
10.  If the graft inserts easily with little or no friction on the tubing, the tubing is expanded 
sufficiently. 
11.  If the tubing is not expanded in diameter enough, repeat the above steps with a larger 
diameter expansion rod. 
C.3 Graft-Tubing Connection 
1. Perform all steps in a fume hood with appropriate PPE. 
2. Cut Tygon R-3603 tubing into small pieces. 
3. Dissolve tubing in a glass jar using cyclohexanone (100 mL cyclohexanone to 12.5 g tubing) 
4. Adjust concentration of cyclohexanone in the mixture until the mixture has the consistency of 
syrup. 
Figure C.2: An aluminum expansion 
rod. 
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5. Using a natural hair brush, paint the first inch of the 
graft with pvc-cyclohexanone mixture.  The graft will 
absorb the mixture.  
6. Paint the expansion section of the expanded tube 
lightly with pvc-cyclohexanone mixture. 
7. Use a stainless steel weighing spatula to remove air 
bubbles between the graft and tubing.  
8. Fill any spaces between the tubing and graft with pvc-
cyclohexanone mixture. 
9. Stand the assembly vertically by inserting the unused end of the tubing on the coating base. 
10. Let the assembly dry for a day to allow for cyclohexanone to evaporate off. 
C.4 Graft Coating 
1. Perform all steps in a fume hood while using appropriate PPE. 
2. Thread the extension connector onto the 
graft material and zip tie in place. (Figure 
C.3) 
3. Tie the extension connector to a supporting 
structure to allow for graft extension.  The 
Graft should be extended just far enough to 
allow for coating between the graft ridges, but 
not extended so far as to limit graft flexibility. 
(Figure C.4) 
Figure C.3: An extension connector 
threaded onto a synthetic graft. 
Figure C.4: Proper extension of a graft-tubing 
assembly demonstrated with a used assembly. 
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4. Paint the pvc-cyclohexanone mixture onto the 
graft material starting from the top and working to 
the bottom. 
5. Wipe away any excess material that drips down 
the length of the tubing. 
6. Allow the assembly to dry for at least two hours.  
7. Apply additional coats until the desired graft stiffness is achieved. (typically 4-6 coats 
depending on pvc concentration) 
8. Allow the grafts to dry at least one day. 
C.5 Graft Finishing 
1. Perform all steps in a fume hood with appropriate PPE. 
2. Cut a rectangle of felt that is 5 inches long and with a width that corresponds to circumference 
of the tubing. 
3. Pull the felt to flare out the last inch of the felt to allow for attachment on the expanded section 
of the tubing. 
4. Paint pvc-cyclohexanone mixture onto the outside of the tubing that extends from the 
expansion section of the tubing to a distance 5 inches from the expansion end of the tubing. 
5. Apply the felt onto the section of tubing that was coated with the pvc-cyclohexanone mixture.   
6. Using a silk suture, suture the felt together on the tubing using a simple continuous suturing 
technique and tie off. (Figure C.5) 
7. Allow to dry for at least three days.  The longer it dries, the better. 
8. Remove the graft-tubing assembly from the extension assembly and rinse thoroughly with 
water. 
Figure C.5: A completed graft assembly 
with felt sutured on. 
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9. Dry the assembly fully. 
10. Sterilize with ethylene oxide sterilization 
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Appendix D: Bundle Path Length Calculation 
 With an array of frontal and surface areas known the first step in modeling the fiber bundle 
was to calculate the height or path length of the fiber bundle.  This was accomplished by first 
finding the surface area of a single fiber, then finding the surface area of a single layer of fiber, 
and then calculating how many layers are needed to achieve the desired surface area.  The surface 
area of an individual fiber, SAif, was calculated using Equation D.1 
       𝑆𝐴𝑖𝑓 =
𝜋∗Φ𝑓∗𝑤
cos𝜃
           (D.1) 
where Φf is the diameter of a single fiber, w is the width if the fiber bundle, and θ is the distortion 
angle that the angled fiber of the fiber mat makes with the axis across the width of the fiber bundle 
as shown in Figure 4.3.  The surface area of a single layer of fibers, SAlayer, was calculated using 
Equation D.2 
     𝑆𝐴𝑙𝑎𝑦𝑒𝑟 = 𝐿 ∗ 𝑠𝑝𝑎𝑐𝑖𝑛𝑔 ∗ 𝑆𝐴𝑖𝑓          (D.2) 
where L is the length of the fiber bundle and spacing is the density of fiber packing in the fiber 
mat expressed as the number of fibers per unit length.  The surface area of the entire fiber bundle, 
SA, was calculated using Equation D.3 
         𝑆𝐴 = 𝑛𝑜𝑙𝑎𝑦𝑒𝑟𝑠 ∗ 𝑆𝐴𝑙𝑎𝑦𝑒𝑟         (D.3) 
where nolayers is the number of layers of fiber mat that comprise the fiber bundle.  Combining 
Equations D.1-D.3 yields Equation D.4 
            𝑆𝐴 =
𝜋∗Φ𝑓∗𝑤∗𝐿∗𝑠𝑝𝑎𝑐𝑖𝑛𝑔∗𝑛𝑜𝑙𝑎𝑦𝑒𝑟𝑠
cos𝜃
        (D.4) 
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Since the frontal area is equal to the width times the length Equation D.4 can be further simplified  
into Equation D.5 
    𝑆𝐴 =
𝜋∗Φ𝑓∗𝐹𝐴∗𝑠𝑝𝑎𝑐𝑖𝑛𝑔∗𝑛𝑜𝑙𝑎𝑦𝑒𝑟𝑠
cos 𝜃
         (D.5) 
where FA is the frontal area of the fiber bundle through which blood flows.  The pathlength or 
height of the fiber bundle, PL, can be found using Equation D.6 
      𝑃𝐿 = 𝑛𝑜𝑙𝑎𝑦𝑒𝑟𝑠 ∗ (Φ𝑓 + 𝑔𝑎𝑝)         (D.6) 
where gap is the space between layers of stacked fibers, which was modeled as 20 microns for 
these analyses.  Equations D.5 and D.6 can be combined and solved for PL to yield Equation D.7 
           𝑃𝐿 =
(Φ𝑓+𝑔𝑎𝑝)∗𝑆𝐴∗cos𝜃
𝜋∗Φ𝑓∗𝐹𝐴∗𝑠𝑝𝑎𝑐𝑖𝑛𝑔
          (D.7) 
Equation D.7 was solved for the array of frontal and surface areas to yield an array of pathlengths 
for future analyses.   
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Appendix E: Matlab Bundle Modeling Code 
E.1 Main Matlab Bundle Modeling Program 
%%Comprehensive Bundle Design Program V8.1  
%%Setting up graph variables  
clear all  
gap=20e-6; 
CO=input('Enter the device flowrate in L/min > ');%cardiac output L/min 
CO=CO/(60*1000);%cardiac output m^3/sec 
SA=(input('Enter the bundle surface area in m^2; \n minimum > '):input('step size > 
'):input('maximum > '));%surface area m^2 
FA=(input('Enter the bundle frontal area in cm^2; \n minimum > '):input('step size > 
'):input('maximum > '));%frontal area cm^2 
FA=FA/(100*100);%frontal area m^2 
[SA,FA]=meshgrid(SA,FA);%%array form of surface area and frontal area 
L_W_ratio=1;  
%%Initializing variables-path length  
%%Fiber Initialization 
standard_fiber_input_question=input('Do you want to keep the standard fiber specs 
(spacing=43fibers/in(porosity~0.75), fiber diameter 203 microns, crossing angle 30 degrees? 
Enter "y" or "n" > ','s');  
if strcmp(standard_fiber_input_question,'y') 
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phif=203;%%fiber diameter microns   
theta=30;%%fibercrossing angle degrees  
spacing=43;%%fibers/inch 
elseif strcmp(standard_fiber_input_question,'n') 
spacing=input('Enter the fiber spacing in fibers/inch (standard 43) > ');%%fiber diameter 
microns 
phif=input('Enter the fiber diameter in microns (standard 203) > ');%%fibercrossing angle 
degrees 
theta=input('Enter the fiber crossing angle in degrees (standard 30) > ');%%fibers/inch 
end  
theta=(theta/2);%% fiber angle with horzontal degrees  
phif=phif/1000000;%%fiber diameter m 
theta=(theta*pi)/180;%%fiber angle with horizontal radians 
spacing=spacing/0.0254;%%fibers/m  
%%Initializing variables-resistance  
%%permiability calcs from hard shell paper 2012 
standard_permiability_input_question=input('Do you want to keep the fiber bundle permiability 
data from the 2012 hard shell paper? Enter "y" or "n" > ','s'); 
if strcmp(standard_permiability_input_question,'y') 
muexp=0.003;%%dynamic viscosity of blood from hard shell paper 2012 kg/(m*sec) 
Rbexp=0.29;%%bundle resistance from hardshell 2012 mmHg/(L/min) 
Rbexp=Rbexp*(60*1000*133.322368);%kg/(sec*m^4) 
Afexp=0.016;%bundle frontal area from hardshell 2012 m^2 
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Lexp=0.038;%bundle path length from hardshell 2012 m 
perm=(muexp*Lexp)/(Afexp*Rbexp);%permiability calculated from hard shell 2012 m^2 
elseif strcmp(standard_permiability_input_question,'n'); 
yes_standard_permiability_input_question=input('Do you want to enter a permiability or 
experimental data? Enter "p" for permiability or "e" for experimental data > ','s'); 
if strcmp(yes_standard_permiability_input_question,'p') 
perm=input('Enter the fiber bundle permiability in kg/(m*sec) > '); 
   elseif strcmp(yes_standard_permiability_input_question,'e') 
muexp=input('Enter the dynamic viscosity in kg/(m*sec)(standard 0.003) > 
');%%dynamic viscosity of blood kg/(m*sec) 
Rbexp=input('Enter the fiber bundle resistance in mmHg/(L/min) (standard 0.29) 
> ');%%bundle resistance mmHg/(L/min) 
Rbexp=Rbexp*(60*1000*133.322368);%kg/(sec*m^4) 
Afexp=input('Enter the fiber fundle frontal are in cm^2 (standard 160 cm^2) > 
');%bundle frontal area cm^2 
Afexp=Afexp/(100*100);%bundle frontal area m^2 
Lexp=input('Enter the bundle path length in cm (standard 3.8) > ');%bundle path 
length cm 
     Lexp=Lexp/100;%bundle path length m 
         perm=(muexp*Lexp)/(Afexp*Rbexp);%permiability m^2 
end 
end  
%%Initializing variables-gas exchange  
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%%User input data 
standard_gas_exchange_question=input('Do you want to keep the standard bundle gas transfer 
constants from the Cook 2005 paper, m=0.214 phi=0.82? Enter "y" or "n" > ','s'); 
if strcmp(standard_gas_exchange_question,'y') 
mb=0.214;%bundle gas transfer constant 
     phib=0.82;%bundle gas transfer constant 
elseif strcmp(standard_gas_exchange_question,'n') 
mb=input('Enter the bundle gas exchange constant m (standard 0.214) > ');%%user input 
gas exchange constant 
phib=input('Enter the bundle gas exchange constant phi ( standard 0.82) > ');%%user 
input gas exchange constant 
end  
por=1-(pi*phif*spacing/4);%porosity of the device as a fraction  
standard_gas_exchange_question=input('Do you want to keep the standard bundle CO2 transfer 
constant from the unpublished data from 2005 Cook paper unpublished data, k_CO2=4.61? 
Enter "y" or "n" > ','s'); 
if strcmp(standard_gas_exchange_question,'y') 
     k_CO2=4.61;%bundle gas transfer constant 
elseif strcmp(standard_gas_exchange_question,'n') 
k_CO2=input('Enter the bundle CO2 exchange constant k (standard 4.61) > ');%%user 
input gas exchange constant 
end  
k_CO2=k_CO2/(60*1000*1000*133.322368);  
187 
 
standard_sweep_gas_question=input('Do you want to keep the standard partial pressure of 
oxygen in the sweep gas from 760 mmHg?  Enter "y" or "n" > ','s'); 
if strcmp(standard_sweep_gas_question,'y') 
     Pg=760;%pO2 of sweep gas mmHg 
elseif strcmp(standard_sweep_gas_question,'n') 
Pg=input('Enter the sweep gas partial pressure of oxygen in mmHg > '); 
end 
Pg=Pg*133.322368;%kg/(m*sec^2)  
standard_blood_condition_question=input('Do you want to keep the AAMI blood conditions and 
assume equal inlet and outlet pH (inlet pH=outlet pH=7.40, fractional inlet oxygen saturation = 
0.65, hemoglobin concentration=12 g/dL, fractional hematacrit=0.4, blood temp = 37 deg. 
celsius) Enter "y" or "n" > ','s'); 
if strcmp(standard_blood_condition_question,'y') 
     pHo=7.40;%pH of the blood at the outlet 
     pHi=7.40;%pH of the blood at the inlet 
     si=0.65;%venous saturation 
     cHb=12;%hemoglobin concentration g/dL 
     H=0.4;%fractional hematocrit 
     T=37;% body temp in celsius 
elseif strcmp(standard_blood_condition_question,'n') 
     pHo=input('Enter the outlet pH (standard 7.40) > '); 
     pHi=input('Enter the inlet pH (standard 7.40) > '); 
si=input('Enter the inlet oxygen saturation as a fraction (standard 0.65) > '); 
188 
 
cHb=input('Enter the hemoglobin concentration in g/dL (standard 12) > '); 
H=input('Enter the hematacrit as a fraction (standard 0.4) > '); 
     T=input('Enter the body temp in celsius (standard 37) > '); 
end 
cHb=cHb*10;%%hemoglobin concentration kg/L 
mu=(2.205e-5)*exp(((1965/(273.15+T))+(2.31*H)));%dyn visc blood poise 
mu=0.1*mu;%%dyn visc blood kg/(m*sec) 
rho=(1.09*H)+(1.035*(1-H));%density of blood g/mL 
rho=rho*1000;%density of blood kg/m^3  
%%Blood constants for Humans 
standard_blood_constants_question=input('Do you want to keep the standard blood constants for 
humans? (aspect ratio of RBC,m, 0.283, hill equation parameter for blood,n, 2.7) Enter "y" or 
"n" > ','s'); 
if strcmp(standard_blood_constants_question,'y') 
     mrbc=0.283;%aspect ratio of RBC for humans 
     nrbc=2.7;%Hill equation parameter for human blood 
elseif strcmp(standard_blood_constants_question,'n') 
     mrbc=input('Enter the aspect ratio of a RBC, m > '); 
nrbc=input('Enter the hill equation parameter for human blood,n > '); 
end  
%%Actual Coding 
PLi=pathlength_solid_rect_V1_1(SA,FA,spacing,phif,theta,gap,L_W_ratio); 
R_B_array=bundle_resistance_calc_darcy_v1_1(FA,PLi,perm,mu);     
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[VO2,so]=gas_exchange_v4_2(SA,FA,CO,PLi,phif,mb,phib,por,Pg,pHo,pHi,si,cHb,H,T,mrbc,nr
bc,mu,rho); 
[V_CO2_1,V_CO2_2,Qg]=CO2_exchange_v1_2(SA,Pg,k_CO2); 
FA=FA*100*100; 
PLi=PLi*100; 
sqrtFA=FA.^0.5; 
sqrtFA_ratio_PLi=sqrtFA./PLi; 
R_B_array=R_B_array/(133.322368*60*1000); 
VO2=VO2*60*1000*1000;  
V_CO2_1=V_CO2_1*60*1000*1000; 
V_CO2_2=V_CO2_2*60*1000*1000; 
Qg=Qg*60*1000; 
so=so*100;   
if size(SA(1,:))==1 
     SA_labels=['Surface Area ',num2str(SA(1)),' m^2']; 
else 
     i=0; 
     for g=SA(1,1):(SA(1,2)-SA(1,1)):SA(1,end) 
         i=i+1; 
SA_labels{i}=['Surface Area ',num2str(SA(1,i)),' m^2']; 
     end 
end  
figure 
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set(gcf,'name','Path_Length','numbertitle','off') 
plot(FA,PLi,'LineWidth',3) 
set(gca,'FontSize',20) 
legend(SA_labels,'FontSize',16) 
xlabel('Frontal area (cm^2)','FontSize',20) 
ylabel('Bundle Path Length (cm)','FontSize',20) 
title ('Bundle Path Length','FontSize',20)  
figure 
set(gcf,'name','Aspect_Ratio','numbertitle','off') 
plot(FA,sqrtFA_ratio_PLi,'LineWidth',3) 
set(gca,'FontSize',20) 
legend(SA_labels,'FontSize',16) 
xlabel('Frontal area (cm^2)','FontSize',20) 
ylabel('Bundle Aspect Ratio ( (cm^2)^0^.^5 / cm )','FontSize',20) 
title ('Bundle Aspect Ratio','FontSize',20)  
figure 
set(gcf,'name','Bundle_Resistance','numbertitle','off') 
plot(FA,R_B_array,'LineWidth',3) 
set(gca,'FontSize',20) 
legend(SA_labels,'FontSize',16) 
xlabel('Frontal area (cm^2)','FontSize',20) 
ylabel('Bundle Resistance (mmHg/(L/min))','FontSize',20) 
title ('Bundle Resistance','FontSize',20)   
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figure 
set(gcf,'name','VO2','numbertitle','off') 
plot(FA,VO2,'LineWidth',3) 
set(gca,'FontSize',20) 
legend(SA_labels,'FontSize',16) 
xlabel('Frontal area (cm^2)','FontSize',20) 
ylabel('VO2 (mL/min)','FontSize',20) 
title ('Oxygen Exchange','FontSize',20)  
figure 
set(gcf,'name','Oxygen_Saturation','numbertitle','off') 
plot(FA,so,'LineWidth',3) 
set(gca,'FontSize',20) 
legend(SA_labels,'FontSize',16) 
xlabel('Frontal area (cm^2)','FontSize',20) 
ylabel('Outlet Oxygen Saturation (%)','FontSize',20) 
title ('Outlet Oxyhemoglobin Saturation','FontSize',20)  
figure 
set(gcf,'name','CO2 Exchange with 1 Device','numbertitle','off') 
flat_V_CO2_1=V_CO2_1(:); 
min_V_CO2_1=roundnum(min(flat_V_CO2_1),-1,10); 
max_V_CO2_1=roundnum(max(flat_V_CO2_1),1,10); 
plot(Qg(:,:,1),V_CO2_1(:,:,2),'LineWidth',3) 
set(gca,'FontSize',20) 
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legend(SA_labels,'FontSize',16) 
xlabel('Sweep Gas Flowrate (L/min)','FontSize',20) 
ylabel('VCO2 (mL/min)','FontSize',20) 
ylim([min_V_CO2_1 max_V_CO2_1]) 
title ('Carbon Dioxide Exchange with 1 Module','FontSize',20)  
figure 
set(gcf,'name','CO2 Exchange with 2 Devices','numbertitle','off') 
flat_V_CO2_2=V_CO2_2(:); 
min_V_CO2_2=roundnum(min(flat_V_CO2_2),-1,10); 
max_V_CO2_2=roundnum(max(flat_V_CO2_2),1,10); 
plot(Qg(:,:,1),V_CO2_2(:,:,2),'LineWidth',3) 
set(gca,'FontSize',20) 
legend(SA_labels,'FontSize',16) 
xlabel('Sweep Gas Flowrate (L/min)','FontSize',20) 
ylabel('VCO2 (mL/min)','FontSize',20) 
ylim([min_V_CO2_2 max_V_CO2_2]) 
title ('Carbon Dioxide Exchange with 2 Modules','FontSize',20)  
E.2 Path Length Subprogram  
function PLi = pathlength_solid_rect_V1_1( SA,FA,spacing,phif,theta,gap,L_W_ratio) 
%UNTITLED2 Summary of this function goes here 
%   Detailed explanation goes here 
PLi=(((phif+gap)*SA*cos(theta))./(FA*pi*phif*spacing)); 
End 
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E.3 Resistance Calculation Subprogram  
function [ R_B_array ] = bundle_resistance_calc_darcy_v1_1( FA,PLi,perm,mu ) 
%bundle_resistance_calc_darcy calculates the Darcy fiber bundle resistance  
%    This function calculates the estimated fiber bundle 
resistance using 
%    the Darcy law porous media assumption coupled with previous prelininary 
%    data.  
%% resistance 
R_B_array=(mu.*PLi)./(FA.*perm);%kg/(sec*m^4)  
end  
E.4 Oxygen Exchange Calculation Subprogram  
function [ VO2,so ] = gas_exchange_v4_2( 
SA,FA,Qal,PLi,phif,mb,phib,por,Pg,pHo,pHi,si,cHb,H,T,mrbc,nrbc,mu,rho ) 
%UNTITLED6 Summary of this function goes here 
%    Detailed explanation goes here  
%%Calculated Values 
kc=(4.658e-5)*(1.01)^(37-T);%solubility constant for cells mL o2/mL blood*mmHg 
kc=kc/133.322368;%solubility constant for cells in L O2 *m*sec^2/L blood* kg 
kp=(2.855e-5)*(1.01)^(37-T);%solubility constant for plasma mL o2/mL blood*mmHg 
kp=kp/133.322368;%solubility constant for palsma in m^3 O2 *m*sec^2/m^3 blood* kg 
k=(kc*H)+(kp*(1-H));%overall solubility constant m^3 o2*m*sec^2/m^3 blood*kg 
p50=26.6*(10^((0.42*(7.4-((pHo+pHi)/2)))-(0.024*(37-T))));%p50 eq for humans mmHg 
p50=p50*133.322368;%kg/(m*sec^2) 
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nu=mu/rho;%kinematic viscosity of blood m^2/sec 
Dc=(0.76e-5)*((1.025^(T-25)));%diffusivity in cells cm^2/sec 
Dc=Dc/(100*100);%diffusivity in cells m^2/sec 
Dp=(1.62e-5)*((1.025^(T-25)));%diffusivity in plasma cm^2/sec 
Dp=Dp/(100*100);%diffusivity in plasma m^2/sec 
N=(kc*Dc)/(kp*Dp);%constant in calcuating D with Frick 
beta=((N-1)/3)*(((2/(1+((N-1)*(mrbc/2))))+(1/(1+((N-1)*(1-mrbc))))));%con 4 Fick 
chi=(1-(N*(1-beta)))/(N-1-beta);%con 4 Fick 
G=H*((N-1)/(N+chi));%con 4 Fick 
D=Dp*(kp/k)*((1+(chi*G))/(1-G));%diffusivity of O2 in blood using Fick m^2/sec 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%% 
%%Start of the actual coding 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%% 
%%gas exchange 
pin=p50*((si/(1-si))^(1/nrbc)); 
Ls=0.0000005; 
VO2=zeros(size(FA)); 
so=zeros(size(FA)); 
rcheck=size(FA,1); 
ccheck=size(FA,2); 
if size(SA(1,:))==1 
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   c=1; 
     r=0; 
     FAi=FA; 
     for rows=1:1:rcheck 
          r=r+1; 
          if isnan(PLi(r,c)) 
              VO2(r,c)=nan; 
              so(r,c)=nan; 
          else 
              P=pin;%kg/(m*sec^2) 
              L=0;%m 
              Af=FA(r,c);%m^2 
              while L<PLi(r,c) 
                   L=L+Ls; 
lambda=(1.34*cHb*nrbc*((P/p50)^(nrbc-
1)))/(1000*k*p50*((1+((P/p50)^nrbc))^2));%%unitless, base units 
for all variables, units of 1.34 mL O2 / g hb, the equations do the 
unit conversions 
dPdx=phib*((((1-por)*Af*nu)/(Qal*phif))^mb)*((4*(1-
por))/(por*phif))*((D/nu)^(2/3))*((Pg-
P)/((1+lambda)^(2/3)));%kg/((m^2)*(sec^2)) 
                   P=P+(Ls*dPdx);%kg/(m*sec^2) 
              end 
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              po(r,c)=P;%kg/(m*sec^2) 
so(r,c)=((po(r,c)/p50)^nrbc)/(1+((po(r,c)/p50)^nrbc)); 
VO2(r,c)=Qal*((k*(po(r,c)-pin))+((1.34*cHb*(so(r,c)-
si))/(100*10)));%VO2 transferred m^3/sec 
end 
          %r=r+1; 
end 
     %c=c+1; 
else 
     c=1; 
     for columns=1:1:ccheck 
          r=1; 
          FAi=FA; 
          for rows=1:1:rcheck 
              if isnan(PLi(r,c)) 
                   VO2(r,c)=nan;    
                   so(r,c)=nan; 
              else 
                   P=pin;%kg/(m*sec^2) 
                   L=0;%m  
                   Af=FA(r,c);%m^2 
                   while L<PLi(r,c) 
                        L=L+Ls; 
197 
 
lambda=(1.34*cHb*nrbc*((P/p50)^(nrbc-
1)))/(1000*k*p50*((1+((P/p50)^nrbc))^2));%%unitless, 
base units for all variables, units of 1.34 mL O2 / g hb, the 
equations do the unit conversions 
dPdx=phib*((((1-por)*Af*nu)/(Qal*phif))^mb)*((4*(1-
por))/(por*phif))*((D/nu)^(2/3))*((Pg-
P)/((1+lambda)^(2/3)));%kg/((m^2)*(sec^2)) 
                        P=P+(Ls*dPdx);%kg/(m*sec^2) 
                   end 
                   po(r,c)=P;%kg/(m*sec^2) 
so(r,c)=((po(r,c)/p50)^nrbc)/(1+((po(r,c)/p50)^nrbc)); 
VO2(r,c)=Qal*((k*(po(r,c)-pin))+((1.34*cHb*(so(r,c)-
si))/(100*10)));%VO2 transferred m^3/sec             
              end        
              r=r+1; 
          end 
          c=c+1; 
end 
end 
end 
E.5 Carbon Dioxide Exchange Calculation Subprogram 
function [ V_CO2_1,V_CO2_2,Qg ] = CO2_exchange_v1_2( SA,Pg,k_CO2 ) 
%bundle_resistance_calc_darcy calculates the Darcy fiber bundle resistance  
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%   This function calculates the estimated fiber bundle resistance using 
%   the Darcy law porous media assumption coupled with previous prelininary 
%    data.  
P_CO2_blood=35:5:50; 
P_CO2_blood=P_CO2_blood*133.322368; 
Qg=0:0.01:10; 
Qg=Qg/(60*1000); 
SA=SA(1,:);  
[SA,Qg,P_CO2_blood]=meshgrid(SA,Qg,P_CO2_blood);  
V_CO2_1=(2*P_CO2_blood.*Qg*k_CO2.*SA)./((2*Qg)+(k_CO2*SA*Pg)); 
V_CO2_2=(2*P_CO2_blood*2.*Qg*k_CO2*2.*SA)./((2*2*Qg)+(k_CO2*2*SA*Pg)); 
end 
  
 
 
 
